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CHAPTER I 
 
INTRODUCTION 
 
Hemozoin:  A Paradigm for Biominerals in Disease1,2 
 
 Biomineralization is the biologic formation of organic-inorganic composites 
generally organized on a nucleating template of organic material.  During bone and teeth 
formation, hydroxyapatite, which is a calcium phosphate derivative enriched with 
carbonate, mineralizes on a template of collagen fibrils and other proteins.3  Likewise, 
calcium oxalate monohydrate crystals mineralize on a biologic matrix of proteins in both 
plants and humans.  Although these crystals function as tissue support in plants,4 they 
cause painful inflammation in humans.5  In fact, biomineralization is associated with 
several human diseases.  Nephrolithiasis is the mineralization of calcium oxalate 
monohydrate in the urinary tract of patients as kidney stones.  In gout or metabolic 
arthritis, monosodium urate crystals accumulate in the articular joints.  A patient’s innate 
immune response or the on-rush of monocytes and neutrophils at the sites of crystal 
sedimentation causes the characteristic tissue inflammation and pain associated with 
these diseases.  Biomineralization can also contribute to the pathology of parasitic 
diseases like malaria and schistosomiasis.  When the malarial protozoa Plasmodium 
falciparum deposits heme-derived aggregates in host vasculature, these aggregates travel 
through the bloodstream and collect in the brain, spleen and liver.  When they are 
phagocytosed by innate immune cells such as monocytes and neutrophils, the cells’ 
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ability to produce reactive oxygen and nitrogen species is impaired.  This 
immunomodulation is typical of the pathogenesis caused by many biomineral-associated 
diseases.   
 
Heme Homeostasis 
 
 Over 40% of the world’s population is at risk from malaria.  The disease causes 
severe illness in over 500 million people and results in over 1.7 million deaths each year.  
Transmission is most prevalent in the world’s poorest countries, predominantly sub-
Saharan Africa, and accounts for 40% of public healthcare costs.  In addition, a 2007 
World Health Organization report estimates a 1.3% decline in annual economic growth 
for countries with high rates of malarial infection.  Compounded over time, this drop 
contributes significantly to GDP disparities between those countries where malarial 
infection is endemic and those where it is not.   
 Over 100 Plasmodium species contribute to the spread of malaria, but only four of 
these (P. falciparum, P. vivax, P. ovale, and P. malariae) account for human infection, 
the deadliest being P. falciparum.  The malaria life cycle exists first in a mosquito, and 
then it passes to a human host.  An infected female Anopholes mosquito is the host of the 
parasite’s sporogonic life cycle.  Mature P. falciparum sporozoites reach the salivary 
glands of the mosquito, and the parasite is transmitted to a human host when the 
mosquito feeds.  During this blood meal, sporozoites are released into the bloodstream 
where they penetrate hepatic cells and mature into schizonts.  The liver cells rupture after 
approximately two weeks, discharging merozoites into the bloodstream whereupon they 
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infect red blood cells (RBCs).  Every 48 to 78 hours, mature merozoites rupture from 
spent RBCs and either they differentiate into gametocytes or they infect more RBCs.  
This blood stage is responsible for the clinical manisfestation of the disease.6   
 P. falciparum ingest and degrade up to 80% of host erythrocyte hemoglobin (Hb) 
to provide the parasite with essential amino acids for growth and maturation.6  During 
high parasitemia (20%), up to 100 g of the 750 g of circulating host Hb can be 
catabolized by the parasite.6   
 
 
Scheme 1  Ordered pathway of hemoglobin catabolism.  Host Hb cleavage is initiated by PfPM1 and 
PfPM2.  Hb unfolds, releases heme and exposes other peptide bonds to the falcipains.  Resultant protein 
fragments are degraded even more by falcilysin and transported to the cytosol where they are broken down 
into needed amino acids.  The heme released in the first step aggregates via biomineralization to form HZ. 
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Hb is broken down in the parasite’s acidic (pH 4.5-5.2) digestive food vacuole 
(DV) by a suite of proteinases that includes four aspartic acid proteinases (plasmepsins 
PfPM1, PfPM2, PfHAP, and PfPM4), three cysteine proteinases (falcipains PfFP2, 
PfFP2’, and PfFP3), and a metalloproteinases (falcilysin) (Scheme 1).7  This ordered 
catabolic process is initiated by PfPM1 and PfPM2, which cleave between residues 
α33Phe and α34Leu in the hinge region of Hb.  Recent quadruple knockout studies show 
individual plasmepsin redundancy and suggest that although each aspartic proteinase may 
not be essential to the intraerythrocytic stage, they could play unique roles outside Hb 
digestion.  On plasmepsin cleavage, the protein unfolds, which releases free heme and 
exposes other peptide bonds to the cysteine proteinases.  Knockout studies suggest gene 
redundancy between PfFP2 and PfFP2’, which shows no effect on parasite development 
with changes in the falcipain present.  In the complete absence of cysteine proteinases, 
however, undigested Hb accumulates in the parasite’s DV and causes lysis.  After 
falcipain cleavage, subsequent protein fragments are broken down by falcilysin.  The 
remaining peptide fragments are transported from the DV to the cytoplasm where they 
are degraded into the final amino acids needed by the parasite.7  
The French military physician Charles Louis Alphonse Laveran was credited with 
the 1880 discovery of the malaria protozoa Oscilliaria malariae, which was later termed 
Plasmodium.  In malaria necropsies, Laveran noted the presence of dark pigmented 
bodies in the bloodstream and in the brain, spleen, and liver.8  This pigmented body was 
later characterized as a unique biomineral composed of a dimeric ferriprotoporphyrin IX 
(Fe(III)PPIX) aggregate, which is known commonly as hemozoin (HZ).   
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 Although the nutritional needs of P. falciparum are met by Hb catabolism, the 
parasite is endangered by the release of heme.  During intraerythrocytic phases, free 
heme can accumulate at concentrations that reach 400 mM in the DV.  Subsequently, the 
heme can cause disruption of cellular function by the inhibition of enzymes, the 
generation of oxidative free radicals, and the peroxidation of membranes,6 which leads 
ultimately to parasite death.  Unlike higher organisms, P. falciparum lacks a heme-
oxygenase pathway for the cellular disposal of heme.  Rather, the protozoa achieves 
effective detoxification by removing the heme from solution through biomineralization 
mechanisms, which results in crystalline HZ.9   
 
Biomineralization 
 
 Over 570 million years, the complex process of organizing inorganic molecules, 
which generally contain calcium, iron or silicon, into crystal aggregates evolved as a 
protective mechanism for organisms.  Fossil records show that biomineralization surfaced 
first in the form of organism scales and skeletons during the neoproterozoic era,10 and 
now, biominerals are recognized commonly in a range of functional structures including 
shells,11 vertebrate teeth, and bone,12,13 diatom silicates14 and unicellular silver deposits.15  
The formation of these materials is attributed to two processes:  1) biologically-induced 
mineralization, which is the deposition of minerals via adventitious precipitation16 and 2) 
biologically-controlled mineralization, which is the regulated formation of minerals that 
have a specific function and structure.17  Generally, induced minerals are heterogenous in 
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character, whereas minerals that result from cellularly controlled processes exhibit 
uniform composition and morphology.3 
 The processes of crystal nucleation and growth are driven by the basic laws of 
thermodynamics in which a greater free energy must exist in the original solution phase 
than the resultant crystalline phase.18  However, it must be noted that the free energy 
distribution at the crystal surface differs from these phases.5  Since molecules on the 
crystal surface are not bound as strongly as molecules in the preliminary bulk solution, 
their free energy contribution to the system is greater.  This energy difference between 
molecules at the surface and in solution is known as the interfacial free energy.  Acting 
on the destabilization of crystal nuclei, the interfacial free energy can cause either nucleus 
dissolution or growth of the nucleus to a large enough size that its stability prevails over 
the affects of surface free energy, and a crystal is formed.  The nucleation pathways that 
lead to the most stable crystal phase are the foundations of the Ostwald-Lussac law of 
phases, which explains that nucleation occurs in a series of pathways with increasing 
stability before reaching the final crystalline state.5  The propagation and continued 
growth of a stable crystal is attributable to a uniform nucleation template from which a 
new phase is formed from an old phase that has become higher in free energy.5,19 
 In the context of crystal nucleation and growth, the formation of biominerals can 
be cast as a three-step process that involves the supermolecular preorganization of a 
template, the interfacial molecular recognition of crystal nuclei and the cellular 
processing of resultant aggregates.20  The first-order assembly of organic matrices such as 
protein and lipid networks provides a foundation for the second-order assembly of 
inorganic species.  Typically, these frameworks have functionalized surfaces that behave 
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as templates for inorganic nucleation and are governed by electrostatic, structural and 
stereochemical complementarity at the organic-inorganic interface.  Without cellular 
intervention to control the flux of metal ions, crystal nuclei would continue to grow along 
these scaffolds, proceeding to their bulk state.  Clearly, such unconstrained growth 
represents a danger to cellular integrity.  The final stage of biomineral construction is 
cellular processing, which is often the distinguishing step between native biomineral 
morphology and that of its synthetic analogs.  The intracellular or extracellular 
environment in which a crystal grows ultimately influences its crystallographic structure 
and morphology20 and ensures the function of laden cells. 
 
Search for Hemozoin’s Bionucleating Template 
 
 Investigations into the mechanisms of HZ formation have centered on protein or 
lipid-rich nucleating templates.  Early hypotheses of a catalytic heme-polymerase in 
trophozoite lysates were abandoned because of failed attempts at identification and 
purification of the enzymatic activity.  An alternative to such a heme polymerase was 
proposed by Sullivan21 from their investigations of a family of histidine-rich proteins 
(HRP) isolated from the DVs of P. falciparum.  HRPII is a 30 kDa protein with 76% of 
its composition being His or Ala residues.  HRPIII is 27 kDa and is 56% His or Ala 
residues.  Both proteins have repeats of the tripeptide Ala-His-His, 51 repeats in HRPII 
and 28 repeats in HRPIII.  This Ala-His-His recurring domain provides an archetypal 
biomineralization scaffold for the nucleation and propagation of free heme into HZ.  
When HRPII or HRPIII were incubated with heme in aqueous acetate solution, the 
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protein templates bound 17 molecules of heme, mediated the formation of HZ and was 
inhibited by the antimalarial drug chloroquine. 
 This HRP nucleating domain was explored even more by Ziegler et al.22 who used 
template design principles to construct a dendrimer-based template model system.  These 
bionucleating templates (BNT I and II) were composed of the nucleating domain of 
HRPII of P. falciparum coupled to a tetralysine dendrimer core.  The templates could 
bind to near stochiometric amounts of Fe(III)PPIX, although substrate specificity 
experiments suggested that substrate recognition was dependent on the porphyrin moiety 
rather than specific metal recognition.  Moreover, HRP substrate recognition was not 
shown to be mediated by histidine axial ligation to a metal ion, but rather it was attributed 
to π-stacking and electrostatic interactions.  Chloroquine inhibition of the bionucleating 
templates was comparable with HRP II and III impaired formation of HZ when treated 
with the antimalarial.22  
 These templates, like HRPII, were shown to promote HZ formation at a parasite 
DV relevant pH 4.0-4.5.  In fact, HRPII is active from pH 4.5 to pH 6.0.  HZ formation 
slows at pH values below 2.0 and above 5.0.23  Although an increase in pH does cause an 
increase in binding of heme to HRPII, the HZ produced actually decreases leading, 
instead, to the formation of µ-oxo-heme dimers.23  Therefore, the bis-histidyl heme 
binding observed on other proteins like histidine-rich glycoprotein (HRG) at physiologic 
pH 7.0 differs from the HRPII nucleation of HZ in the parasite’s acidic DV,24 although a 
pH 7 HRPII model was attempted by Schneider and Marletta in 2005.25  At this pH, 
binding is consistent with a nucleating template that serves as an organizing function 
rather than a tight heme-binding function. 
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 Subsequent experiments revealed, however, that the HRP’s were not the likely 
template for HZ formation.  Double deletion mutants of HRPII and HRPIII did not 
prevent the formation of HZ in the DV,21 which suggests the existence of an alternative 
template.  In addition, HRPII is not located solely in the DV, but rather it is secreted into 
the serum of victims at high concentrations.  Histology labeling experiments show that 
HRPs in the DV are simply captured during the endocytosis of host Hb and not 
specifically targeted to the DV.21  Such surreptitious colocalization would also suggest 
the existence of a non-HRP template.  In light of these experimental results, the search 
for HZ’s biomineralization template turned toward other possibilities. 
 Lipids are a possible template for HZ biomineralization.  As a bionucleating 
template, lipids can increase the solubility of Fe(III)PPIX, localize high concentrations of 
Fe(III)PPIX with iron-hydrophobic headgroup interactions and provide a layer of free 
heme intercalation.  The propionate groups of free heme within the lipid layer draw into 
their positively charged Fe(III) centers, which weakens any hydrogen bonds of 
Fe(III)PPIX dimers.  Fitch et al.26 showed that HZ formation could be mediated at pH 5.0 
in the presence of fatty acids like arachidonic acid and glycerols of oleic acid as well as 
detergents like polyoxyethylene sorbitan monooleate (TWEEN 80).  Increasing support 
for a lipid template led to the membrane sacrifice theory by Hemplemann et al.,27 which 
suggested that inner membranes of RBC transport vesicles in the parasite cytosome were 
degraded by free heme, releasing lipids that increase heme solubility and aggregation.  In 
the sacrifice of the inner membrane, the outer membrane is preserved to prevent 
additional oxidative damage to the parasite.27  In vitro lipid-initiated HZ crystallization 
was reported by Egan et al.28 using a range of lipids that includes myristoyl, oleoyl and 
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palmitoyl glycerides; phosphocholines and cholesterol to initiate HZ formation along the 
lipid-water interface.  Simulation of HZ formation in these studies indicated that the 
hydrophobic Fe(III)PPIX dimer was more stable in the lipid layer to foster hydrogen 
bonds between the protonated propionic acid groups and thus, HZ crystal assembly.28  
Transmission electron microscopy images of HZ localized in lipid nanospheres within an 
infected trophozoite stage RBC provided increased support of a lipid-mediated HZ 
bionucleating process.  The extraction of these fatty acyl glycerides (including 
monostearic, monopalmitic, dipalmitic, dioleic and dilinoleic glycerols) and their 
incubation with substrate hemin developed a competent in vitro template for HZ 
formation.29   
 
Target of Antimalarials 
 
 Interruption of the parasite heme biomineralization pathway is a logical target of 
antimalarial drug development.  As antimalarials amass in the parasite’s DV, HZ 
formation is inhibited, and the parasite becomes flooded in toxic heme.  Beginning with 
the hypothesis that neutral lipid droplets indeed serve as biomineralization templates for 
the formation of HZ, a variety of limiting cases exist in which inhibitors may disrupt the 
aggregation of HZ (Figure 1).  An inhibitor may bind the heme substrate in such a 
manner that the heme-inhibitor complex cannot be recognized by the template.  
Alternately, a drug could interact with the template, blocking the heme binding site.  
Finally, a HZ aggregation inhibitor might trap the heme bound to the template, which 
prevents formation of the dimeric unit or nucleation of the extended crystal.  These 
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possible modalities, which are derived from the paradigm of biomineral formation, can be 
used to understand the mechanism of action of some antimalarial compounds. 
 
 
Figure 1  Modes of hemozoin inhibition.  On a neutral lipid droplet template (T), heme can aggregate to 
form the biomineral HZ.  Antimalarials may inhibit this aggregation by binding heme substrate, interacting 
with the lipid template or trapping heme bound to the template.  All actions serve to prevent the formation 
of HZ. 
 
 Well-known quinoline-based drugs like chloroquine and amodiaquine are thought 
to target this HZ biomineralization pathway.  These drugs have been the standards in 
treatment of malaria, but growing parasite resistance threatens their use.  Quinoline-based 
drugs include the well-known 4-aminoquinoline derivatives chloroquine, amodiaquine, 
halofantrine, quinine and bisquinoline.30  These drugs are thought to cap monomeric 
heme or bind the μ-oxo-dimer of oxidized heme to prevent HZ formation.  The π-π 
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interactions at the { }010  heme face control resultant adduct formation.  Computational 
models of HZ and quinoline interactions indicated that drug adsorption occurred on the 
{ }001  and { }011  crystal faces (Figure 2).31  These highly symmetrical crystals also 
showed tapering at each drug-bound { }001  or { }011  ledge, which suggested weakening 
of the quinoline inhibition along the crystal’s c-axis which resulted in thinner crystal 
cross-sections.31 
  
 
Figure 2  Hemozoin-chloroquine binding model.  Chloroquine is thought to bind to the { }001  and { }011  
faces of heme as well as π-π stacking at the { }010  face.  To prevent HZ formation completely, chloroquine would 
have to bind both faces of each heme monomer or crystal extension would be blocked in only one direction as shown. 
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Other inhibitors of HZ formation are thought to act similarly to the quinoline 
family.  Binding of the antifungal azole-based drugs (clotrimazole, ketoconazole and 
miconazole) to heme is thought to damage parasite cell membranes and cause death.30  
The isonitrile terpenes (diisocyanoadociane and axisonitrile-2), isolated from marine 
sponges and the synthetically derived methylene blue analogs (azures A, B and C; thion; 
celestine blue; and phenosaphranin) most likely prohibit HZ formation by binding 
monomeric heme.  The xanthone family of antimalarials, such as the hydroxyxanthones 
and the bis-(N,N-diethylamino)-ethoxy xanthones, were found also to bind at the HZ 
crystal faces { }001  and { }011 .  Specifically, the drugs’ terminal groups bind the carboxyl 
group exposed at each face, which inhibits the nucleation and growth of the crystal.31  
The crystal engineering prospect of future drug design is an interesting one that beckons 
additional exploration and promises applications in a variety of biomineral-associated 
diseases. 
 
Hemozoin Characterization 
 
 Prior to the definitive X-ray powder diffraction characterization of HZ, the true 
structure of the aggregate remained elusive because of its limited solubility.  HZ was 
soluble only in NaOH, which completely degraded the structure and prevented any 
attempt to determine the intramolecular atomic interactions.  The insolubility of the 
product rendered useless many “standard” experimental methods for the characterization 
of bioinorganic systems.  This aspect of the biomineral’s identification undoubtedly 
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contributed to Ridley’s description of HZ as “a black insoluble mass of material that can 
be soul-destroying to work with”.32 
 Studies by Slater et al.33 provided an initial “fingerprint” of HZ’s chemical 
structure by applying Fourier-transform IR (FT-IR) spectroscopy to intact HZ crystals.  
The IR spectrum of HZ revealed intense absorbance patterns at 1664 and 1211 cm-1, 
which indicate the axial propionate C=O and C-O stretching, respectively (Figure 3A).  
These peaks were absent from the spectra of the synthetic substrates hemin chloride and 
hematin.  These data suggested a direct coordination between the carboxylate of one 
heme monomer and the iron center of another, which rules out a direct iron-carbon bond 
that would have characteristic stretching near 1900 cm-1.  Imagining a long carboxyl-
propagated “polymer,” this structure accounted for the aggregate’s insolubility. 
 Using field emission inlens scanning electron microscopy, gross physical analysis 
of isolated HZ crystals obtained from mammalian Plasmodium species show a uniform 
morphology that resembles smooth-sided bricks arranged at right angles.34  Unlike the 
smooth, flat sides of the aggregates, the crystals’ tapering, square ends indicate a face of 
continuous nucleation and growth.  The average dimensions of these crystals were 100 
nm x 100 nm x 300-500 nm.  Even strains of P. falciparum that lack HRPII or HRPIII 
were shown to produce uniform HZ crystals.34  This observed consistency in morphology 
is caused by the final step of in vivo biomineralization, which is cellular processing.  In 
this stage, cells organize HZ crystals to best fit the confines of their storage vacuole as 
illustrated in an in situ HZ RBC electron micrograph image (Figure 3C).24  This differs 
from the seemingly less-ordered in vitro production of HZ’s synthetic analog, which is 
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known as β-hematin (BH), in a reaction vessel, which fosters continued crystal extension 
without cellular restraint (Figure 3D).  
 
 
Figure 3  Physical characterization of hemozoin.  (A) The axial propionate linkages between heme units 
in HZ are seen by FT-IR fingerprints of C=O and C-O stretching at 1664 and 1211 cm-1, respectively.  (B) 
Characteristic 2:1 peaks are seen at 7°: 21° and 24° 2θ for (i) native and (ii) synthetic HZ.  Absent from 
these aggregates is the 23° 2θ peak observed in the diffraction pattern of (iii) substrate hemin chloride.  (C) 
Electron micrograph of HZ in P. falciparum infected RBC where (i) is the host RBC, (ii) is the parasite and 
(iii) is the DV.  Image courtesy of Daniel E. Goldberg.  (D) SEM image of uniform BH crystals. 
  
 The introduction of high-resolution synchrotron X-ray radiation enabled the X-ray 
powder diffraction of both native HZ and BH.  Their structure was determined using 
simulated annealing techniques on the diffraction data.35  This method included the use of 
the Le Bail algorithm to compare integrated peak intensities, the Rietveld refinement of 
the structure’s molecular bonding geometry and Fourier difference calculations of atomic 
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positions.  The resultant diffraction pattern confirmed a triclinic unit cell with a space 
group of P-1, which demonstrates an inversion of symmetry between the unit cells of the 
Fe(III)PPIX dimer (Figure 3B).  This pattern led to the definitive structure of a five-
coordinate Fe(III)PPIX dimer bound by reciprocal monodentate carboxylate interactions 
with the propionic side chains of each PPIX.  Hydrogen bonding between these heme 
dimers accounted for the aggregate’s stable, extended crystalline network.  Importantly, 
this work established that HZ and BH were crystallographically, chemically and 
spectroscopically identical.35  
 
Identification of Native Lipid Components of Hemozoin 
 
 In vivo native HZ transmission electron microscopy images from trophozoite-
infected RBCs depicted the localization of HZ crystals within neutral lipid nanospheres.29  
Trophozoite DVs were isolated using Percoll/sucrose bottom separation techniques, and 
the lipid content of these isolates was extracted by Bligh-Dyer (chloroform/methanol) 
lipid extraction.  Methyl ester fatty acid characterization by gas chromatography-MS 
(GC-MS) and lithium (Li+) adduct electrospray ionization mass spectrometry of 
trophozoite fractions revealed a suite of neutral lipids adhered to the crystal’s surface.  
When these lipid extracts (a ratio of 4 monostearic-: 2 monopalmitic-: 1 dipalmitic-: 1 
dioleic-: and 1 dilinoleic glycerol) were incubated in the presence of substrate hemin, HZ 
formation was observed.29  This competent nucleating template of fatty acyl glycerides is 
consistent with the hypothesis of a lipid scaffold for heme aggregation in P. falciparum. 
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 Also extracted from native HZ were polar hydroxylated fatty acids derived 
presumably from cellular arachidonic and linoleic acids.  Native HZ was purified from 
infected RBCs by a series of centrifugation steps followed by organic extraction of its 
lipid coat.  Analysis of the lipid coat revealed the presence of hydroxylated 
polyunsaturated fatty acids.  These polar lipids were separated using reverse phase-, 
normal phase- and chiral phase high performance liquid chromatography and 
subsequently examined by GC-MS.  Native HZ lipid coat GC-MS analysis revealed the 
presence of 15-, 12-, 11-, 9-, 8- and 5-hydroxyeicosatetraenoic acids (HETEs) as well as 
13- and 9-hydroxyoctadecadienoic acids (HODEs).36 
  
Chemical Reactivity and Immunomodulation 
 
 Native HZ produced in the parasite DV most likely encounters cellular debris 
such as arachidonic and linoleic fatty acids or other lipids when released from a bursting 
RBC.  Redox cycling of surface exposed heme units within HZ can lead to the initiation 
of lipid peroxidation (LPO).  Abstraction of a bisallylic hydrogen atom from a fatty acid 
such as arachidonic acid results in an unpaired electron on the methylene carbon.37  This 
unpaired electron promotes the rearrangement of the double bonds adjacent to the 
methylene group that produces an alkyl radical (L•).  In the presence of oxygen, alkyl 
radicals react to form peroxyl radicals (LOO•) that can abstract a hydrogen atom that 
yields a lipid peroxide (LOOH) and can propagate more reactions.  Reduction of the 
peroxyl radical would result in the production of racemic mixtures of hydroxylated fatty 
acids like the HETEs and HODEs described previously in the HZ lipid coat.  Secondary 
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oxidation and chain β-cleavage results in reactive 4-hydroxy-2-nonenal (HNE) (Scheme 
2). 
 
 
Scheme 2  Hemozoin-mediated lipid peroxidation.  Redox cycling of iron in complexes like HZ can 
initiate lipid peroxidation of fatty acids like arachidonic acid (LH).  Abstraction of the bisallylic hydrogen 
leaves an unpaired electron on the methylene carbon that can rearrange to form a reactive alkyl radical (L•).  
Oxidation of this radical leads to a peroxyl radical (LOO•), and upon reduction, forms a lipid peroxide 
(LOOH) that can undergo additional reactions to yield a variety of secondary oxidation products. 
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 Lipid peroxidation was demonstrated in vitro by reacting arachidonic acid with 
native HZ purified of all cellular lipid and protein content.38  Resultant HETE products 
were extracted from the reaction supernatant and identified using reverse phase high 
performance liquid chromatography.38  Recent studies of BH reactions with arachidonic 
acid revealed an identical reaction profile to that of HZ with all six positional HETE 
isomers identified by ultra high pressure reverse phase and chiral phase liquid 
chromatography tandem MS/MS (chiral-RP-LC-MS/MS).39  LC-MS analysis has enabled 
the separation and identification of these cellular metabolites at femtomole levels of 
detection.  The presence of these oxidation products in the lipid coat of native HZ and 
their formation upon arachidonic acid incubation with purified HZ and BH strongly 
supports the HZ-mediated LPO of cellular fatty acids.  Additionally, the known 
immunomodulatory activity of these lipid peroxidation products is intriguing given the 
reported ability of HZ to disrupt the function of innate immune cells. 
 Once thought to be a simple “inert” detoxification biomineral, an increasing 
appreciation exists of HZ’s reactivity and subsequent perturbation of the host immune 
response.  HZ reactivity in the modulation of innate and adaptive immunity has been 
attributed to a range of effects that include toll-like receptor 9 (TLR9) activation, 
cytokine production, LPO and dendritic cell development.  Recent studies found that the 
P. falciparum DNA that remained on native HZ extracts was the true source of TLR9 
activation, and once native HZ was treated with nuclease, no activation was observed.40  
HZ disruption of dendritic cell function was shown to cause a decline in T cell activation 
that led to a weakened adaptive immune response.  The role of HZ as an immunoreactive 
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aggregate may impact the high rates of patient secondary infection as well as the decline 
in vaccine efficacy. 
 Functionally, phagocytosis of HZ has been reported to impair macrophage 
oxidative burst, to downregulate inducible nitric oxide synthase (iNOS) activation, and to 
perturb cytokine profiles in infected patients.  It has also been shown to correlate with 
increased levels of immunomodulatory LPO products such as prostaglandin E2 (PGE2), 
HNE and HETEs in monocytes.41  The biologic activity of these compounds is generally 
derived from either of two mechanisms.  In the first mode of action, the reactive 
intermediates or products may form adducts to DNA or proteins.  Thus, a variety of 
chain-terminating reactions of peroxyl, alkoxyl or epoxyperoxyl radicals can result in 
oxidative cross-links to DNA or proteins.  Furthermore, the electrophilic alkenals, such as 
HNE, readily form Schiff-base adducts to lysine residues and Michael addition adducts to 
histidine and cysteine residues to perturb the function of many proteins.42  In the second 
mode of action, the LPO products may act as alternate ligands to several different 
proteins and receptors to initiate an ultimately pathogenic signaling cascade.  The 
hydroxylated fatty acids 9- and 13-HODE, as well as 15-HETE, have all been found to be 
activators of the important nuclear receptor protein PPAR-γ, which is involved in key 
cellular regulatory and differentiation functions in monocytes.43  15-HETE has also been 
found to stimulate RBC adherence to capillary endothelia, to enhance vascular 
permeability and edema and to induce chemotaxis and chemokinesis, although the precise 
pathways remain unclear.  From these examples, it is easy to imagine how such 
promiscuous reactivity often manifests itself in the pathogenesis of disease states.  These 
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findings suggest that HZ’s ability to rectify cellular responses may actually be caused by 
formation of primary and secondary LPO products.41 
 To study this hypothesis, BH was incubated with ghost RBC membrane lipids, 
which are similar to those that the native biomineral would be exposed to upon RBC 
rupture.41  RAW macrophage-like cells were treated with the supernatant of this reaction, 
and reactive oxygen and nitrogen species (ROS and RNS) produced via the NADPH 
oxidase and iNOS pathways were inhibited.  The levels of inhibition paralleled the effects 
of individual LPO products such as 15-HETE or HNE at pathologically reported 
concentrations.  Additionally, treatment of cells with either BH or unreacted ghost 
supernatant did not cause a decrease in ROS and RNS production, which indicates that 
the products of HZ-mediated LPO were responsible for the observed disruption of 
macrophage function, not the dimeric heme component of the aggregate itself.41  
Mechanisms for such malarial host-pathogen interactions and, more broadly, biomineral-
to-cell relationships are primarily undefined, which creates a significant treatment barrier.  
Unraveling the formation and role of HZ in the pathogenesis of P. falciparum infection 
may provide additional insight into the prevention and treatment of a variety of diseases 
that result from pathogenic biominerals. 
 
Conclusions 
 
 Biomineralization results in an expansive array of complex materials.  These 
natural biominerals often represent unique crystal forms that extend over several size 
domains that are synthesized under ambient conditions.  Increasingly, it is understood 
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that biomineralization processes play important roles in the pathologies of several 
diseases.  In malaria, the parasite forms the HZ biomineral in response to the heme 
released during hemoglobin catabolism.  HZ serves an important detoxification role that 
allows the organism to maintain homeostasis during its intraerythrocytic phases.  Despite 
the fact that HZ represents a validated drug target for P. falciparum, many fundamental 
questions remain concerning its formation; questions such as how or if the parasite 
assembles neutral lipid droplets specifically, how the heme is transported and deposited 
in these lipid domains, and whether new strategies exist that could be used to design 
drugs to disrupt this process.  Tackling the rational drug design problem from a crystal 
engineering perspective offers an interesting direction for drug discovery, whether 
designing crystal-specific antibodies or fabricating selectively binding compounds.  
Consequently, studies on the in vivo formation of HZ afford an opportunity for chemists 
with a variety of interests (e.g., organic, inorganic, biologic, supramolecular, materials) to 
make significant contributions in attacking this neglected and devastating disease. 
 A second, emerging area of research is the pathophysiologic responses between 
biominerals and immune cells.  A commonality between the diseases that maintain a 
pathogenic biomineral is the inflammatory response.  Be it an autoimmune reaction, as in 
the case of gout, or down-regulation of the innate immune system as in malaria, it is clear 
that the interface between biominerals and cells is important in mitigating these 
responses.  In the case of HZ, growing evidence suggests that the biomineral reacts with 
cellular fatty acids to produce a suite of reactive oxidized eicosanoids.  The 
immunoreactivity of these oxidation products is likely a significant contributor to the 
inflammation and discomfort experienced by patients.  Developing therapies for these 
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effects and for the cause of infection could provide a dual approach in the treatment of 
many pathogenic biominerals and proffers the potential for novel initiatives in disease 
prevention and treatment. 
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CHAPTER II 
 
IDENTIFICATION OF HYDROXYEICOSATETRAENOIC ACID COMPONENTS OF 
SCHISTOSOMAL HEMOZOIN39,44 
 
 Schistosomiasis is a parasitic disease that chronically infects over 200 million 
people in 74 countries and is responsible for more than 200,000 deaths each year.45-47  
Based on recent reports, schistosomiasis ranks second only to malaria as a cause for 
chronic morbidity among tropical diseases.48  Parasitic infection by Schistosoma mansoni 
occurs via a complex digenetic life cycle.  In order to obtain requisite amino acids for 
growth and development, the blood fluke catabolizes host Hb from RBCs.  Adult female 
schistosomes consume an estimated 330,000 RBCs per hour.49  Erythrocytic Hb is broken 
down by proteolytic enzymes in the gut releasing significant quantities of potentially 
toxic free heme.50  To avoid these cytotoxic effects,38,51 blood feeding organisms have 
developed novel mechanisms for heme detoxification. 
 In the protozoan P. falciparum, toxic free heme accumulates in the DV and is 
sequestered by aggregation into an inert crystalline pigment, HZ.52  S. mansoni appears to 
employ a similar heme detoxification pathway.  During Hb catabolism in the digestive 
cavity of the trematode, free heme aggregates, and the subsequent pigment is regurgitated 
by the parasite into the surrounding host vasculature.  This dark-brown pigment was 
recently characterized by Oliveira and coworkers as being structurally identical to P. 
falciparum HZ (PfHZ) and its synthetic analogue BH.53,54 
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 HZ has long been considered an inert, detoxification end-product, but recent 
studies suggest that native PfHZ is capable of modulating host immunity.  Schwarzer and 
coworkers showed that phagocytosis of native PfHZ by human monocytes disrupts the 
normal cellular function of professional phagocytes.36,55  The accumulation of native HZ 
in circulating monocytes and neutrophils inhibits normal phagocytic function by inducing 
oxidative stress and down-regulating intercellular mechanisms that generate potent 
oxidative molecules used to defend against foreign invaders, namely ROS and RNS.56  
Furthermore, HZ has been shown to induce lipid peroxidation of polyunsaturated fatty 
acids (PUFAs) resulting in the formation of potentially cytotoxic and immunomodulatory 
molecules including HETEs36,38,57 and HNE.58,59  Consequently, HZ-mediated production 
of arachidonic acid (AA) metabolites, such as HETEs and HNE, are of significant interest 
in schistosomiasis since that role of HZ in the disease’s pathogenesis remains largely 
unexplored. 
 
Experimental 
 
β-Hematin synthesis.  BH was synthesized via dehydrohalogenation of hemin, as 
described by Bohle.60  The reaction vessel was sealed, protected from light and stood 
undisturbed for three months.  The resulting mixture was filtered, and the precipitate was 
washed exhaustively with methanol, 0.1 M sodium bicarbonate (pH 9.1) and deionized 
water.  The purified product was dried under vacuum at 150°C for 48 h and stored under 
dessicant. 
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SmHZ isolation.  Adult schistosomes were obtained by mesenteric perfusion of 
mice 42 days post-infection.61  Cultivated adult female worms were homogenized in 
phosphate buffered saline (PBS, pH 7.4) using a 15 mL glass homogenizer.  Homogenate 
was centrifuged twice at 1000 x g for 60 s, and the tissue pellet was discarded.  The 
supernatant was centrifuged 2 h at 5445 x g.  The resulting dark-brown pellet was 
resuspended in 5 mL sterile PBS after vortexing and gentle sonication for 5 min.  SmHZ 
recovery was quantified as described by Sullivan et al.62 with 20 mM NaOH, 2% SDS at 
25°C for 2 h.  Heme content was determined from absorbance at 400 nm ( 5101×=ε M-1 
cm-1) using an Agilent 8453 UV-Visible Spectrophotometer. 
Native SmHZ lipid extraction.  The native SmHZ lipid component was extracted 
twice from 2.5 mg/mL native SmHZ in 25 mM chelexed-phosphate buffer (pH 7.4) using 
1:1 (v/v) ethyl acetate.  The emulsion was vortexed 60 s and centrifuged 30 min at 5445 x 
g.  The organic layer was removed and evaporated under nitrogen.  The lipids were 
reconstituted in 1 mL of ethanol and stored at -80°C. 
In vitro HZ-mediated HETE production.  Purified native SmHZ, complete 
removal of lipids confirmed by NP-HPLC, was used in these experiments.  The reaction 
was performed by adding 5.32 mM AA to a 2 mL suspension of either SmHZ or BH (0.3 
mg/mL) in 25 mM chelexed-phosphate buffer (pH 7.4) for 4 h at 25°C.  Reaction 
products were extracted with ethyl acetate and stored in ethanol at -80°C. 
LC-MS/MS HETE identification.  HETE standards and lipid samples were dried 
under nitrogen and resuspended in acetonitrile/water (30:70), 10 mM ammonium 
carbonate and 0.1 M BHT prior to injection.  The LC-MS/MS analysis was performed on 
a Waters Acquity UPLC system (Waters, Milford, MA) connected to a Thermo Fisher 
  27
Scientific, Waltham, MA) using a Thermo Hypersil Gold C18 column (1.9 µm, 2.1 x 150 
mm).  LC conditions were as follows:  solvent A contained 10 mM ammonium carbonate 
in acetonitrile/water (10:90) and solvent B contained 10 mM ammonium carbonate in 
acetonitrile/water (10:90).  The following gradient program was used with a flow rate of 
600 µL/min:  0-0.25 min, 30% B; 0.25-9 min, linear gradient 30-45%; 9-10 min, 45% B; 
10-10.50 min, linear gradient 45-30% B; 10.50-17 min, 30% B.  Sample injection volume 
was 10 µL.  The following optimized parameters were used for the detection of analyte 
and internal standard:  N2 sheath gas 36 psi; N2 auxiliary gas 20 psi; capillary temperature 
300°C; source voltage 3.8 kV; source current 100 µA; skimmer offset 0.00 V; capillary 
offset -44.00 V; tube lens offset -103.30 V; activation time 30 ms (MS), 50 ms (MS2); 
isolation width 1 m/z (MS), 2 m/z (MS2).  Data acquisition and quantitative spectral 
analysis was conducted using the Thermo-Finnigan Xcaliber software, version 2.0 Sur 1. 
LC-MS/MS chiral separation.  Normal phase LC (NP-LC) analysis was 
performed prior to chiral RP-LC-MS/MS in order to isolate HETE isomers for individual 
analysis.  The NP-LC was performed on a Waters 600 HPLC connected to a Waters 996 
photodiode array (Waters, Milford, MA) using a Beckman Ultrasphere silica column (5 
µm, 4.6 mm x 25 cm; Beckman Coulter, Fullerton, CA).  An isocratic gradient of 98.8% 
hexane, 1.2% isopropanol and 0.1% acetic acid was used at a flow rate of 1.00 mL/min.  
HETE absorbance was detected at 237 nm. 
Chiral-RP-LC-MS/MS.  The LC-MS/MS analysis was performed as before using 
a CHIRALPAK AD-RH column (5 µm, 2.1 mm x 150 mm; Chiral Technologies, Inc., 
West Chester, PA).  LC conditions were as follows:  solvent A contained 0.25% formic 
acid in acetonitrile/water (5:95) and solvent B contained 0.25% formic acid in 
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acetonitrile/water (95:5).  The following gradient program was used with a flow rate of 
200 µL/min:  0-5 min, 50% B; 5-20 min, linear gradient 50-100% B; 30-32 min, 50% B.  
The following optimized parameters were used for the detection of analyte and internal 
standard:  N2 sheath gas 36 psi; N2 auxiliary gas 20 psi; capillary temperature 300°C; 
source voltage 3.8 kV; source current 100 µA; skimmer offset 0.00 V; capillary offset -
44.00 V; tube lens offset -103.30 V; activation time 30 ms (MS), 50 ms (MS2); isolation 
width 1 m/z (MS), 2 m/z (MS2).  Data acquisition and quantitative spectral analysis were 
conducted using Thermo-Finnigan Xcaliber version 2.0 Sur 1. 
iNOS inhibition.  Effects of 5-, 12- and 15-S-HETE, HNE and SmHZ on LPS-
stimulated iNOS activity in RAW 264.7 cells ( 5101× cells/well in 96-well culture plates 
at 37°C in 5% CO2 for ≥8 h) was examined.  Cell viability was confirmed using Trypan 
Blue exclusion.  Stock solutions of 5-, 12- and 15-S-HETE were prepared by evaporating 
each 100 µg vial to near dryness under nitrogen and reconstituting in RPMI complete 
medium (ethanol concentrations below 0.5%).  Additionally, 0.1 mg/mL stock solutions 
of native SmHZ, BH and 17.5 µM HNE were prepared in RPMI complete medium.  
Following stock solution treatment in the presence of LPS (1 µg/mL), cell cultures were 
incubated at 37°C in 5% CO2 for 24 h.  The Griess reaction was used to measure nitrite 
concentration.63  Absorbance of the resultant azo complex was measure at 540 nm using a 
Bio-Tek Synergy HT Multidetection Microplate Reader. 
SEM.  Dry purified SmHZ was suspended in ethanol, sonicated for 10 min, 
applied to a polished aluminum specimen mount and dried at 25°C overnight.  Each 
sample was sputter-coated with gold for 20 s and imaged using a Hitachi S4200 scanning 
electron microscope at 5.0 kV accelerating voltage. 
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Results and Discussion 
 
 Schistosomal pigment (SmHZ) is typically found accumulated in resident tissue 
macrophages of the liver.  Adult worm pairs reside in the hepatic portal system of the 
host and regurgitate hemozoin and cellular debris into the surrounding vasculature.  Adult 
female worms exhibit a much heavier degree of pigmentation relative to males due to the 
nutritional demands of oogenesis (Figure 4A).  Following perfusion of the hepatic portal 
vein in S. mansoni-infected Swiss Webster mice, adult female and male worms were 
separated, counted and homogenized to determine SmHZ burden per worm as previously 
described.62  On average, adult females were found to accumulate 1.729 ± 0.29 µg of 
hemozoin while the adult males were found to amass only 0.114 ± 0.07 µg per worm.   
 
 
Figure 4  Hemozoin from S. mansoni.  (A) Adult female (left) and male (right) S. mansoni laden with 
hemozoin.  Female worms accumulate a heavier hemozoin burden, as seen by their darker pigmentation, 
due to the nutritional demands of oogenesis.  (B) SEM image of schistosomal hemozoin isolated from 
homogenized S. mansoni. 
 
Isolated SmHZ was purified and characterized using X-ray powder diffraction 
(characteristic 2:1 intensity of the signature 2θ peaks at 7°: 21° and 24°) and Fourier 
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transform infrared spectroscopy (1664 and 1211 cm-1 of C=O and C-O stretching) 
confirming a dimeric ferriprotoporphyrin IX aggregate identical to PfHZ and BH (Figure 
5).  While PfHZ and BH SEM images portray a biomineral of elongated rectangular 
crystals with well-defined crystal facets, SmHZ images depict the characteristic 
heterogeneous morphology and large size distribution often attributed to the extracellular 
environment of HZ formation in S. mansoni (Figure 4B).54   
 
 
Figure 5  IR and XRD of HZ.  (A) The presence of axial propionate linkages in HZ’s  dimeric 
ferriprotoporphyrin IX structure was confirmed using infrared spectroscopy showing the C-O stretching at 
1211 cm-1 and C=O stretching at 1664 cm-1.  (B) Characterization by powder x-ray diffraction (Cu Kα 
radiation) reveals the 2:1 intensity of 2θ peaks at 7˚: 21˚ and 24˚.  Reduced peak distinction compared to 
BH in SmHZ pattern is attributed to limited sample size. 
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 The nature and function of the lipid environment surrounding the heme aggregate 
of native HZ is complex.  In a recent study, transmission electron microscopy (TEM) 
showed the localization of SmHZ at the hydrophilic-hydrophobic interface of lipid 
droplets in the S. mansoni gut lumen.64  Similarly, Pisciotta and coworkers extracted a 
suite of neutral lipids coating native HZ from the digestive food vacuole of P. 
falciparum.29  In both cases, the lipid extracts provided a competent scaffold for 
hemozoin formation in vitro.29,64  Polar hydroxylated fatty acids derived from arachidonic 
and linoleic acids have also been extracted from native PfHZ, as has the secondary 
oxidation product HNE.36,38,59  These compounds have been shown to be capable of 
significantly altering the function of macrophage cells during the course of malarial 
infection.   
 
 
Figure 6  HETE-containing lipid coat of native SmHZ.  (A) Lipids were extracted from native SmHZ 
using ethyl acetate, blown dry under N2(g) and redissolved in RP-LC-MS/MS mobile phase.  All six 
hydroxylated fatty acid derivatives of arachidonic acid were identified (15-, 11-, 12-, 8-, 9- and 5-HETE).  
Insert shows the representative chiral resolution for 15-HETE (11.5 min. R and 14.5 min. S).  (B) 
Representative MS/MS fragmentation for 12-HETE.  All isomers were confirmed using authentic standards 
and extracted ion profiles from MS/MS. 
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 To investigate the presence of biologically active AA metabolites in native SmHZ, 
the hydroxylated fatty acid component of native SmHZ was isolated and analyzed by 
liquid chromatography-tandem mass spectrometry (LC-MS/MS).  The identification of 
each HETE positional isomer peak was achieved using time dependent MS/MS in which 
the isobaric carboxylate [M-H]-, 319 m/z, precursor ion was trapped and subsequently  
 
 
Figure 7  Extracted ion profile of SmHz lipid coat.  The identification of all six positional isomers of 
HETE in the SmHz lipid coat was achieved by extracting the characteristic MS/MS fragment masses of 
each isomer from the collected 319 m/z reverse-phase-LC-MS ions.  Individual isomers from the total ion 
chromatogram (A) of the SmHz lipid coat are shown:  (B) 15-HETE at 6.16 min., (C) 11-HETE at 7.04 
min., (D) 12-HETE at 7.19 min., (E) 8-HETE at 7.99 min., (F) 9-HETE at 8.10 min. and (G) 5-HETE at 
9.42 min.  Characteristic MS/MS fragments were confirmed using authentic HETE standards. 
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fragmented to give product ions of each HETE isomer (Figure 6).  All six HETE 
positional isomers derived from AA were observed in the SmHZ lipid extract, with the 
most abundant species being 15-, 12- and 5-HETE ([M-ROH]-: 219, 179 and 115 m/z, 
respectively) (Figure 7).  In contrast to previous HETE identifications in hemozoin 
producing parasites,36 the LC-MS/MS method presented herein is a marked advancement  
 
 
Figure 8  Chiral-RP-LC-MS/MS of SmHz lipid coat.  R and S HETE enantiomers were separated using 
chiral-reverse-phase-LC-MS/MS (R- and S-HETE retention times shown in figure key).  Each HETE 
isomer was identified by its characteristic MS/MS fragment masses as determined from authentic HETE 
standards.  A 1:1 ratio was observed for all HETE enantiomers with the exception of 12-HETE which 
exhibited a 70:1 distribution of 12-S-HETE to 12-R-HETE. 
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including MS/MS confirmation of all identified HETEs during separation and an 
increased instrument sensitivity reaching the femtomole range.  Such a limit of detection 
is especially important when working with the extracted lipids of limited native HZ 
samples, as is the case of S. mansoni yields from Swiss Webster mice (1 mg SmHZ/ 60 
mice).   
Chiral purity of biologically derived hydroxylated fatty acids is typically 
attributed to the lipoxygenase (Lox) family65-72 with preference usually shown for S-
stereo-isomer products.  In the absence of Lox, however, free radical-mediated 
peroxidation of AA can yield a racemic mixture of each hydroxylated isomer.  Given the 
presence of all six HETE isomers in the SmHZ lipid coat, additional chiral analysis was 
performed to examine the enantiomeric chiral analysis was performed to examine the 
enantiomeric distribution of the monohydroxy derivatives.  Chiral LC-MS/MS of the 
SmHZ lipid extract revealed an equivalent stereoselective distribution of all HETEs with 
the exception of 12-S-HETE (Figure 8).  Based on integrated peak area, a 70:1 abundance 
of 12-S-HETE to 12-R-HETE was observed suggesting accumulation of enzymatically 
produced HETE.  This is in marked contrast to the equivalent stereoisomeric ratios 
observed for the 12-HETEs in the lipid coat of PfHZ.36  Previously, murine host 12-Lox 
activity has been described in the immunomodulation of schistosomiasis.73,74  Three types 
of murine 12-Lox (epidermal-, leukocyte- and platelet-type 12-Lox) have been reported, 
but none of these were observed in a recent proteomic analysis of gut contents from S. 
mansoni.73,75  In S. mansoni, only the activity of a 15-S-Lox has been reported, although 
sequence analysis of the partially sequenced S. mansoni genome76 suggests the possible 
presence of a 12-S-Lox gene.  Regardless of the origin of the observed 12-S-HETE, the 
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racemic mixture of all other HETE isomers is indicative of HZ-mediated lipid 
peroxidation of fatty acids. 
 In order to confirm the expected HZ-driven lipid peroxidation of fatty acids, in 
vitro, reactions of AA incubated with either purified SmHZ or BH were performed under 
aerobic conditions.  The resultant oxidized lipids were extracted and characterized by RP- 
and chiral-LC-MS/MS.  Relative to AA controls, both purified SmHZ and BH produced 
significant quantities of the six HETE positional hydroxylation isomers, with 15- and 5-
HETE as the most prominent (Figure 9-11).   
 
 
Figure 9  Hemozoin-mediated lipid peroxidation of arachidonic acid.  Oxidation studies by incubation 
of 0.3 mg/mL BH or SmHZ with 5.32 mM AA were conducted.  The hydroxylated fatty acid isomers 15-, 
11-, 12-, 8-, 9- and 5-HETE were identified in the reactions’ lipid extracts using RP-LC-MS/MS.   
 
 
These findings are in good agreement with earlier literature concerning the reactivity of 
both purified PfHZ and BH.38,77  Upon subsequent chiral analysis, the positional HETE 
isomers were separated with a stereoselective ratio of nearly 1, suggesting no preferential 
stereochemical orientation of the substrate during oxidation.  As expected, the 
stereoselective bias for 12-S-HETE seen in the native SmHZ lipid coat was absent in the 
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reaction of either purified SmHZ or BH with AA.  Taken together, these results 
demonstrate that SmHZ mediated peroxidation of PUFAs is the likely source for the 
 
Figure 10  Extracted ion profile of HETEs from the BH-AA reaction.  All six positional isomers of 
HETEs were extracted and confirmed by MS/MS from the BH-AA reaction.   
 
 
enantiomeric population of observed HETE isomers in the lipid coat. 
 Lipid metabolites have been shown to elicit immunomodulatory effects ranging 
from impairment of both PMA-stimulated oxidative burst and nitric oxide (NO) 
production in macrophages to altering endothelial cell permeability and initiating 
chemotaxis.36,41,78  Investigation of the HETE isomers’ individual effects on macrophage-
like cell function following LPS challenge revealed that the predominate 5-, 12- and 15-
S-HETEs impaired NO production in a dose-dependent manner (Figure 12A).  12-S-
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HETE was the most potent inhibitor of iNOS, attenuating NO production by 50%.  The 
immunosuppressive activity of native SmHZ’s hydroxylated fatty acids suggest that 
 
Figure 11  Extracted ion profile of HETEs from the SmHZ-AA reaction.  All six positional isomers of 
HETEs were extracted and confirmed by MS/MS from the SmHZ-AA reaction. 
 
phagocytosis of native SmHZ by resident macrophages may partially disrupt the innate 
immune response.  In fact, further study revealed a 25% reduction in NO production in 
lipid-coated SmHZ-laden macrophages relative to control experiments, implicating native 
SmHZ as a biologically active agent (Figure 12B). 
The lipid coat of native SmHZ is a complex mixture of both neutral lipids and 
PUFA peroxidation products.  Previous analysis of the neutral lipids revealed the 
presence of monopalmitic-, monostearic-, dipalmitic-, dioleic- and dilinoleic glycerols.29 
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A      B 
         
Figure 12  Impact of native SmHZ and components on iNOS activity.  (A) RNS production in 
macrophage cells monitored following treatment with increasing concentrations of (●) 15-, (■) 12- and (▲) 
5-S-HETE by the Griess assay.  (B) Cells were treated with 0.1 mg/mL BH or SmHZ, as well as 40 µM 15-
S-HETE or HNE.  The activity of cells stimulated with LPS was used as a control. 
 
    
Conclusions 
 
Herein, the composition of the arachidonate metabolites has been determined to consist 
of an enantiomeric mixture of all positional hydroxylated isomers with 15-, 12- and 5-
HETE as the dominant species.  These findings are consistent with HZ-mediated lipid 
peroxidation of host arachidonate.  Additional chiral analysis revealed an accumulation of 
a biologically derived 12-S-HETE of an unknown origin.  When the immunosuppressive 
activity of native SmHZ and its major HETE components was examined in macrophage-
like cells, iNOS activity was impaired.  Further exploration of this unique biomineral’s 
composition and its ability to modulate host immunity is crucial in developing a better 
understanding of the possible role of hemozoin in the host-pathogen interactions 
involving S. mansoni. 
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CHAPTER III 
 
IMMUNOMODULATORY ACTIVITY OF HEMOZOIN41,79 
 
 The most common and deadly form of the malaria parasite, Plasmodium 
falciparum, is responsible for 1.5-2.7 million deaths and 300-500 million acute illnesses 
annually.80,81  These statistics combined with the development of drug-resistant parasitic 
strains and vectors place a multibillion dollar annual burden on precisely those 
populations least capable of shouldering it.81-83  According to the World Health 
Organization,81 malaria is considered to be one of the major public health challenges 
responsible for inhibiting development in underdeveloped regions of the world side by 
side with HIV/AIDS and tuberculosis.  Consequently, despite its absence in the 
developed world, malaria represents a significant global health issue.  Historically, the 
disease was thought to stem from fetid marshes and was thus named mal aria, literally 
bad air.81  In truth, malaria is a parasitic disease of the genus Plasmodium that is 
transmitted to humans through the bite of an infected female Anopheles mosquito.  The 
parasitic lifecycle inside the host is complex, and it is the intraerythrocytic stage that is of 
interest herein.   
During this stage, nourishing amino acids are acquired when hemoglobin is 
catabolized within the acidic lysosome known as the digestive food vacuole (DV).84  As a 
result, toxic free heme is released as well, and its accumulation leads to lipid 
peroxidation,38 DV protease inhibition, oxidized free radicals85,86 and finally, parasite 
lysis.87  Therefore, the parasite has evolved a detoxification pathway leading to the 
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aggregation of heme into the insoluble biomineral known as hemozoin.88  When HZ is 
formed, it remains in the infected RBC until the cell bursts, releasing the parasite and the 
HZ along with the cell’s lipid membrane and other debris into the host vasculature.82  The 
host’s innate immune system launches a defensive surge of monocytes and neutrophils in 
order to phagocytose and destroy the dispersed particulate.  Ideally, these phagocytes 
would then activate the NADPH oxidase and inducible nitric oxide synthase (iNOS) 
pathways which would produce ROS and RNS, respectively.  It is these reactive species 
that possess the ability to destroy the engulfed material during oxidative burst.89   
Recent images with confocal microscopy, however, have shown that PfHZ can 
withstand the ROS and RNS onslaught by macrophages up to 72 hours.90  Additionally, 
engulfed HZ has been linked to impaired phagocyte function, including PMA induced 
oxidative burst,55,59 rephagocytosis,55,91 interferon γ response92 and the destruction of 
other particulate such as bacteria, fungi or tumor cells.93  Altered cytokine production and 
an upregulation of PGE2 molecules have also been reported.91  Likewise, HZ 
phagocytosis in vivo has been shown to correlate with increased levels of HNE59 and 
hydroxylated fatty acids.36,78  In support of these findings, in vitro work with BH, the 
synthetic form of HZ, has demonstrated that the biomineral does indeed have the ability 
to mediate the oxidation of polyunsaturated fatty acids (PUFAs) into hydroxylated fatty 
acids36,39 and HNE.58   
 Controversy over the immunosuppressive nature of HZ and BH litters earlier 
works.  While HZ has since been acknowledged as an immunomodulatory agent, reports 
on the behavior and effects of BH have varied greatly.  Whether inflammatory94-96 or 
anti-inflammatory,92,97-99 the response of the immune system to HZ and BH, two 
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structurally identical biominerals, should differ only in their external composition, or 
coat.  This coat contains lipids in the case of HZ because it has been exposed to a lipid-
rich cell environment during formation and cell rupture.  The synthetic BH produced in 
vitro in the laboratory would be absent of this lipid component.  Therefore, a look at these 
lipid constituents on macrophage function was explored in order to examine more 
carefully the source of HZ’s immunomodulatory activity. 
 
Experimental 
 
 BH preparation and characterization.  BH was synthesized via 
dehydrohalogenation of hemin, as described by Bohle.60  The reaction vessel was sealed, 
protected from light and stood undisturbed for three months.  The resulting mixture was 
filtered, and the precipitate was washed exhaustively with methanol, 0.1 M sodium 
bicarbonate (pH 9.1) and deionized water.  The purified product was dried under vacuum 
at 150°C for 48 h and stored under dessicant.  The BH was characterized using FT-IR, 
SEM and XRD and compared to previously reported spectra.33-35 
 Cell culture.  Adherent murine macrophage cell line, RAW 264.7, was maintained 
in continuous culture with RPMI 1640 medium, supplemented with 10% (v/v) heat-
inactivated fetal bovine serum and 100 µg/mL penicillin/streptomycin in an atmosphere 
of 5% CO2, 5% humidity at 37°C.  Cell viability was determined by Trypan Blue 
exclusion using a hemocytometer. 
 Measurement of ROS and RNS production.  Measurement of ROS was 
accomplished using luminol-dependent luminescence.  In these experiments, RAW 264.7 
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cells were plated overnight in complete medium at a density of 4x106 cells/well in a 6-
well plate.  The following day, the medium was removed, the cells gently washed with 
phosphate-buffered saline (PBS) and treated.  After 3 hours of incubation at 5% CO2, 5% 
humidity at 37°C, the supernatant was removed and cells gently washed with PBS, and 
NADPH oxidase was activated by the addition of 1.0 mL of 100 nM PMA in PBS.  After 
4 minutes, 950 µL of this supernatant was collected into a luminescence tube followed by 
the addition of 50 µL of 1.0 mM luminol (in PBS).  Luminescence was immediately 
measured using a Monolight 3010 luminometer for 10 seconds.  Alternatively, ROS were 
monitored using dichlorofluorescein diacetate (DCF-DA).  In these reactions, cells were 
plated overnight in complete medium at a density of 5x105 cells/well in a 24-well plate.  
The next morning, the cells were washed, then treated with HNE and 15-HETE, 100 nM 
PMA in PBS and 8 µM (final) DCF-DA for 1 hour at 37°C and 5% CO2, 5% humidity.  
The formation of the fluorescent dichlorofluorescein was monitored with the Bio-Tek 
Synergy HT multidetection microplate reader using a 485/20 excitation filter and a 
528/20 emission filter.  It is important to recognize that this assay, unlike the luminol 
assay described earlier, does not involve pre-incubation of the cells with HNE or 15-
HETE.  All assays were performed in triplicate, and the average value reported with 
standard deviation. 
 Triplicate measurement of RNS was accomplished using the Griess assay.63  For 
these experiments, RAW 264.7 cells were plated overnight in complete medium at a 
density of 5x105 cells/well in a 24-well plate.  The next day, cells were treated and then 
stimulated by the addition of 10 µL of 50 µg/mL LPS (1 µg/mL final) followed by 
incubation in 5% CO2, 5% humidity at 37°C.  After 24 hours, 300 µL of the supernatant 
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was removed from the cells and spun down at 13,200 rpm for 5 minutes.  A 100 µL 
aliquot of the supernatant was then transferred to a 96-well plate, and the production of 
NO was monitored using the Griess assay.  For this assay, 100 µL of each sample was 
reacted with 50 µL of 1% sulfanilimide in 5% phosphoric acid, followed by 50 µL of 
0.1% NED.  After 5 minutes, the absorbance of the resulting azo complex was measured 
at 540 nm using a Bio-Tek Synergy HT multidetection microplate reader.  To investigate 
the effect of BH on the production of ROS and RNS, 120 µg/mL (final) of BH was 
suspended in complete medium and used in all cases unless otherwise noted.    
 Degradation of BH by ROS.  To study the ability of ROS to degrade BH in vitro, 
reactions between BH and standardized 0-100 mM hydrogen peroxide100 and 0-10 mM 
sodium hypochlorite101 were prepared in triplicate.  Briefly, to a 1.5 mL microcentrifuge 
tube, 100 µL of a 2.0 mg/mL suspension of BH in 100 mM sodium acetate buffer pH 4.8 
was added to 300 µL of sodium acetate buffer, followed by addition of 100 µL of the 
appropriate concentration of hydrogen peroxide or sodium hypochlorite.  Prior to 
incubation in a 37°C water bath for 20 h, the solutions were capped, covered with 
parafilm and vortexed.  After incubation, the samples were centrifuged at 16.1x103 x g 
for 30 minutes to pellet the remaining BH.  The clear supernatant was removed, and the 
pellet was washed once with DI water and re-centrifuged.  Finally, the BH was 
dissociated into free heme by dissolving the pellet in 1.0 mL of 1.0 M NaOH, and the 
absorbance of free heme was monitored at 400 nm using a Bio-Tek Synergy HT 
multidetection microplate reader to quantify the remaining heme. 
 Degradation of BH by RNS.  To study the ability of RNS to degrade BH in vitro, 
reactions between BH and 0-100 mM DeaNO, a nitric oxide releasing agent, were 
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prepared in triplicate.  Briefly, to a 1.5 mL microcentrifuge tube, 100 µL of a 2.0 mg/mL 
suspension of BH in 100 mM sodium phosphate buffer pH 7.4 was added to 390 µL of 
sodium phosphate buffer, followed by the addition of 10 µL of the appropriate 
concentration of DeaNO.  Prior to incubation in a 37°C water bath for 20 h, the solutions 
were capped, covered with parafilm and vortexed.  After incubation, the samples were 
centrifuged at 16.1x103 x g for 30 minutes to pellet the remaining BH.  The brown 
supernatant was removed and the pellet washed once with deionized water and re-
centrifuged.  Finally, the BH was dissociated into free heme by dissolving the pellet in 
1.0 mL of 1.0 M NaOH and the absorbance of free heme was monitored at 400 nm using 
a Bio-Tek Synergy HT multidetection microplate reader.  At DeaNO concentrations of 25 
mM or greater, it was necessary to add 10 µL of 5.0 M NaOH and allow the tube to rotate 
overnight to obtain complete dissociation of the BH pellet.  Finally, the absorbance of 
free heme was monitored at 400 nm using a Bio-Tek Synergy HT multidetection 
microplate reader in order to quantify the remaining BH.  Additionally, FT-IR was used 
to analyze the formation of a Fe-NO complex at the 50 mM DeaNO concentration.  The 
amount of NO released by DeaNO in this experiment was verified by running a series of 
control reactions.  Here, the samples were prepared and treated exactly as those described 
earlier except that the 100 µL of BH was replaced with 100 µL of sodium phosphate 
buffer.  To analyze the amount of NO produced, the Griess assay63 was employed.  It 
should be noted that Fe(III)PPIX solutions may absorb onto plasticware and can exist in 
different aggregation states, resulting in minor changes in absorbance. 
 Confocal microscopy.  The localization of BH inside an acidic phagolysosome 
was demonstrated using lysotracker, a pH-sensitive dye.  Here, 5x104 cells were plated 
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overnight, followed by gentle PBS wash.  Next, the cells were treated with 100 µL of 
0.12 mg/mL BH suspended in complete medium and allowed to phagocytose in an 
atmosphere of 5% CO2, 5% humidity at 37°C.  After 1.5 h, the cells were washed twice 
with PBS and were treated with 2 mL of 100 nM PMA diluted in complete medium.  
After 10 minutes at 5% CO2, 5% humidity at 37°C, the PMA was removed, the sample 
washed with PBS and covered with 2 mL of fresh PBS.  Approximately 5 minutes prior 
to imaging, 4 µL of 20 µM lysotracker diluted in PBS was added to the dish.  
Fluorescence imaging of BH was accomplished by excitation at 514 nm followed by 
collection using a band-pass filter from 533.2 to 542.9 nm.  Lysotracker fluorescence was 
obtained by excitation at 543 nm followed by the use of a long-pass 585 nm filter for 
emission.  The images were stacked into a composite figure in order to determine 
colocalization.   
 Confocal microscopy was also utilized to determine the fate of BH that has been 
phagocytosed by RAW 264.7 macrophage-like cells.  Cells were plated and treated with 
BH as before.  The incubation of these dishes was varied at 0, 48 and 72 hour increments 
in an atmosphere of 5% CO2, 5% humidity at 37°C.  At each time point, the samples 
were gently washed once with PBS, covered with 2 mL of fresh PBS and immediately 
imaged on the Zeiss LSM 510 Meta inverted confocal microscope using the same 
parameters as before.  In order to quantify the fluorescence emission from the samples, 
projections were made of the z-stacks from 200-300 cells per sample, and Metamorph 
software was used to quantify the amount of fluorescence above the background 
threshold.   
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 Superoxide Cytochrome C Assay.102  A non-differentiated human myeloblastic 
HL60 (ndHL60) cell line was differentiated with 1.3% DMSO for five days.  Cell 
suspensions (100 μL of 1E5 cells/well) in phenol red-free media were added to black 96-
well plates and incubated 30 min.  Prepared reaction mixtures, 150 μL of 32 μM PMA, 
320 μM cytochrome c, and 20 μL of 10,000 U/mL of SOD in HBSS, were added to the 
appropriate wells.  The plate was incubated another 30 min at 37°C and read at 550 nm.  
To measure the inhibition of superoxide, varying concentrations of HNE were incubated 
4 h in the cell suspensions before addition of reaction mixtures.                 
H2O2 Amplex Red Assay.103  Five day differentiated HL60 cells (20 μL) were 
added to black 96 well plates at 1.5E4 cells/well in phenol red-free RPMI 1640.  Prepared 
reaction mixture (100 μL of 50 μM Amplex Red reagent, 0.1 U/mL HRP, and 16 μM 
PMA in KRPG) was added to the wells.  The plates were incubated 30 min. at 37°C 
before fluorescence readings were taken at an excitation 530/25 and emission 590/35.  To 
measure the inhibition of H2O2, varying concentrations of HNE were incubated 30 min in 
the cell suspensions before addition of reaction mixtures. 
Reaction of HNE and 15-HETE on stimulated RAW 264.7 cells.  The ability of 
HNE and 15-HETE to inhibit PMA and LPS stimulated oxidative burst was analyzed.  To 
examine the effects of HNE and 15-HETE on the activation of NADPH oxidase, 5x105 
cells/well were plated in 24-well plates.  The following day, the cells were treated in 
triplicate with HNE (0-100 µM) or 15-HETE (0-12 µM) and incubated in 5% CO2, 5% 
humidity at 37°C.  After 1 hour, the cells were examined for NADPH oxidase activity 
using DCF-DA, a dye that is converted to the fluorescent dichlorofluorescein in the 
presence of oxidizing species (described earlier).  To investigate LPS inhibition, 5x105 
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cells/well were plated in 24-well plates overnight.  Subsequently, the cells were washed 
once with PBS, followed by treatment with HNE (0-20.5 µM) or 15-HETE (0-20 µM), 
followed by stimulation of iNOS with LPS (1 µg/mL final).  These samples were allowed 
to incubate for 24 hours before analysis of the supernatant via the Griess assay. 
 Ghost cell preparation.  Red blood cell ghosts were prepared from expired whole 
blood obtained from the Vanderbilt Medical Center Blood Bank.104,105  Whole blood was 
kept at 4˚C until use and mixed inside the bag before use.  A 22 gauge needle fitted to a 
disposable syringe was used to draw 3 mL of whole blood which was then expelled into a 
15 mL polypropylene centrifuge tube.  PBS (11 mL) was added, and the tube was gently 
inverted to mix.  The solution was then centrifuged at 1000 x g for 10 minutes.  The 
supernatant was discarded in bleach, and this wash was repeated until the supernatant 
appeared clear.  The RBCs were then lysed by dissolving the pellet in 0˚C 5 mM sodium 
phosphate buffer in 50 mL polypropylene tubes and vortexing.  The solution was 
centrifuged at 10,000 x g, the supernatant was discarded, and wash repeated until no trace 
of red could be seen in the membrane pellet.  The pellet was then dissolved in a minimum 
amount of PBS and stored at -80˚C.  A Biorad assay was used to determine the protein 
content of the final solution.  Briefly, standards were made with bovine serum albumin 
from 1.5 mg/mL to 0.2 mg/mL.  Standards and samples were pipetted (5 µL) into a clear 
96 well plate.  Bio-rad reagent A (25 µL), an alkaline copper tartrate solution, was added 
to each sample followed by 200 μL of reagent B, a dilute 1,2-naphthoquinone-4-sulfonate 
solution.  The plate was allowed to sit for 15 minutes at room temperature, after which 
the absorbance was read at 750 nm.  RBC ghosts were used for reactions at protein 
concentrations of 1 mg/mL. 
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 Reactions between RBC ghosts and BH were prepared in test tubes with a total 
volume of 2 mL.  RBC ghosts, normalized to an absorbance of 0.7 at 280 nm, were added 
first, followed by 500 µL of 3 mg/mL BH (0.75 mg/mL final), and the samples were 
taken up to 2 mL total volume with RPMI 1640 complete medium.  After stirring for 24 
hours at room temperature, the reaction mixtures were centrifuged for 15 minutes at 
5,445 x g to pellet ghost membranes and BH.  RAW 264.7 murine macrophage cells were 
then treated in triplicate with varying amounts of the supernatant (from 0 to 100%).  
Luminol-dependent luminescence was used to measure the effect of the supernatant of 
the ghost-BH reaction on the production of ROS and the Griess assay was used to 
monitor the effects on the production of RNS. 
 
Results and Discussion 
 
 Biologically, the production of ROS and RNS in phagocytic cells is 
predominantly mediated by the action of two enzymes:  NADPH oxidase and iNOS.  The 
production of ROS during oxidative burst is a result of the activation of NADPH oxidase.  
Activation of this constitutively expressed enzyme results in the reduction of molecular 
oxygen to the superoxide anion which is rapidly converted to secondary species such as 
hypochlorous acid (HOCl), the hydroxyl radical (•OH) and hydrogen peroxide (H2O2).106-
108  RNS are initiated by the induction of nictric oxide synthase.  Once translated, iNOS 
produces nitric oxide, which in turn can react with molecular oxygen to form a variety of 
derivatives, including NO2, N2O3, NO2- and NO3-.63  Together, these species act to 
degrade foreign pathogens.  Considering the innate toxicity of these reactive microbicidal 
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agents, their modulation is an important component in establishing a successful parasitic 
infection.   
 
 
Figure 13 Effect of BH on the production of ROS and RNS.  ROS production was assessed by DCF-DA 
(first 3 columns), showing the percent activity of (white) unstimulated cells, (gray) cells stimulated with 
PMA and (black) cells treated with BH and stimulated with PMA.  The Griess assay was used to measure 
RNS production (last 3 columns), showing (gray with vertical lines) unstimulated cells, (gray with 
diagonal lines) cells stimulated with LPS  and (gray with horizontal lines) cells treated with BH and 
stimulated with LPS.      
 
 BH’s ability to modulate the activity of NADPH oxidase was examined.  As 
shown, BH does not inhibit the production of ROS in PMA-stimulated RAW 
macrophage-like cells (Figure 13).  Pre-incubation with up to 0.4 mg/mL BH showed no 
inhibitory effect on superoxide anion production as measured by luminol-enhanced 
luminescence.  Reports have similarly indicated no inhibition of ROS in mouse 
macrophage-like B10R, BV2 microglial and peritoneal macrophage cell lines.99,109  In 
contrast, phagocytosis of native HZ by human monocyte-derived macrophages resulted in 
inhibition of PMA-stimulated NADPH oxidase55,59 in a dose-dependent fashion.   
Challenge of LPS-stimulated iNOS in RAW macrophage-like cells with BH does 
not inhibit the production of RNS either (Figure 13).  In control reactions with 
unstimulated cells, levels of detected NO increased as levels of BH were increased, 
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owing to particulate activation (data not shown), indicating healthy, functioning 
macrophage cells.  Additionally, 24 hour pre-incubation of RAW macrophage cells with 
BH does not inhibit re-stimulation with LPS (Figure 14).  The results shown in Figure 16 
are consistent with studies in macrophage-like B10R and N11 microglial cells which 
show no BH-dependent inhibition110 of NO but are contradictory to a report with murine 
peritoneal macrophages that appears to indicate BH inhibition of NO.97  Further, HZ 
directly isolated and exhaustively purified to remove all absorbed proteins, lipids and 
carbohydrates consistently has been shown not to inhibit NO production in human 
peripheral blood mononuclear cells and macrophage B10R microglial cells.110,111   
 
 
Figure 14  Effect of preincubation of RAW cells with BH on RNS production as measured by the 
Griess assay.  The black column corresponds to RNS production of cells stimulated with LPS, the gray 
column is cells treated simultaneously with BH and LPS and the white column represents cells first treated 
for 24 hr with BH, followed by restimulation with LPS for another 24 hr. 
 
Consequently, the results presented herein and the preponderance of published data 
suggest that NO production is not inhibited by BH treatment.  In contrast, native (crude) 
HZ has been shown to decrease NO production in peritoneal macrophages.112  The stark 
contrast concerning the immunoreactivity of BH versus native HZ with regards to 
modulating ROS and RNS production implies that there exists a biochemical distinction 
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between the two.  If BH does not effectively inhibit the intracellular production of ROS 
and RNS, then these molecules should be available to react with the phagocytosed heme 
aggregate; however, experiments suggest that hemozoin can persist for up to 72 hours 
within the phagolysosome.90  Consequently, the effects of these microbicidal agents on 
BH stability may provide some degree of insight into the apparent biochemical 
differences between BH and hemozoin.  In a series of in vitro studies, BH stability was 
examined in the presence of HOCl, H2O2 and NO.   
 BH displays a marked sensitivity to HOCl at pH 4.8, the pH of the 
phagolysosome, with an EC50 of 5.5 mM (Figure 15A).  Its degradation in the presence of 
HOCl results in the loss of aggregate integrity and formation of an insoluble orange 
product.  The HOCl-mediated oxidation of the protoporphyrin IX methylene bridge likely 
results in the opening of the ring and release of iron.  The consequence of such a reaction 
would be the dissolution of the aggregate and formation of a product similar to bilirubin, 
the tetrapyrole end product of biological heme degradation by heme oxygenase.113  
Analysis of the orange product by UV-Vis spectroscopy is consistent with the production 
of such an oxidized pyrrole-base material (data not shown). 
Reactions between BH and H2O2 at pH 4.8 also show BH degradation with 
increasing concentrations of the reactive agents (Figure 15B), with an EC50 of 38 mM.  
This value is consistent with H2O2 degradation of BH reported by Chen et al.,114 who 
examined pigment stability in the context of Hb catabolism within the digestive vacuole. 
Reactions between Fe(III)PPIX and H2O2 have been reported to result in formation of 
four dipyrrolic propentdyopents, hematinic acid and methylvinylmalemide.115  Heme-
Fe(III) can react with H2O2 to generate a formal perferryl species116 [•+heme-Fe(IV)=O or 
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heme-Fe(V)=O] which can then react with the olefinic porphyrin bridge to form a glycol 
and regenerate the ferric heme (Scheme 3).  The ferric heme reacts with another molecule 
of H2O2 to cleave the glycol and form an amide and an α-formyl pyrrolic species. 
 
 
Figure 15  Degradation of BH in the presence of (a) sodium hypochlorite, (b) hydrogen peroxide and (c) 
nitric oxide. 
 
Repeating this reaction in other methene bridges results in the breakdown of the 
porphyrin to dipyrroles and monopyrroles.115,116  Further enhancement of the degradation 
process is obtained when the reaction of heme-Fe(III) and H2O2 results in the formation 
of heme-Fe(II) and the superoxide anion.  The superoxide anion is able to oxidize the 
tetrapyrrole rings of heme, leading to the degradation of heme and the release of iron.117  
With hemozoin being a dimer consisting of Fe(III)PPIX units, it is plausible that its 
degradation process in the presence of H2O2 is similar to those described for other metal-
containing porphyrin systems. 
 To examine BH sensitivity to RNS, DeaNO, a surrogate for nitric oxide release 
was employed.  Exposure to NO was found to degrade BH in a concentration-dependent 
manner with and EC50 of 33 mM (Figure 15C).  NO binding to ferric heme and formation 
of a ferric nitrosyl complex likely results in the spontaneous autoreduction of the iron to 
the ferrous state.118  In terms of stability, reduction of the iron will result in an increased 
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radius, weakening the iron-nitrogen bonds of the porphyrin.  Further, NO acts as an 
extremely strong ligand and its binding to the iron of heme groups has been shown to 
exert a large repulsive force on the ligand trans to the NO,119 potentially disrupting the 
reciprocating propionate linkages within the crystal lattice of hemozoin.  IR analysis of 
isolated reaction products prior to complete degradation revealed a vibration at 1636 cm-1 
consistent with NO coordination in Fe(II) porphyrin complex (data not shown).118   
 
 
Scheme 3  Purported pathways of heme degradation by hydrogen peroxide.113-115 
 
Regardless of the potential mechanisms of degradation, the insoluble BH 
biomineral is sensitive to the ROS and RNS that are generated upon phagocytosis.  
Further, it is recognized that the crystals of BH are large enough to allow water into the 
lattice.120  Therefore, it is feasible that small molecules such as HOCl, H2O2 and NO 
work their way into the crystal lattice, disrupting the structural integrity of hemozoin 
from within as well as on the surface.  The lower EC50 value (5.5 mM) of HOCl 
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compared with that of H2O2 (38.0 mM) is consistent with it being a much more reactive 
microbicidal agent.108  Additionally, the ability of H2O2 to degrade heme is known to 
decrease in acidic environments, whereas HOCl degradation is inversely affected by the 
acidity.121  NO is not a particularly strong microbicidal agent either, so it is not surprising 
that its EC50 value is also higher than that of HOCl.89  Finally, it is important to note that 
the concentration regimes of HOCl, H2O2 and NO examined here are relevant to 
biologically reported concentrations produced within professional phagocytic cells.89,122  
To investigate the fate of BH inside RAW cells, BH was phagocytosed and its in vivo 
stability examined by confocal microscopy. 
 
 
Figure 16  Colocalization of BH inside the acidic vacuoles as examined by confocal microscopy at x40 
magnification.  (A) The differential interference contrast image of the cell.  (B) Excitation at 514 nm 
followed by emission using a band-pass filter from 533.2-542.9 nm allowed for the imaging of BH 
fluorescence.  (C) Excitation at 543 nm followed by the use of a long-pass 585 nm filter for emission 
allows for visualization of the lysotracker fluorescence.  (D) Composite figure of A-C demonstrating the 
colocalization of BH inside the acidic vacuoles. 
 
 RAW macrophage cells were treated with BH and allowed to phagocytose for 1.5 
h.  The co-localization of BH inside the acidic vacuoles was shown using the innate 
fluorescence of BH and a dye specific to acidic compartments such as the phagolysosome 
(Figure 16).  Here, the images of HZ fluorescence and the fluorescence of the lysotracker 
dye clearly show BH co-localizing to acidic vacuoles of the macrophage cells.  No bleed-
through was found to occur between the two channels, indicating the fluorescence 
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intensity obtained from one setting was not being contaminated by fluorescence from the 
other.  The orthogonal slices (XY and XZ) of the confocal image also revealed segregation 
of BH exclusively within the cell, confirming that it had indeed been phagocytosed.90  
 The quantitative analysis of BH stability as a function of time was probed at 0, 48 
and 72 h.  Normalizing the fluorescence at time zero, we determined that by 48 h, BH had 
been degraded by 67.2 ± 6.5% and that by 72 h, it had been degraded by 76.8 ± 2.7%.  
Visually, the results clearly show diminishing fluorescence (Figure 17), noted by a 
marked decrease in the amount of red fluorescence over the time course of the 
experiment.  Controls in the absence of cells showed that BH fluorescence itself did not 
decrease with time, indicating the degradation observed was not due to photobleaching of 
BH (data not shown).  The in vivo degradation of phagocytosed BH is at odds with the 
apparent stability of native HZ within human peripheral blood monocytes.90,123  These 
results, together with the observation that the ROS and RNS production was not inhibited 
by BH, and that the model reactions highlight BH sensitivity to microbicidal agents, 
indicate that the fate of BH is vastly different from that of native HZ despite the structural 
identity of the heme dimer core. 
Associated with HZ phagocytosis in the pathophysiology of malaria are high 
levels of HNE and 15-HETE.59,78  Recently, it has been determined that HZ is able to 
nonenzymatically generate significant quantities of hydroxylated fatty acids36,38 and to 
mediate the oxidation of fatty acids such as arachidonic and linoleic acid to produce 
secondary oxidation products like HNE.58  Levels of HNE and 15-HETE within HZ-
laden macrophages have been found up to be 230 nmol per 1010 cells59 and 33-39 μM,36 
respectively.  At relatively low concentrations, HNE disrupts cytoskeletal integrity, 
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impairs mitochondrial respiration, inhibits DNA, RNA and protein synthesis, stimulates 
neutrophil chemotaxis, and modulates platelet aggregation and changes in response to 
second messenger pathways.124  Similarly, 15-HETE has been shown to generate 
pathophysiological effects such as altered permeability of endothelial cells, edema, 
increased adherence of RBCs and induced chemotaxis and chemokinesis.36,38  
Consequently, macrophage function may be impaired by the presence of these 
immunoreactive molecules. 
  
 
Figure 17  Confocal images (x40 magnification) of BH degradation inside RAW cells at time zero (A) 
and after 72 hr (B).  Fluorescence images were obtained by excitation at 514 nm followed by collection of 
the emission spectra using a band-pass filter from 533.2 to 542.9 nm. 
 
The cytochrome c superoxide assay and amplex red H2O2 assay were optimized to 
measure the effects of HNE on cellular superoxide.  These assays were conducted on 
human myeloblastic neutrophil-differentiated HL60 cells and showed EC50 values of 4.6 
μM and 1.1 μM, respectively (Figure 18A&B).  Low EC50 values were indicative of the 
significant cellular sensitivity to the cytotoxic HNE.  RAW cells treated with HNE 
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followed by stimulation with PMA demonstrated a concentration-dependent inhibition of 
oxidative burst (Figure 18C).  As the concentration of HNE increased up to 100 μM, 
stimulation of NADPH oxidase was inhibited, with an EC50 value of 45.9 μM.  Studies of 
HNE inhibition of superoxide in human neutrophils have shown a similar response, with 
an EC50 value of 27 μM, consistent with the results reported here for macrophage cells.125  
LPS-activated iNOS was similarly inhibited by HNE in a concentration-dependent 
manner, with EC50 values of 9.2 μM (Figure 18D).   
 
 
Figure 18  Concentration-dependent effect of HNE treatment on oxidative burst.  (A) Inhibition of 
superoxide production with increasing concentrations of HNE in differentiated HL60 cells was measured 
using the cytochrome c superoxide assay.  Dosing revealed an EC50 of 4.6 µM.  (B) Inhibition of H2O2 
production with increasing concentrations of HNE in differentiated HL60 cells was monitored by the 
Amplex Red H2O2 assay.  Dosing revealed an EC50 of 1.1 µM.  (C) Inhibition of ROS production with 
increasing concentrations of HNE in RAW 264.7 cells as assessed by DCF-DA.  Dosing indicated an EC50 
of 45.9 µM.  (D) Inhibition of RNS production with increasing concentrations of HNE in RAW 264.7 cells 
as assessed by the Griess assay.  Dosing indicated an EC50 of 9.2 µM. 
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Generated from the most abundant class of PUFAs, HNE contains three 
functional groups, is lipophilic and easily diffusible, and highly reactive with cellular 
components, all characteristics that make HNE an efficient means of disrupting the host 
immune system.126  Previous reports have demonstrated that at concentrations over 10 
μM, HNE is capable of inhibiting the activity of protein kinase C, a key signaling protein 
in NADPH oxidase activation.59  HNE is highly reactive with proteins, disrupting 
function by forming adducts on cysteine, lysine and histidine residues.126  In fact, there 
has been a suggestion of the possible formation of HNE adducts on protein kinase C.59,127  
This is just one potential target that HNE may interact with once inside the macrophage 
that may lead to inhibition of oxidative burst. 
 The cytochrome c assay was used to measure the effects of 15-(S)-HETE, but 
collected data showed variable inhibition from 0-5 μM and were completely inhibited 
from 5-25 μM.  A similar incongruous pattern was observed using the amplex red H2O2 
assay.  Cells exposed to 15-(S)-HETE showed an increase in H2O2 rather than the 
expected inhibition seen in assays with HNE.  Since HETEs are known to cause 
degranulation in neutrophils,128 the 15-(S)-HETE was hypothesized to have caused 
degranulation and disrupted the assay readings through the release of lysozymes.  
Similarly, incubation with 15-HETE resulted in a concentration-dependent inhibition of 
PMA-stimulated burst, with an EC50 value of 8.0 μM (Figure 19A).  Human monocytes 
treated with 15-HETE have displayed a similar trend, with 100% inhibition of ROS 
production at 15 μM 15-HETE.36,78  LPS-activated iNOS was also inhibited up to 28.5% 
in the presence of 15-HETE (Figure 19B).  While treatment of phagocytic cells with 15-
HETE clearly results in the loss of ROS and RNS production, the mechanism of 
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inhibition is not immediately obvious other than by subsequent degradation of 15-HETE 
to HNE.  The inhibition of oxidative burst with these highly reactive agents points toward 
the importance of HZ not as a toxic substance itself, but rather as a mediator of the 
oxidation of fatty acids to form highly reactive and toxic molecules such as HNE and 15-
HETE.  Additionally, the particulate nature of the detoxification biomineral ensures that 
it will be targeted by the innate immune system. 
 
 
Figure 19  Concentration-dependent effect of 15-HETE treatment on oxidative burst.  (A) Inhibition 
of ROS production with increasing concentrations of 15-HETE in RAW 264.7 cells as assessed by DCF-
DA.  (B) Inhibition of RNS production with increasing concentrations of 15-HETE as assessed by the 
Griess assay.   
 
 The aforementioned results suggest that the inhibitory effects of HZ are due to its 
ability to react with membrane lipids and form highly reactive, immunosuppressive 
molecules.  To examine the effects of the constitutive components of the malaria pigment 
on macrophage response in an appropriate model system, BH was reacted with 
membrane lipids from erythrocyte ghosts.  Following the overnight reaction, RAW 
macrophage cells were treated with the reaction supernatant.  NADPH oxidase in PMA-
activated RAW cells was inhibited in a concentration-dependent manner (Figure 20A), as 
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was the activation of iNOS in LPS-activated cells (Figure 20B).  There was no detectable 
inhibition of ROS or RNS production upon treatment of BH or ghost supernatants alone, 
 
 
Figure 20  Inhibitory effect of the products of ghost and BH interactions on oxidative burst.  (A) 
Inhibition of ROS production was obtained using luminol-enhanced chemiluminescence and (B) inhibition 
of RNS was obtained using the Griess assay. 
 
indicating that it is the products from the reaction between the two that cause the 
inhibition (data not shown).  These results strongly suggest that erythrocytic rupture 
releases the detoxification product HZ into a milieu of cellular debris, providing the 
substrate for the nonenzymatic, heme-catalyzed peroxidation that results in a toxic 
gradient of primary and secondary fatty acid oxidation products (data not shown).  
Although the precise mechanism and cellular targets remain unclear, it is indeed these 
products, not the aggregate of dimeric heme units, which effectively inhibit RAW 
NADPH oxidase and iNOS activity within macrophage cells. 
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Conclusions 
 
 The composition of native HZ released upon RBC rupture has been reported to be 
65.1% proteins, 15.5% Fe(III)PPIX, 5.9% carbohydrates and less than 1% lipids and 
nucleic acids.122,129  Both HZ and BH are able to interact with membrane lipids to 
generate high levels of reactive secondary metabolites such as HNE and 15-HETE.  
Inside HZ-laden macrophages, levels of these agents reach between 20 and 40 μM.36,59  
These molecules act as immunosuppressive agents that are capable of disrupting 
oxidative burst (both NADPH oxidase and iNOS-activated) and represent the key to 
understanding reactivity differences between structurally identical native HZ and BH.  
Clearly, native HZ inhibits the activation of oxidative burst and is stable inside 
macrophages for long periods of time.59,90  In contrast, BH is sensitive to the microbicidal 
agents of oxidative burst, and macrophages are capable of degrading this material.  
Significantly, native HZ which has been thoroughly washed to remove debris from RBC 
rupture (including lipids) reacts in a fashion identical to BH, where it does not inhibit 
oxidative burst. 
 Native HZ is a complex material with a similarly complex reactivity.  By 
systematically examining each of the malaria pigment’s components, we have been able 
to dissect their impact on the immune reactivity of a macrophage cell line.  Further, via 
the reaction between synthetic BH and RBC ghosts, we were able to effectively 
reconstruct the observed immunomodulating reactivity of native HZ.  In this fashion, we 
propose that HZ functions to construct a toxic minefield which disrupts the immune 
response to the parasitic infection.  The presence of particulate HZ and RBC debris 
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invites the professional phagocytic cells to the site, trapping the cells into a veritable sea 
of reactive and toxic species which freely diffuse across the cell membrane and/or are 
brought inside as HZ is phagocytosed.  Once there, the highly reactive molecules, 
generated from the HZ-mediated oxidation of membrane lipids, disrupt macrophage 
function. 
 The HZ-mediated immunomodulation presented here represents but one aspect of 
how this biomineral helps regulate the host/parasite interaction.  Recent results also 
suggest a role for immunomodulation activity originating from the dimer heme moiety in 
Toll-like receptor 9 activation130 and cytokine production perturbation.92,96  HZ has also 
been shown to suppress the adaptive immune system by modulating dendritic cell 
function and maturation, thus allowing further evasion of the immune system.  T cells 
which are subsequently activated by these modulated dendritic cells are characterized by 
decreased proliferation and effector functions.  This modulation of adaptive immune 
system activation may contribute to the reduced vaccine efficacy and increased secondary 
infection seen in malaria-endemic areas.131  Thus, the parasitic survival strategy involves 
native HZ modulation of the host immune system on multiple fronts, innate and adaptive, 
ensuring parasitic success throughout the centuries despite host adaptations.  Continued 
efforts to elucidate the exact mechanisms behind these immunomodulations are critical 
for the development of new approaches to fighting this disease. 
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CHAPTER IV 
 
IN SITU ISOLATION OF SCHISTOSOMAL HEMOZOIN 
 
Endemic in 74 countries, 650 million people live at risk of Schistosomiasis 
infection.132  Of the 200 million people infected, 120 million are symptomatic and 20 
million of those suffer from severe pathology.132  The disease is caused by the parasitic 
bloodfluke Schistosoma spp., first identified by a German physician and parasitologist 
Theodore Bilharz in 1851.  In his letters to his former professor, Bilharz described the 
worms as containing “numerous blood corpuscles throughout its whole length.”133  These 
“blood corpuscles” have since been characterized as aggregates of dimeric 
ferriprotoporphyrin IX (Fe(III)PPIX), biominerals commonly called hemozoin 
(HZ).44,54,114   
HZ and its synthetic analog, β-hematin (BH), are chemically, crystallographically 
and spectroscopically identical.35  The aggregate is composed of five-coordinate 
Fe(III)PPIX dimers stabilized by hydrogen bonding.  Binding between the monomeric 
Fe(III)PPIX units occurs by way of reciprocal monodentate carboxylate interactions 
between each PPIX and its propionic side chains.  Consequently, the resultant HZ is a 
stable and primarily insoluble crystal,32 resisting the onslaught of professional phagocytes 
and persisting in liver and spleen macrophages 6-9 months following parasite 
clearance.134   
During Schistosoma spp. infection, HZ forms as a detoxification byproduct of the 
schistosomes’ catabolism of host hemoglobin and subsequent release of toxic free heme.  
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While the exact method of HZ formation in vivo remains elusive, recent transmission 
electron micrographs (TEMs) revealed HZ localized along nanosphere neutral lipid 
droplets of the worms’ gut lumen.64  HZ accumulates in the gut until the worm 
regurgitates the excess pigment into the host vasculature.  It is in the vasculature that the 
HZ is recognized as a foreign particulate, attacked and engulfed by professional 
phagocytes.122,135  The number of HZ-laden phagocytes continues to grow as the worms 
feed, causing a concentration of dark brown pigment in the host tissue as observable in 
the liver and spleen.135,136   
Already burdened by the hepatomegaly caused from schistosomal egg deposition, 
the spleen and primarily the liver suffer from an inexorable fibrosis that can eventually 
cause hepatic portal vein occlusion, hypertension and gastrointestinal varices.137  The 
most common and more subtle effects of the disease include anemia, abdominal pain and 
cognitive impairment.138  These side effects have been linked to the initial immune 
response of reactive oxygen species (ROS) released by the concentrate of eosinophils 
attacking eggs trapped in the tissue.139  The accumulation of released superoxide anions 
(O2-•) and hydroxyl radicals (•OH) in tissues can initiate lipid peroxidation of surrounding 
fatty acids, ultimately leading to a fibrogenesis cascade.139-141  In fact, antioxidant studies 
with a S. mansoni-infected murine model revealed that mice receiving doses of the free 
radical scavenger melatonin showed restored levels of nitric oxide (NO), glutathione 
(GSH) and superoxide dismutase (SOD) compared to controls.139  Consequently, the 
melatonin-treated mice showed reduced liver granuloma formation, fewer spleen 
megakaryocytes and near-normal kidney tubule structure.139   It is this familiar gap 
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between inflammation and pathogenesis that remains the most obscure and yet, of the 
utmost interest in disease progression.             
Bridging the gaps between oxidative stress and the loss of tissue function requires 
first, a thorough evaluation of the potential sources of inflammation.  While leukocytes 
are certainly the predominant contributors to the increased levels of ROS and reactive 
nitrogen species (RNS) at the onset of schistosome maturation, other mediating factors 
are thought to surface as cells begin to lose their normal antioxidant abilities.139,142  Like 
the transition metals copper and manganese in Alzheimer’s disease and diabetes,143-145 
iron-complexes have long been associated with redox cycling and hence, capable of 
releasing a free radical leading to the initiation of lipid peroxidation.37  In HZ, this occurs 
when the surface-exposed Fe(III) of heme is reduced to Fe(II) by the addition of a 
hydroxyl group from its aqueous environment (Scheme 4).37  Once thought to be an  
 
 
Scheme 4  Initiation of lipid peroxidation by HZ redox cycling.  There are two predominant pathways in 
which HZ, as an iron complex, can initiate lipid peroxidation.  The first is by producing lipid radicals such 
as LOO• and OLOO•.  The second is through the formation of hypervalent iron complexes, albeit unstable 
ones.  Both routes yield mediators capable of abstracting hydrogen atoms from PUFAs and initiating lipid 
peroxidation.  Adapted from Cheng et al.37 
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‘inert’ byproduct of hemophagous parasites,146 HZ has surfaced, in this respect, as a 
proinflammatory mediator in infection.41,147 
HZs oxidation in vitro of the cellular fatty acids arachidonate and linoleate has 
been shown to form a variety of lipoxidation products including hydroxyeicosatetraenoic 
acids (HETEs),39 hydroxyoctadecadienoic acids (HODEs) and the secondary oxidation 
product 4-hydroxy-2-nonenal (HNE).36,43,58  Additionally, these lipids have been 
identified in the extracted lipid coat of native HZ, and also from the lipid coat of BH 
incubated with red blood cell ghosts (RBCGs).  These lipid products have been shown to 
be inflammatory and in many cases, inhibit cellular function.  As more is understood of 
HZ’s reactivity in vitro and its ability to mediate lipid peroxidation,39,41,58 intrigue into its 
reactivity in vivo continues to grow.  Using a S. mansoni-infected murine model, we 
present herein an 8-week time study in which we monitored both the accumulation of HZ 
and the swell of HNE in situ.   
 
Experimental 
 
Schistosomiasis-infected murine model.  Female Swiss Webster mice were 
infected with 150 S. mansoni cercariae via percutaneous exposure of the tail.  The 
schistosomiasis life cycle and infection was completed by the Schistosomiasis Resource 
Center of the Biomedical Research Institute, Rockville, MD under the direction Dr. Fred 
Lewis.   
β-Hematin synthesis.  BH was synthesized via dehydrohalogenation of hemin, as 
described by Bohle.60  The reaction vessel was sealed, protected from light and stood 
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undisturbed for three months.  The resulting mixture was filtered, and the precipitate was 
washed exhaustively with methanol, 0.1 M sodium bicarbonate (pH 9.1) and deionized 
water.  The purified product was dried under vacuum at 150°C for 48 h and stored under 
dessicant. 
Schistosome HZ isolation.  Adult schistosomes were obtained by mesenteric 
perfusion of mice 42 days post-infection.61  Cultivated adult female worms were 
homogenized in phosphate buffered saline (PBS, pH 7.4) using a 15 mL glass 
homogenizer.  Homogenate was centrifuged twice at 1000 x g for 60 s, and the tissue 
pellet was discarded.  The supernatant was centrifuged 2 h at 5445 x g.  The resulting 
dark-brown pellet was resuspended in 5 mL sterile PBS after vortexing and gentle 
sonication for 5 min.  SmHZ recovery was quantified as described by Sullivan et al.62 
with 20 mM NaOH, 2% SDS at 25°C for 1 h.  Heme content was determined from 
absorbance at 400 nm (ε=1x10-5 M-1 cm-1) using an Agilent 8453 UV-Visible 
Spectrophotometer. 
Tissue HZ isolation.  Hemozoin was isolated from collected liver and spleens by 
homogenizing the organ samples with an electric homogenizer for 45 seconds in 50 mL 
of DI water.  This mixture was centrifuged at 1000 x g for 2 minutes.  The tissue pellet 
was discarded, and the supernatant was centrifuged at 5445 x g for 2 hours.  The resulting 
dark brown pellet was gingerly vortexed with 1 mL of PBS to remove the top layer of 
gray tissue.  Afterwards, the lower layer of dark HZ was resuspended in 5 mL sterile PBS 
and 5 mL of ethyl acetate after vortexing and gentle sonication for 5 min.  A series of 20 
minute centrifugations at 5445 x g were then carried out in this 1:1 PBS, ethyl acetate 
wash solution in order to remove as much lipidous tissue as possible.  The HZ was finally 
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quantified as described by Sullivan et al.62 with 20 mM NaOH, 2% SDS at 25°C for 1 h.  
Heme content was determined from absorbance at 400 nm (ε=1x10-5 M-1 cm-1) using an 
Agilent 8453 UV-Visible Spectrophotometer.   
HZ purification.  Isolated schistosomal HZ was purified following the method of 
Chen et al.114  Briefly, HZ was suspended in 5 mg/mL proteinase K buffer containing 10 
mM TrisHCl, pH 8, 0.5% SDS and 1 mM CaCl2.  The mixture was incubated at 37°C for 
24 h under constant agitation.  The sample was then washed thrice with 2% SDS, 
centrifuging at 16.1x103 for 5 min to precipitate the HZ.  The HZ was resuspended in 6 
M urea and incubated 3 h at 37°C under constant agitation.  This suspension was washed 
thrice more with 2% SDS, centrifuging at 16.1x103 for 5 min to precipitate the HZ.  The 
sample was then washed 8 times with DI water.  The final HZ pellet was dried under 
argon and stored under dessicant at -20°C. 
XRD characterization.  Powder x-ray diffraction with Cu Kα radiation was used 
to confirm HZ structure.  Purified HZ was suspended densely in DI water and a droplet 
placed on the Si XRD wafer and dried at 100°C.    
SEM characterization.  Dry purified SmHZ was suspended in ethanol, sonicated 
for 10 min, applied to a polished aluminum specimen mount and dried at 25°C overnight.  
Each sample was sputter-coated with gold for 20 s and imaged using a Hitachi S4200 
scanning electron microscope at 5.0 kV accelerating voltage. 
Ion-Coupled Plasma Mass Spectrometry (ICP-MS).  For ICP-MS analysis, all 
glassware was washed in a 1.9 M potassium hydroxide, ethanol base bath.  Livers and 
spleens from each week were homogenized in a sterile environment (biosafety cabinet).  
A 10 mg sample of homogenate was added to a conical Wheaton vial along with 1 mL of 
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concentrated HNO3, covered with parafilm and allowed to sit at room temperature for 3 
h.  When dissolved, 10 mL of DI water was added to the sample in a 15 mL Falcon 
polypropylene tube, therefore containing 5.9% HNO3 (upper limit of tube resilience).  
These solutions were filtered through a Millipore 50 mL (0.22 µm) steriflip tube, capped 
and stored at -40°C until further dilution for analysis.  Ultimately, 1 mL of this defrosted 
sample was diluted to 10 mL in DI water prior to analysis.  The final concentration of the 
sample prior to analysis was 0.59%.  The iron content of these samples were determined.  
Tissue-section preparation.  Tissues were perfused and placed into 15 times the 
volume of 10% formalin fixative to tissue overnight at room temperature.  Tissues were 
sent to Vanderbilt University Immunohistochemistry Core to be sectioned into 5µm 
paraffin slices with two tissue slices per slide; one for a negative control and the other for 
staining sample.  Hematoxylin & eosin (H&E) tissue stains were performed by the 
Vanderbilt University Immunohistochemistry Core, following standard protocols.148 
Anti-4-Hydroxy-2-nonenal tissue stains.  A R&D Systems monoclonal anti-HNE 
primary antibody was used to label HNE present in liver and spleen tissue sections as 
previously described.149  Briefly, a R&D Systems HRP-AEC system was used to stain the 
tissue sections, in which detection is obtained from the formed avidin-biotin complex 
with the anti-HNE.  Horseradish peroxidase (HRP) enzymatic conversion of 3-amino-9-
ethylcarbazole (AEC) yielded the red precipitate seen with bright field microscopy.  
Initially, samples were blocked with 3% H2O2 to cover the sample, followed by mouse 
serum blocking reagent, avidin blocking reagent (avidin, 0.1% NaN3) and biotin blocking 
reagent (biotin, 0.1% NaN3).  Between washes, samples were rinsed with phosphate 
buffered saline (PBS), pH 7.4.  Samples were incubated at 37°C with primary HNE 
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antibody (25 µL of 25 µg/mL stock) for 1 h.  Samples were rinsed with PBS and 
incubated with a biotinylated secondary anti-mouse antibody for 1 h at 37°C.  The 
samples were rinsed again with PBS and incubated at 37°C for 30 min. in a high 
sensitivity streptavidin-HRP (HSS-HRP) solution.  Following rinses with PBS, the 
sample was incubated at 37°C for 1.5 h in 0.08% AEC, 0.1% H2O2 acetate buffer.  The 
sample was rinsed with DI water and mounted with aqueous mounting medium.  All 
samples were imaged with an Olympus BH2-RFCA light microscope with Olympus 
DP70 camera equipped with DP controller software.        
Isoketal (IsoK) analysis of BH reaction with arachidonic acid.  Lipid peroxidation 
was initiated by the addition of 0.48 mM β-hematin to 10 mM arachidonic acid (Nu-Chek 
Prep, Inc., Elysian, MN) in 5 mL of 100 mM phosphate buffer (pH 7.4) for 2 h while 
stirring.  Pyridoxamine (PM) (100 µM final concentration) (Sigma-Aldrich, St. Louis, 
MO) was added to scavenge isoketals (IsoK) and the reaction was stirred for an 
additional 2 h before extraction with diethyl ether (2×2 mL). Combined organic layers 
were condensed, and the residue was reconstituted in 200 µL of acetonitrile.  IsoK-PM-
lactam adducts were analyzed by LC-MS/MS using a Magic Bullet C18AQ micro 
column (3 µm, 100 Å, Michrom BioResources, Auburn, CA) with the gradient 
programmed from 100% solvent A (5 mM ammonium acetate with 0.1% acetic acid) to 
100% solvent B (acetonitrile/methanol 95:5) from 0.5 min to 3 min and then continuing 
at 100% B for an additional 1.5 min. The column was then equilibrated to 100% A for 2.5 
min. The flow rate was set to 190 µL/min and the injection volume was 5 µL. Eluant was 
directly coupled to a ThermoFinnigan TSQ Quantum triple quadrupole mass 
spectrometer (San Jose, CA) equipped with a standard electrospray ionization source. 
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Nitrogen was used for both the sheath and auxiliary gas. The mass spectrometer was 
operated in the positive ion mode and the electrospray needle was maintained at 3700 V. 
The heated capillary was operated at 35 V and 210 ºC and the tube lens voltage was set to 
90 V. Source CID was 5 V and the collisional energy for all transitions was 30 eV. 
Product scan spectra of the IsoK-PM-lactam adduct ([M+H+] m/z 501) were acquired 
from 50 m/z to 520 m/z. Selective reaction monitoring was used to identify m/z 501→ 
m/z 152 and m/z 501→ m/z 332 transitions, calculated as -17 Da (deamidation by 
fragmentation of the β-amine) from the parent IsoK-PM-lactam mass. 
Isoketal (IsoK) immunohistochemistry.  Tissues were placed in paraffin blocks, 
sliced into 5 µm sections and air dried onto slides.  Slides were treated with xylene (5 
min., 3x), 100% ethanol (2 min., 2x), 95% ethanol (2 min., 1x), 0.3% hydrogen peroxide 
in methanol (20 min., 1x) and PBS (2 min., 3x).  Incubated slides 20 min. at room 
temperature in a humid chamber in Dako protein block (Dako Cat #X0909) and rinsed in 
PBS for 2min. 100 µL of antibody (20 µg/mL) D11 ScFv (provided by Dr. L.J Roberts, 
Vanderbilt University Medical Center, Nashville, TN) diluted in PBS was added to one 
of the tissue slices while PBS only was added to the second tissue slice and incubated 
overnight at 4°C in a humid chamber.  Slides were rinsed with PBS (2 min., 3x) and 
added 100 µL 1:500 dilution of anti-E/HRP (Pharmacia cat #27-9413-01) in Dako 
antibody diluent (Dako cat #S0809).  Samples were incubated 1 h at 37°C and rinsed 
with PBS (2 min., 3x) and developed with DAB liquid chromogen solution (Sigma 
D6067) and liquid buffer solution (Sigma D6067) for 7 min. and rinsed with water to stop 
the reaction. 
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Isoprostane (IsoP) and isofuran (IsoF) analyses.  Tissues were homogenized and 
F2-isoprostane and isofuran were purified and analyzed as described in Morrow et al.150 
and Fessel et al.151  Samples of liver and spleen tissue (0.05-1 g) were homogenized in 20 
mL of ice-cold Folch solution (chloroform/methanol, 2:1 v/v) containing 0.005% BHT.  
Following a 1 h incubation at room temperature under nitrogen, 4 mL of 0.9% sodium 
chloride was added and the solution vortexed, centrifuged for 10 minutes at 800 x g and 
the lower organic layer separated from the semisolid proteinaceous layer.  The organic 
layer contains the extracted lipids and was transferred to a 100 mL conical bottom flask 
and evaporated to dryness under vacuum.  The sample was redissolved in 4 mL of 
methanol, 0.005% BHT and 4 mL of 15% potassium hydroxide, incubated at 37°C for 30 
min., which causes hydrolysis and release of F2-IsoPs.  The mixture was acidified to pH 3 
with 1 M HCl and diluted to a final volume of 80 mL with pH 3 water in preparation for 
extraction of free F2-IsoPs.   
 The F2-IsoPs were quantified by GC-negative ion chemical ionization-MS with 
detection limits reaching 1-5 pg.  To a sample, 200-1000 pg of a deuterated standard 
([2H4]8-iso-PGF2α) was added (Cayman Chemical, Ann Arbor, MI).  The mixture was 
vortexed and ran through a C18 Sep-Pak column (Waters Associates, Milford, MA) 
preconditioned with 5 mL of methanol and 5 mL of pH 3 water.  Samples and subsequent 
solvents were eluted through a Sep-Pak with 10 mL plastic syringe.  Column washes 
were sequential rinses with 10 mL of pH 3 washes and 10 mL heptane, and the F2-IsoPs 
were eluted with 10 mL ethyl acetate/heptane (50:50 v/v).  The eluant was dried over 
anhydrous sodium sulfate and applied to a silica Sep-Pak (Waters Associates).  The 
cartridge was washed with 5 mL of ethyl acetate followed by elution of F2-IsoPs with 5 
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mL ethyl acetate/methanol (50:50 v/v) which were dried under nitrogen. The F2-IsoPs 
were converted to pentafluorobenzyl (PFB) esters via reaction with a mixture of 40 µL of 
10% PFB bromide (PFBB) in acetonitrile and 20 µL of 10% N,N-diisopropylethylamine 
in acetonitrile at room temperature for 30 min.  This process was repeated and samples 
were subjected to TLC on chloroform/ethanol (93:7 v/v).  The samples are visible upon a 
spray of 10% solution of phosphomolybdic acid in ethanol and heating.   
The PGF2α band was scraped and extracted with ethyl acetate, dried under 
nitrogen and converted to trimethylsilyl ether derivatives upon addition of 20 µL N,O-
bis(trimethylsilyl)-trifluoroacetamide (BSTFA) and 10 µL dimethylformamide with 
incubation at 40°C for 20 min.  This was dried under nitrogen and redissolved in 10 µL 
calcium hydride-dried undecane for GC-MS analysis.  Separation is achieved on a 15 m 
DB1701 fused silica capillary column (J and W Scientific, Folsom, CA).  Column 
temperature was from 190°C to 300°C at a rate of 20°C/minute.  The carrier gas was 
methane at a flow rate of 1 mL/min., and the ion source temperature was 250°C.  The 
electron energy was 70 eV and filament current was 0.25 mA.  For F2-IsoPs and IsoFs, 
the carboxylate anions at 569 m/z and 585 m/z, respectively, were monitored for the [M-
181] loss of ·CH2C6F5 fragments.             
 
Results and Discussion 
 
Schistosomal inflammation and hence, disease-induced oxidative stress has been 
the topic of extensive inquiry as it relates to host immunity and clinical treatment.  As a 
result, much of the previous focus has centered on the role of granulomas in egg 
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deposition and the ensuing loss of tissue function.  These studies have revealed a range of 
schistosomal-induced stresses, including tissue decreases in antioxidant activity,152-155 
losses in micronutrient levels,139,153 changes in regulatory enzymes,139,155 reports of DNA 
genotoxicity152,156 and rises in lipid peroxide products.139,155,157  It is this lipid 
peroxidation that occurs in the membranes of the cell and subcellular organelles that has 
been proposed as the primary source of lost membrane and tissue function in chronic 
liver diseases like schistosomiasis.154  Stimulated initially by the antigens released at the 
surface of the egg, eosinophil peroxidase induces the production of the O2-• and •OH 
radicals capable of initiating a reported 2-fold increase in lipid peroxidation.155  These 
enzyme-induced ROS are diffuse throughout the granulomatous tissue, but recent studies 
have noted a fibrotic “barrier” trapping the ROS to the area of the collagen-rich 
granuloma and protecting the surrounding tissue from the intensity of this oxidative 
stress.155,158  Herein, an 8-week murine schistosomiasis study was undertaken in order to 
evaluate the progression of oxidative stress as it may relate to the accumulation of tissue-
deposited HZ. 
S. mansoni-infected mice in this study developed distended abdomens during 
disease progression as compared to controls.  The livers and spleens were measured at 
each week’s collection (Figure 21 A-L).  Compared to uninfected controls, livers and 
spleens were noted to darken and become thicker and more fibrotic to the touch.  The 8 
week p.i. liver was an unhealthy, densely-pigmented organ as compared to the  
uninfected, smooth pink liver.  The measured length of the liver at 8 weeks p.i. was 
approximately 5 cm while the uninfected liver was 3 cm, indicating a 67% increase in 
size.  Similarly, the size  
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Figure 21  Growth of S. mansoni-infected livers and spleens through 8 weeks p.i.  Collected livers were 
measured from weeks (C) 4, (E) 5, (G) 6, (I) 7 and (K) 8 p.i. as compared to (A) controls.  Spleens were 
also measured from weeks (D) 4, (F) 5, (H) 6, (J) 7 and (L) 8 p.i. as compared to (B) controls.  Compared 
to controls, livers were found to increase in size 67% and spleens 36%.     
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of the spleen was found to increase 36% in length from 2.5 cm to 3.4 cm during an 8 
week infection. 
Although the collected livers and spleens were shown to increase significantly in 
size, the weights of the mice were found to remain constant (Figure 22A).  Their liver and 
spleen weights, however, increased 3-fold throughout the infection (Figure 22B&C).  
Much of this increase is believed to correlate to the increase in collagen deposited at the 
sites of the tissue-trapped eggs.  Previous studies of female CF1 mice (~20 g) infected 
with 50 S. mansoni cercariae were shown to amass 20-fold more collagen in 9 weeks p.i. 
livers than uninfected mice.159  Decreases in the surface area of functioning tissue are 
also thought to play a role in water-retention and swelling of the livers and spleens.       
 
 
Figure 22  Variation in mice and organ weight.  (A) Mouse weight was found to remain constant 
throughout the time study, averaging 30 g each.  The (B) liver and (C) spleen weights, however, increased 
nearly 3-fold from week 4 to 8 p.i.   
           
At weeks 4, 5, 6, 7 and 8 post-infection (p.i.) and uninfected controls, 5 µm thin 
tissue sections were taken of the collected livers and spleens.  Hematoxylin and eosin 
(H&E) stains were applied to each week p.i., illustrating the degree of granuloma 
formation in the livers and megakaryocyte clustering in the spleens (Figure 23).  In 
uninfected mice, healthy hepatocytes and splenocytes were observed.  By week 6 p.i.,  
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Figure 23  Hematoxylin and eosin (H&E) immunostaining of liver and spleen tissue sections.   H&E 
stains were applied to the thin tissue sections of collected livers and spleens.  The progressive formation of 
granulomas was observed in the liver sections, and the emergence of megakaryocytes was seen in the 
spleen sections.  HZ (liver, week 8 insert arrows) was shown to accumulate in the surrounding phagocytes.  
Scale bars are 100 µm.    
 
however, a delayed type hypersensitivity to the liver-deposited schistosome eggs was 
observed, as denoted by the torrent of immune cells at the egg surface.  This response 
  78
continued to escalate through week 8 p.i. in which a fibrous area containing leukocytes 
had formed around the eggs.  Coarse to the touch and dark in color, the livers bore 
several granulomas and increasing amounts of HZ-laden cells.  Scattered deposits of dark 
HZ pigment were discernible in the week 8 p.i. H&E stains (Figure 23 box insert and 
arrows).  The deposits of HZ were absent from the H&E stains of the spleen, however, 
most likely due to the 2-fold less HZ in the spleen and the lower fibrotic density of cells 
found therein.  Few megakaryocytes in the spleen were seen at week 6 p.i., but by week 8 
p.i., large (4-cell) megakaryocyte clusters were observed, demonstrative of an acute 
disease state especially that found in helminth infections.   
 The suspected dark HZ pigment was isolated from the livers and spleens each 
week p.i. and characterized (Figure 24).  The isolates’ sharp Bragg peaks in the XRD 
spectra were indicative of a crystalline structure.  The characteristic 2θ peaks and their 
respective 2:1 intensity between 7° and 21°, 24° were observed, confirming an identical 
structure to that of synthetic BH (Figure 24A).  Additionally, SEM morphological 
comparisons between the HZ of the schistosome and that isolated from the livers and 
spleens yielded analogous images (Figure 24C&D).  Although the HZ isolated from the 
host tissue required exhaustive processing to remove salt and other cellular debris prior to 
characterization, ultimately, the HZ from both the schistosome and the host organs were 
expected to appear near-identical since they were formed in the same environment of the 
schistosome gut.  HZ isolated previously from the schistosome was shown to be 
amorphous in shape, ranging from 50 nm-3 µm, and spherical in appearance.44,54  Indeed, 
this description is consistent with the images of the liver and spleen HZ isolates herein.  
This differs from other hemophagous parasites like the malarial Plasmodium falciparum 
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in which significant cellular processing within an infected RBC would be expected to and 
in fact, does yield packed, uniform brick-like aggregates within the cell.1,28  The 
sharpness of these “bricks” was seen in BH (Figure 24B), but the organization of these 
crystals appeared more varied than that seen in an infected RBC.  
 
 
Figure 24  Physical characterization of isolated schistosomal HZ.  (A) X-ray diffraction spectra of (red) 
BH, (black) HZ isolated from the schistosome, (green) HZ isolated from an S. mansoni-infected liver and 
(blue) HZ isolated from an S. mansoni-infected spleen.  All spectra displayed the characteristic 2:1 
intensity of the 2θ peaks 7° to 21° and 24°.  (B) SEM image of BH. (C) SEM image of HZ isolated from 
liver.  (D) SEM image of HZ isolated from spleen.    
          
The HZ isolated from each organ was quantified by measuring sample absorbance 
within the heme Soret band, specifically at 400 nm (Figure 25).  The average schistosome 
age of sexual maturity is 5½ weeks p.i.,61 and the first trace of HZ was measured in the 
host liver to be 39.1 ± 11.2 µg at 4 weeks p.i. (Figure 25A).  By 6 weeks p.i., this 
quantity had doubled to 94.5 ± 29.7 µg at the peak of schistosome maturity and doubled 
5 10 15 20 25 30 35
In
te
ns
ity
2θ
A B
DC 
  80
again by 8 weeks p.i. to 203.8 ± 51.1 µg.  Measurable quantities of HZ in the spleen were 
not reached until 5 weeks p.i., amassing to 25.6 ± 4.3 µg (Figure 25B).  This quantity 
held constant through schistosome maturity before tripling at 7 weeks p.i. to 84.9 ± 15.6 
µg.  Hence, the cumulative increase in host HZ at schistosome maturity from week 6 to 7 
p.i. was estimated roughly at 125 µg, attributing 1 µg/day to each adult worm pair.  While 
the liver would be expected to trap and shoulder the majority of the burden from HZ 
regurgitated into the hepatic portal vein, both the liver and spleen were found to 
experience 3-fold increases in HZ content between weeks 5-8 p.i., further emphasizing 
the inability of leukocytes to break down and remove HZ. 
 
 
Figure 25  Quantification of HZ isolated from the livers and spleens of S. mansoni-infected mice.  The 
HZ from collected (A) livers and (B) spleens was isolated and quantified by measuring its absorbance in 
the heme Soret band at 400 nm, (ε=1x105 M-1cm-1).  A 3-fold increase in HZ deposited in the liver and 
spleen was observed between weeks 5 and 8 p.i.   
 
Iron content of each organ was measured with ICP-MS (Figure 26).  Changes 
over the course of infection in iron content were not distinguishable in the collected livers 
(Figure 26A).  Although an observable change in HZ content was found, the iron 
composition of the biomineral is only 10% and therefore does not provide a significant 
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increase in total organ iron content.  The dynamic changes in iron content of the spleen, 
however, are intriguing (Figure 26B).  Like the liver samples, these changes in iron 
content would not be expected to originate from the increasing HZ content, but rather, a 
separate source.  The total iron content in the spleen is nearly 8-fold greater at 6 weeks 
p.i. than the iron content of the liver, and this level then returned to a steady 4-fold 
greater than liver measurements for weeks 7 and 8 p.i.  The significant change in spleen 
iron content is unclear but may be linked to a spike in enzymatic activity following 
schistosome maturity (6 weeks) and egg deposition.  This also may be suggestive of RBC 
sequestration to the spleen during portal hypertension, hepatosplenomegaly, contributing 
to the common disease symptom of anemia.160,161  The development of anemia may also 
explain the drop in iron content at week 7 p.i.   
 
 
Figure 26  ICP-MS determined iron content of collected S. mansoni-infected livers and spleens.  (A) 
Livers from the schistosomiasis time study were found to have an indistinguishable amount of iron per 
week p.i.  (B) The iron content of the spleens collected was found to increase through week 6 p.i. and then 
falling at week 7 p.i.   
                
Regardless of the iron content, the quantity of tissue-trapped HZ and deposited 
eggs was found to increase significantly.  These observations were followed closely by a 
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desire to find a correlative detection method to evaluate the organ’s induced oxidative 
stress.  Since HZ and BH have been shown to mediate lipoxidation in a variety of fatty 
acids, it was proposed that a better understanding of HZ’s presence in oxidative stress 
could be gained by monitoring the accumulation of a particular lipoxidation product.   
 
 
Scheme 5  Potential lipid peroxidation products of arachidonic acid.  Initiation of lipid peroxidation in 
arachidonic acid can lead to the non-enzymatic formation of several oxidized lipids in the prostaglandin 2-
series pathway.  Featured here are the prostaglandin H2 (PG-H2) products PG-F2α isoprostanes (F2-IsoP), 
PG-F2α isofurans (F2-IsoF), secondary oxidation product 4-hydroxy-2-nonenal (HNE) and the isomers of 
levuglandin E2 γ-ketoaldehyde, isoketals (IsoK).   
        
Several lipoxidation products are feasible upon HZ’s reaction with arachidonic acid 
(Scheme 5), but of particular interest was the reactive secondary oxidation product HNE.  
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Therefore, thin tissue sections of the livers and spleens of uninfected through 8-
week p.i. mice were subjected to immunostaining with a monoclonal anti-HNE antibody 
and the light visible AEC chromophore (Figure 27).  The basal levels of HNE in the 
uninfected liver and spleen sections were very low, as depicted by the absence of red 
staining.  By 6 weeks p.i., however, both the liver and spleen sections had a noticeable 
increase in HNE production.  The amount of HNE continued to increase through week 8 
p.i. in both organs.  Several hotspots labeled for the presence of HNE were evident at the 
edges of deposited eggs and throughout the tissue as compared to controls.  These 
hotspots are most likely attributed to the ROS and RNS attacks of surrounding leukocytes 
and the resultant lipoxidation of cellular fatty acids.  There is probable reason to think 
that HZ would also contribute to this increase in HNE since its synthetic analog, BH, has 
been shown to mediate the oxidation of HNE in vitro,58 and the native HZ from malaria 
infection has been reported to increase HNE levels 8-fold when incubated two hours with 
human monocytes.59     
 As a tissue marker of oxidative stress, the immunostaining of HNE therefore 
suggests that the HNE identified outside of the imaged granulomas could be the oxidation 
product of an egg-independent response.  While the diffusion of ROS outside of the 
granuloma is likely possible, there is significant literature precedent that steady-state 
monocyte levels of HNE are raised 50-fold in the presence of phagocytosed HZ.162  
Likewise, other liver diseases such as hemochromatosis that have characteristically high 
iron tissue deposits generate high concentrations of HNE compared to controls.163  In this 
study, the 3-fold increase of HZ measured between weeks 5 and 8 p.i. and the visible 
increase in antibody-labelled HNE of the liver and spleen thin sections suggest an  
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Figure 27  Anti-4-hydroxy-2-nonenal (Anti-HNE) antibody immunostaining of liver and spleen tissue 
sections from the schistosomiasis time study.  The presence of HNE intensifies in both the livers and 
spleens throughout infection.  Minimal staining was seen in the control tissue sections whereas hotspots 
and diffuse localization was found to increase over infection duration, hence identifying HNE as a marker 
of oxidative stress in progressive disease studies.  Scale bars are 100 µm.  
 
increasing state of oxidative stress incapable of being reduced by normal antioxidant 
processes or cleared by the surrounding leukocytes.   
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While its exact contribution to oxidative stress remains elusive, BH has been 
shown to modulate temperature in rats164 and upregulate chemokine and cytokine 
production in BALB/c mice upon inoculation.147  Additionally, the intravenous injection 
of mice with BH also led to a dose-dependent upregulation in mRNA of liver expression 
of chemokines and cytokines.147  Ultimately, these induced conditions modulate and in 
some cases, amplify the host’s immune response.  This potential role as an immuno-
modulatory agent is a more recent attribute of the biomineral.       
As such, purified schistosomal HZ, washed of any lipid, protein or cellular debris, when 
incubated with arachidonic acid, should produce HNE.  Support for this is seen from its 
identical, synthetic analog BH’s ability to mediate the formation of HNE in vitro58 as 
well as its formation of highly reactive γ-ketoaldehyde isomers or isoketals (IsoKs)165 
(Figure 28). 
 
6.50.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.5 6.0
Time (min)
0
100
200
300
400
0
200
400
600
800
1000
0
200
400
600
In
te
ns
ity
 (1
03
)
3.54
3.54
3.54
NL: 7.93E5
TIC 
NL: 1.03E6
TIC F: + p sid=-5.00  
SRM ms2 
501.00@cid-30.00 
[151.50-152.50]  
NL: 4.93E5
TIC F: + p sid=-5.00  
SRM ms2 
501.01@cid-30.00 
[331.50-332.50]  
800
500
In
te
ns
ity
 (1
03
)
In
te
ns
ity
 (1
03
)
5.0
m/z
0
10
20
30
40
50
In
te
ns
ity
 (1
03
)
147.99
151.90
314.21
356.06
385.95
251.01136.23
122.86
291.88217.27 501.08362
*
m/z 332 – H2O
M + H+
*
*
*
332.34
100 150 200 250 300 350 400 450 500
In
te
ns
ity
 (1
03
)
In
te
ns
ity
 (1
03
)
In
te
ns
ity
 (1
03
)
In
te
ns
ity
 (1
03
)
In
te
ns
ity
 (1
03
)
In
te
ns
ity
 (1
03
)
In
te
ns
ity
 (1
03
)
In
te
ns
ity
 (1
03
)
In
te
ns
ity
 (1
03
)
In
te
ns
ity
 (1
03
)
In
te
ns
ity
 (1
03
)
 
Figure 28  LC-MS/MS identification of IsoKs in the reaction of BH with arachidonic acid.  Product 
scan spectra of the IsoK-pyridoxamine-lactam adduct at [M+H+] 501 m/z was confirmed by selective 
reaction monitoring of the ionization transitions at 152 m/z and 332 m/z.  Compliments of Dr. Alexandra C. 
Schrimpe-Rutledge.    
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IsoKs are toxic to a variety of cultured cells, including Neura2A cells, RAW 
macrophage cells and lung fibroblasts, at nanomolar to low micromolar ranges.166  Once 
formed in the cell, IsoKs are thought to resist clearance as evidenced by a 50% reduction 
in protein degradation upon reaction of 1 IsoK adduct per molecule of target protein.167  
This is of particular interest in disease states where oxidative stress is known to play a 
large role in inflammation and aggregates of damaged proteins are reported, as in 
Alzheimer’s disease.  In fact, plasma levels of IsoKs in atherosclerosis and end-stage 
renal disease were found to be approximately 2-fold higher than those of controls.168   
IsoK levels in this study were evaluated by staining the liver and spleen tissue 
sections (Figure 29).  A significant change in labeled pigment could not be distinguished 
at lower magnifications, suggesting lower IsoK level changes in the tissue than that seen 
for the HNE stains.  At 40X magnification, an increase in staining was observed between 
control and lower week p.i. as compared to the image at 8 weeks p.i.  This visible 
increase at the interior of the granuloma and along the edges of the schistome egg may be 
attributed to first, the higher density of immune cells present and secondly, to the greater 
cellular toxicity of IsoKs as compared to HNE.  Since the reactivity of IsoKs has been 
reported as an order of magnitude greater than that of HNE,169 a smaller change would be 
expected than observed in the HNE stains and therefore only visually seen at higher 
magnifications.  In fact, IsoK-induced cell death was observed in exogenously treated 
neuroglial cells at 100-fold less concentrations than those needed to gain the same effect 
with HNE treatment.169  Minimal change was observed in the spleen tissue sections as 
might be expected in an organ indirectly affected by the granuloma and HZ deposition 
responses. 
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Figure 29  IsoK immunostaining of liver and spleen tissue sections collected during schistosomiasis 
infection.  Thin tissue sections of liver and spleens were stained for the presence of IsoKs.  Significant 
changes were not seen at lower magnifications due to lower concentrations of the reactive and low-level 
cytotoxic IsoKs.   At 40X magnification, an increase in staining is observed in the liver from week 6 to 8 
p.i.  Scale bars are 100 µm.   
 
Also measured in this study were the prostaglandin-F2α isoprostanes (IsoPs) and 
isofurans (IsoFs).  These lipoxidation products of arachidonic acid and hence, markers of 
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oxidative stress in vivo, are formed either by preference for intramolecular attack or 
molecular oxygen, respectively.  Therefore, IsoPs are found with greater prominence in 
environments of low oxygen tension and IsoFs at higher oxygen tension.  This trend was 
observed in the liver homogenates of this study (Figure 30A&C).  When the IsoP levels 
of the liver spike at schistosome maturity (5 weeks p.i.) and then decline when oxidative 
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Figure 30  Measurement of IsoP and IsoF levels in liver and spleen samples throughout 
schistosomiasis infection.   PG-F2α isoprostane and isofuran were measured in S. mansoni-infected mice.  
As expected, (A) the liver IsoPs peaked at schistosome maturity (week 5 p.i.), and upon oxidative oxidative 
stress, dropped, leading to (C) an increase in IsoF formation.  The spleens’ (B) IsoP and (D) IsoF levels 
drop upon infection and do not recover throughout the time study.     
 
stress escalates (Figure 30A), the IsoF levels gradually increase until they peak at 8 
weeks p.i. (Figure 30C).  This is not the trend observed in the collected spleens, however 
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(Figure 30B&D).  The levels of IsoPs and IsoFs present in infected spleens are 
significantly reduced at week 4 p.i. and remain lower than controls throughout the study.  
The reason for this drift in the spleen is unclear.  Earlier schistosomiasis studies found 
that treatment of splenic lymphoid cell populations with PG-F2α augmented lymphocyte 
yields, especially those of NK cells and further upregulated the immune response seen in 
splenomegaly.170  By whatever mechanism, the observed decrease in IsoPs and IsoFs in 
the collected spleens may be a host defense method of suppressing a similar immune 
response so evident in the upstream livers.  Regardless, these metabolites have been 
shown to play an immunomodulatory role in the development of common symptoms like 
fever and headache in the hemophagous parasitic infection African trypanosomiasis, or 
sleeping sickness.171  In fact, the effects of these reactive molecules have been implicated 
in the oxidative stress found in a wide range of diseases, including atherosclerosis, 
cancer, Alzheimer’s and generally, the aging process.172             
 
Conclusions 
 
 This study provides the first XRD crystal structure confirmation of schistosomal 
HZ isolated from S. mansoni-infected livers and spleens as the structural identical of the 
synthetic BH and malarial HZ.  The biomineral’s reactivity as evident by reaction with 
fatty acids in vitro39,58,59 and stimulant to immune response in vivo,147 was explored 
further with the monitoring of known markers of oxidative stress in situ.  The direct 
effect of HZ on host oxidative stress is not always certain, though.  Further evaluation of 
these markers during schistosomiasis infection could reveal more clearly HZ’s 
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immunomodulatory role in initiating lipid peroxidation and contributing to observed 
tissue inflammation.  Recent inhibition of HZ formation with the heme-aggregation 
inhibitor chloroquine led to a decline in observed morbidity and schistosome viability.173  
By applying chloroquine treatment to the time study conducted herein, the reduction of 
HZ could be used to evaluate its subsequent effects on metabolite production.  Various 
methods were developed herein to measure oxidative stress in this infection.  Other 
antioxidant treatments could be employed as well in order to assess the severity of HZ’s 
effect on disease symptoms and tissue function.  Regardless, these preliminary studies 
provide an interesting look at schistosomal disease progression as it relates to oxidative 
stress and HZ accumulation.    
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CHAPTER V 
 
LIPOPHILIC MEDIATED ASSAY FOR β-HEMATIN INHIBITORS174 
 
During malarial infection, the parasite catabolizes host hemoglobin to acquire 
amino acids therefore becoming exposed to the oxidative stress caused by liberated free 
heme.6  In order to avoid heme toxicity, the parasite sequesters heme into aggregates of 
dimeric ferriprotoporphyrin IX (Fe(III)PPIX) called hemozoin (HZ).  Throughout history, 
HZ has been reported in association with malaria8 but was not structurally elucidated 
until the late 20th century.175  These dimeric units aggregate via an extended network of 
hydrogen bonds between the propionate groups of the porphyrins.  Native HZ and its 
synthetic analogue, β-hematin (BH), are crystallographically identical.  The two 
structures are dimeric five-coordinate Fe(III)PPIXs with reciprocal monodentate 
carboxylate interactions.175  While the structural makeup of HZ has been examined 
extensively,33,176-178 the crucial step of hemozoin formation in the parasite digestive food 
vacuole (DV) remains a mystery.   
Over the years, several hypotheses have been proposed for the mechanism of HZ 
formation, including enzyme catalysis146 or protein mediated formation,179 lipid mediated 
formation26,180,181 and spontaneous formation182 or autocatalysis.183  Recently, the weight 
of evidence has swung strongly towards a lipid mediated process.  Transmission electron 
microscopy of the trophozoite stage of Plasmodium falciparum infected red blood cells 
revealed nanosphere lipid droplets containing HZ crystals.29  These droplets consist of a 
blend of fatty acyl glycerides (specifically monostearic, monopalmitic, dipalmitic, dioleic 
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and dilinoleic glycerols).  When extracted, they promoted the formation of BH both 
individually and as a blend.29  BH crystallization may be favored in a hydrophobic 
environment in which hydrogen bonds between the hydrophilic Fe(III)PPIX’s propionate 
linkages are preferred.28,184  This beneficial solubility in a lipophilic setting was also 
shown to hold true when the common laboratory surfactants SDS, Tween 80 and Tween 
20 were used to mediate BH crystallization.26,185  
  Conversion of these templates and subsequent reactions into a biologically 
relevant, yet robust, primary screen for compounds that inhibit the HZ pathway presents a  
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Figure 31  Assay development and validation pathway.  Successful assays are fashioned after a 
biological system and designed to mimic the environment of the drug target.  A series of optimization steps 
are used to obtain an assay that is sensitive, reproducible, robust and cost efficient.  Optimized and 
validated assays are cross validated in a separate lab and then applied in high throughput screening 
programs.  Adapted from the NIH Chemical Genomics Center. 
 
challenge.  Like many of its predecessors, the lipid-based assay must meet suitable 
performance criteria with regard to time, expense, resources and validation, which 
cumulatively dictate an assay’s success and future applicability (Figure 31).179,182,186-189  
  93
For instance, the radioactive hematin polymerization assay developed by Kurosawa et al. 
requires trophozoite lysates, overnight incubation and is subject to the expense and 
restrictions imposed on any assay containing a radio-labeled substrate.187  While the 
assay was used to screen over 100,000 compounds for BH inhibition,187 its practical use 
in other labs is limited to those with the training and resources to work with radioactive 
materials and Plasmodium cultures.  Equally problematic, are assays incapable of 
quantifying the degree of BH crystallization182 or assays that require starting materials 
not commercially available.179,188   
By using the neutral lipid blend ratio found in trophozoite HZ extracts to mediate 
BH formation,29 most, if not all, labs should be capable of mimicking the acidic and lipid-
rich environment of the parasite’s DV in vitro.  The potential for further simplification of 
lipid-based assays was shown by Huy et al. with the use of the detergent Tween 20, 
curtailing not only the cost of the assay’s lipophilic template but also the incubation time 
of the assay to 4 hr.185  Both of these assays produced comparable amounts of BH under 
similar acidic and hydrophobic conditions.  However, when used to generate 
concentration response curves of known BH inhibitor chloroquine, the drug IC50 values 
from the Tween 20 mediated assay were approximately 10-fold higher than those 
obtained with the neutral lipid blend.29,185  This significant difference suggests that 
Tween 20 is not the most accurate mimic of the native neutral lipid blend.  Herein, a 
series of lipophilic templates were surveyed for use in BH crystallization assays.  The 
robustness of the assays was then tested in the preliminary screening of a small library of 
natural product extracts (NPEs).     
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Experimental 
 
Dehydrohalogenation BH Synthesis.  BH was prepared following the Bohle 
dehydrohalogenation method.190  The reaction was protected from light and allowed to 
stand for 3 months.  The final product was filtered and washed exhaustively with 
methanol, 0.1 M sodium bicarbonate (pH 9.1) and deionized water.  Once purified, the 
BH was dried 48 hr at 150°C under vacuum and stored under dessicant.   
Neutral Lipid Initiated BH Crystallization Assay.  Lipid mediated BH formation 
was adapted from previous description.29  A 25 mM hematin stock solution was prepared 
by dissolving 16.3 mg of hemin in 1.0 mL DMSO and filtering through a 0.22 μm PVDF 
membrane syringe driven filter unit.  From this 25 mM solution, 177.8 µL was added to 
20 mL of a 0.2 M ammonium acetate solution, pH 4.9 for a final 222.2 μM hematin 
stock.  Lipids (1-Stearoyl-rac-glycerol; 1,2-Dipalmitoyl-rac-glycerol; 1,2-Dioleoyl-rac-
glycerol; 1,3-Dilinoleoyl-rac-glycerol; or 3-Palmitoyl-sn-glycerol) were dissolved at 200 
μM each in ethanol prior to addition to the assay.  Final concentrations of 100 μM 
hematin, 0.1 M acetate buffer, 50 μM lipid solution, and 0-3.5 mM antimalarial 
(chloroquine or amodiaquine) were incubated in clear, 96-well round bottom plates at 
37°C in a water bath and shaken at 55 rpm for 20 hr. 
Detergent Initiated BH Crystallization Assay.  Detergent mediated BH formation 
was adapted from previous description.185  A 25 mM hematin stock solution was prepared 
by dissolving 16.3 mg of hemin in 1.0 mL DMSO and filtering through a 0.22 μm PVDF 
membrane syringe driven filter unit.  From this 25 mM solution, 177.8 µL was added to 
20 mL of the 2.0 M sodium acetate solution, pH 4.9 for a final 222.2 μM hematin stock.  
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Final concentrations of 100 μM hematin, 1.0 M acetate buffer, detergent (9.77 μM Tween 
20, 30.55 μM NP-40, > 58.62 μM Triton X-100, 1.47 mM CHAPS, 0.29 mM SDS, or 
14.88 μM Tween 80), and 0-3.5 mM antimalarial were incubated in clear, 96-well round 
bottom at 37°C in a water bath and shaken at 55 rpm for 4 hr.   
Assay Analysis.  Assays were removed from incubation and centrifuged at 1100 x 
g for 1 hr at 25°C in a Beckman Coulter AllegraX 22R, S2096 rotor.  The supernatant 
was discarded and 200 μL of 0.15 M sodium bicarbonate, 2 % (w/v) SDS was added to 
each well.  Centrifugation was repeated, and the supernatant, containing unreacted heme 
substrate, was removed.  A final addition of 200 μL 0.36 M sodium hydroxide, 2% (w/v) 
SDS was used to dissolve the BH produced.  The absorbance of the plates’ contents was 
measured at 400 nm on a BioTek SynergyHT plate reader.  A molar extinction coefficient 
of 1x10-5 M-1cm-1 was used to calculate the BH formed.  Sigmoidal concentration 
response curves were generated using GraphPad Prism v5.0 (March 7, 2007) software.    
Fermentation.  Production cultures of the actinomycete strain Nonomuraea 
kuesteri were initiated by transfer of 3 mL of seed culture into a 250 mL Erlenmeyer 
flask containing 30 mL “ET” medium containing 60 g/L molasses, 20 g/L Difco soluble 
starch, 20 g/L fish meal, 0.1 g/L CuSO4·5H2O, 0.5 mg/L sodium iodide and 2 g/L 
calcium carbonate dissolved in distilled water, adjusted to a pH 7.2 before autoclaving.  
Fermentation of the production cultures was allowed to proceed at 30°C for 7 days in a 
shaker incubator.  
Natural Product Extraction.  An equal volume of ethyl acetate was added to the 
production culture, an emulsion was created by agitation and the solution was shaken for 
1 hr at 200 rpm.  The extraction solution was transferred to a 50 mL Falcon tube and 
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centrifuged at 3000 x g for 30 minutes in a Sorvall Legend RT, TTH-750 rotor.  The 
ethyl acetate layer was collected, dried over MgSO4 and evaporated.  Alternatively, an 
equal volume of methanol was added to the production culture and the solution was 
shaken for 1 hr at 200 rpm.  The extraction solution was transferred to a 50 mL Falcon 
tube and centrifuged at 3019 x g for 30 minutes as before.  The methanol/water mixture 
was collected and evaporated.  The resulting residue was dissolved in 1mL of methanol, 
0.2 μm filtered and subjected to LC-MS/MS analysis.  Cinchona officianal bark powder 
(0.5 g) was suspended in 10 mL 75% ethanol and shaken in a rotary shaker (200 rpm) at 
30˚C for 24 hrs.  The extract was separated from bark by microcentrifugation at 14,000 
rpm and the supernatant evaporated to dryness in vaccuo. 
LC-MS/MS of Ethyl Acetate Extracts.  Mass spectrometry was performed using 
ThermoFinnigan LTQ linear ion trap mass spectrometer (Thermo Fisher Scientific, 
Waltham, MA) concurrently in negative and positive ion modes.  Nitrogen was used both 
for the auxiliary and sheath gas.  The auxiliary and sheath gases were set to 20 psi and 36 
psi, respectively.  For positive ion mode, capillary temperature 300°C; source voltage 
5.0 kV; source current 100 μA; capillary voltage 21.0 V; tube lens 45.0 V; skimmer 
offset 0.00 V; activation time 50 ms with an isolation width 1 m/z. For negative ion 
mode, capillary temperature 300°C; source voltage 4.5 kV; source current 100 μA; 
capillary voltage -49.0 V; tube lens -148.30 V; skimmer offset 0.00 V; activation time 
50 ms with an isolation width 1 m/z.  Data acquisition and quantitative spectral analysis 
was conducted using the Thermo-Finnigan Xcaliber software, version 2.0 Sur 1.  Samples 
were introduced by a Waters Acquity UPLC system (Waters, Milford, MA) with an 
injection volume of 10 μL. Secondary metabolites were separated on a Phenomenex Luna 
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5 μm C18 column (4.60 x 250mm, Phenomenex, Torrance, CA) with a linear water-
acetonitrile gradient (ranging from 95:5 to 5:95 water:acetonitrile) containing 10 mM 
ammonium acetate over 48 minutes with a flow rate of 1 mL/min split with 900 µL/min 
collected as fractions and 100 µL/min subjected to mass spectral analysis.  Fractions were 
collected every minute in 96-well deep well plates using a Gilson FC204 fraction 
collector (Gilson, Middleton, WI).  Each 96-well deep well plate was separated into 100 
μL aliquots into 96-well plates, evaporated and subjected to assay conditions. 
 
Results and Discussion 
 
 A series of lipophilic templates were evaluated for use in BH crystallization 
assays.  The neutral lipid blend (a ratio of 4:2:1:1:1 monostearoyl-, monopalmitoyl-, 
dipalmitoyl-, dioleoyl-, and dilinoleoyl glycerols, respectively) used by Pisciotta et al., 
and the detergents studied by Shoemaker and Kamei represent biological and abiological 
controls.26,29,185  A variety of detergents were selected, differing in chemical structure and 
ionic character.  Initial detergent assay concentrations were estimated using a ratio of the 
detergent’s critical micelle concentration and the concentration of Tween 20 reported by 
Huy and coworkers.185  The nonionic and non-denaturing detergents Triton X-100, NP-
40, Tween 20 and Tween 80; the zwitterionic detergent, CHAPS; and an anionic, 
denaturing detergent, SDS, were examined for their ability to nucleate BH formation.  
The reaction products were evaluated by differential solubility, characteristic infrared 
spectroscopy stretches at 1664 cm-1 (C=O) and 1211 cm-1 (C-O) and powder x-ray 
diffraction (XRD).  Comparison of the Bohle dehydrohalogenation BH product190 and the 
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NP-40 mediated BH product by XRD revealed a strong match to the representative 7°, 
21° and 24° 2θ peaks (Figure 32).  The lipophilic mediators that were found to promote 
BH formation were evaluated in concentration response experiments with the 
antimalarials amodiaquine and chloroquine.   
 
 
Figure 32  Powder x-ray diffraction (Cu Kα radiation) of BH products.  The XRD patterns of Bohle 
dehalogenation BH (top) and NP-40 mediated BH (bottom) were compared, and the characteristic 7°, 21° 
and 24° 2θ peaks were observed. 
 
Of the six detergents surveyed, the zwitterionic CHAPS, nonionic Triton X-100 
and anionic SDS were found to be inefficient mediators of BH crystallization; while the 
nonionic surfactants Tween 20, 80 and NP-40 effectively mediated the formation of BH 
at ≥69% yield (Table 1).  Since HZ has been shown to aggregate in the presence of 
neutral lipid droplets in P. falciparum infected host red blood cells, the hydrophobic 
nature of the nonionic detergents is thought to effectively mimic the neutral lipid 
environment.  This system allows the localization of high concentrations of heme, 
promoting dimer formation and aggregation.  The analogous nature of the detergents and 
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neutral lipids is supported by the similar yields in BH crystallization between the Tween 
20, 80 and NP-40 detergents and those of the neutral lipid blend (Table 1).   
   
Table 1  Lipophilic Mediators of BH Formation. 
 Lipophilic Mediator Mediator (μM) BH Produced (nmol) Percent Yield (%)
Neutral Lipid Blend 50 7.49 75
NP-40 30.6 7.44 74
Tween 20 9.77 7.11 71
Tween 80 14.9 6.92 69
SDS 1140 1.01 10
Triton X-100 58.6 0.74 7.4
CHAPS 1466 0.70 7.0  
 
The adaptation of reaction parameters for optimal throughput and sensitivity was 
crucial in establishing assay viability for NP-40.  The initial focus was directed at 
mediator concentration.  A titration of neutral lipid and NP-40 was plotted against their 
respective BH yields (Figure 33A&B).  For the neutral lipid blend, similar yields of BH 
were observed over a range of mediator concentrations from 50 nM to 50 µM (Figure 
33A).  These results illustrate the high efficiency of the native neutral lipid blend in 
mediating BH formation even at low nanomolar concentrations.    In contrast, NP-40 
demonstrated an optimal concentration for BH yields at 30.5 µM (Figure 33B).  The 
reasons for the difference between the optimal template concentrations is unclear, but 
could be the result of a variation in the detergent’s ability to encompass substrate heme 
prior to the formation of propionate bonds in the hydrophilic reaction buffer.  
Detergents have long been reported as mimics for native membrane lipids given 
their capability of binding hydrophobic surfaces in a micelle-like manner and facilitating 
ordered packing.191-195  Using neutron diffraction methods, Roth et al. showed that fatty 
acid detergents promoted protein crystallization by exerting interactions that mediate 
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effective molecular packing.196,197  By analogy, the detergent’s role in BH crystallization 
could be its ability to segregate free heme optimally along the lipid-water interface 29,198.  
As the fatty acyl glycerides used in the neutral lipid blend and NP-40 both contain  
A B
C D
 
Figure 33  Assay optimization of substrate heme and lipophilic mediator.  (A) Lipid blend mediator 
concentrations were varied between 50 nM and 250 µM for optimal BH production.  A specific 
concentration of neutral lipids was not observed.  (B) A titration of NP-40 was also carried out.  Here, the 
optimal concentration of 30.5 µM showed the greatest yields of BH.  (C) Substrate heme was added 
increasingly to the neutral lipid blend assay in order to determine the optimal range (100µM) without 
decreasing the assay’s S/N.  (D) Increasing amounts of heme were also added to the NP-40 assay and as 
seen in the neutral lipid assay, were not shown to hinder assay S/N at ranges up to 100 µM heme.  
 
hydrocarbon tails, it may simply be that the phenyl ring of the NP-40 changes the 
template packing enough that a more specific concentration of the detergent is required 
for optimal heme stacking and hence, BH assembly.     
  In order to optimize the assays’ BH yields, the optimal substrate heme 
concentration was determined.  For these experiments, increasing concentrations of 
substrate heme were added to the reactions until a decline in signal to noise (S/N) was 
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observed (Figure 33C&D).  When heme concentrations exceeded 100 µM in both assays, 
a significant reduction (>70%) of S/N was observed due to the variability of a saturated 
system in which there was an increasing quantity of non-aggregated heme among the 
precipitate BH, yet the production of BH remained unchanged (data not shown).  Scaling 
the substrate from 50 µM to 100 µM, however, improved the BH yields approximately 
60% with a S/N value of 14, an increase of 1.8 fold.  Consequently, final optimized assay 
conditions employed 100 µM substrate heme and 30.5 μM NP-40 or 50 μM neutral lipid 
mediator. 
 With established conditions for maximum BH formation, the efficacy of 
antimalarials known to inhibit BH crystallization was evaluated.  Concentration response 
curves were generated for each of the lipophilic mediated assays in the presence of 
amodiaquine and chloroquine.  The detergents Tween 20 and Tween 80 consistently 
exhibited 10-fold higher drug IC50 values than those for the DV neutral lipid blend (Table 
2).  In contrast, the NP-40 assay’s IC50 values (within ± 1.5 µM) closely resembled those 
of the neutral lipids’ and thus, provided an accurate yet inexpensive and accelerated assay  
 
Table 2  Efficacy of Known BH Inhibitors in the Lipophilic Mediated Assays. 
Lipophilic Mediator Amodiaquine IC50 (μM) Chloroquine IC50 (μM)
Neutral Lipid Blend 23.07 85.26
NP-40 25.73 50.99
Tween 20 316.3 262.0
Tween 80 201.8 195.7
SDS 225.4 245.6
Triton X-100 N/A N/A
CHAPS N/A N/A  
 
mimic for BH crystallization (Figure 34A&B).  Inhibition trends consistent with those 
observed from the native neutral lipid blend suggested that the NP-40 assay would be 
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capable of discerning other potential inhibitors of BH crystallization that were similar or 
greater in potency than the control drugs amodiaquine and chloroquine.    
 
 
Figure 34  Amodiaquine concentration response curves of neutral lipid and NP-40 mediated BH 
formation assays.  (A) The IC50 value of amodiaquine in the neutral lipid mediated BH formation assay 
was 23.1 µM.  (B) The IC50 value of amodiaquine in the NP-40 mediated BH formation assay was 25.7 
µM.  Error was within ± 1.5 µM. 
   
Assay performance and plate uniformity were then validated in order to evaluate 
future assay throughput.  Initial studies were conducted in 96-well plates with a 
checkerboard pattern of wells containing the acetate buffer vehicle and the positive 
controls of assay substrates with amodiaquine at its reported IC50 value (Figure 35).  The 
drift responses calculated from both lipid blend- and NP-40-mediated sample signals 
were less than 12%, well under the generally accepted 20% threshold.  Negligible drift 
and edge effects were confirmed using linear regressions of the vehicle and positive 
control data with slopes of less than 2.5 x 10-3 illustrating the minimal shift in data across 
the plate.  These findings reinforced that compound response could be screened with 
equal significance across each assay plate.  
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In these multi-variable systems, there are often more contributing factors in an 
actual screen than accounted for by substrates alone.  Therefore, assay performance was 
evaluated in the presence of possible interfering agents (Table 3).  A number of potential 
contaminants were considered that might arise while screening a simple small molecule 
 
 
Figure 35  Assessment of plate uniformity.  Reaction plates were ran with a checkerboard pattern of 
alternating wells of acetate buffer (negative control) and the assay substrates heme-acetate buffer, NP-40 
and IC50 25.7 µM amodiaquine (positive control).  When plotted, the assay signal did not fluctuate along 
the edges of the plate nor across the plate, as confirmed by slopes of linear regression below 2.5x10-3 and 
low drift calculations of 12%. 
 
drug library or a complex natural product extract.  Organic solvents commonly used in 
extraction methods like methanol and ethyl acetate were found to be compatible at final 
assay concentrations of less than 5% (v/v).  The separation solvent, acetonitrile, did not 
perturb assay S/N measurements or BH yields at levels below 20% (v/v).  Dimethyl 
sulfoxide, a common drug delivery vehicle, did not hinder assay signal below a 10% (v/v) 
final concentration.  Common tannins, thiols and chelating agents at low concentrations 
were observed to have little effect.  Likewise, natural plant pigment chlorophyll a did not 
alter assay output when maintained at concentrations of less than 0.13 mM.  Methanol 
and ethyl acetate extracts of various growth media were not expected to be present at 
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percentages higher than 0.02% (w/v) and no interference was observed at these levels.   
Cumulatively, these controls provided a high level of confidence that future “hits” would 
not be the result of common interfering agents. 
 
Table 3  Evaluation of Common Interfering Agents. 
 Potential         
Interfering Agents
Range             
Tested
Observed   
Interference (≥)
Solvents (v/v)
Methanol 0-30% 5.0%
Ethanol 0-30% 5.0%
Acetonitrile 0-30% 20%
Dimethyl sulfoxide 0-30% 10%
Acetone 0-50% 40%
Ethyl Acetate 0-30% 5.0%
Butanol 0-30% 5.0%
Chelating Agents
EDTA 0-15 mM 15 mM
EGTA 0-15 mM 6.0 mM
Tannins
Catechin 0-1.0 mM 0.26 mM
Gallic Acid 0-1.0 mM 0.13 mM
Tannic Acid 0-1.0 mM 0.13 mM
Thiol groups
DTT 0-1.0 mM 0.13 mM
Cysteine 0-1.0 mM 0.97 mM
GSH 0-1.0 mM 0.26 mM
Pigments
Chlorophyll a 0-1.0 mM 0.13 mM
Media Extracts (w/v)
K26S with Ethyl Acetate 0-0.3% 0.15%
K26S with Methanol 0-0.3% 0.25%
ET with Ethyl Acetate 0-0.3% 0.05%
ET with Methanol 0-0.3% 0.10%  
 
This high degree of optimization is crucial when the assay target is suspected to 
encounter a number of bioactive compounds during a screen.  Such is the case when 
identifying potential drugs from crude natural products.  Between 1981-2002, 52% of all 
new chemical entities introduced into the pharmaceutical pipeline was derived from 
natural products.199  Even prior to this time period, alkaloids from the Cinchona tree and 
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peroxides from the Qinghao shrub gave rise to the vital antimalarials quinine and 
artemisinin, respectively.200  Unfortunately, parasite drug resistance continues to diminish 
what is left of the quinine derivatives’ efficacy, and reports of resistance to artemisinin 
combination treatments have emerged.200  Since these antimalarials are currently to the 
fore in combating the disease, the need for new effective drugs is paramount.   
Given the importance of natural products as a source of effective antimalarials, 
the neutral lipid and NP-40 assays were subjected to trial screens of a small library of 
assembled natural product extracts (NPEs) from actinomycete and myxobacteria 
microorganisms.199,201  An extract of the cinchona tree, known to contain the BH inhibitor 
quinine, was also examined.  These screens served as effective measures of the assays’ 
applicability under “real-world” conditions.  To ensure the proper interpretation of the 
results, all extracts were spiked with the known antimalarial drug amodiaquine at its IC50.  
The NPEs were grown under various media conditions, extracted with either methanol or 
ethyl acetate, and all extracts were separated by an acetonitrile:water gradient using 
reverse phase liquid chromatography tandem mass spectrometery (RP-LC-MS/MS).  One 
milliliter fractions of each sample were collected per minute in 96-deep well source 
plates and transferred to 96-well destination plates for screening, ensuring 
synchronization with the LC-MS/MS data to facilitate spectral identification of each 
well’s compound(s).  The amodiaquine (m/z 356 [M+H+]) was identified using MS/MS 
fragmentation and shown to elute at 21 minutes into well 22 (Figure 36A&B).   
When the NPE plates were screened for activity, well 22 tested positive for 
approximately 50% BH inhibition, the predicted activity (Figure 36C).  The apparent 
activity of other metabolites in the assay are under investigation but may need to be 
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further adapted in the assay with respect to an optimal concentration.  Coupled with the 
observed activity of quinine from the cinchona bark extract (Figure 37), the neutral lipid  
 
 
Figure 36  Natural product extracts in BH crystallization screens.  (A) Separation of amodiaquine from 
spiked K26S ethyl acetate natural product extracts.  Amodiaquine was shown to elute at 21 minutes into 
collection plate well number 22.  (B) ESI+ spectra of amodiaquine.  Amodiaquine’s precursor ion was 
observed at m/z 356 [M+H+].  A 37Cl isotopic ion was seen at m/z 358, and the characteristic MS/MS 
product ion from the 73 unit inductive cleavage of NH(C2H5)2 was detected at m/z 283.  (C) ET extracts in 
BH assay.  Compounds collected from LC separation of ET natural product extracts were screened in the 
NP-40 mediated BH crystallization assay.  The amodiaquine from the extract solution is indicated by the 
cross-hair dotted line.  (D) Cinchona bark extract in BH assay.  Compounds collected from LC separation 
of the Cinchona bark extract were also screened with the NP-40 mediated BH crystallization assay.  
Quinine activity was observed in well 19 (18 minute elutant) and is indicated by the cross-hair dotted line. 
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Figure 37  Red Cinchona bark extract in BH crystallization assay.   A) Separation of quinine from 
Cinchona bark ethanol extracts.  B) ESI+spectra of quinine and cinchonine.  Quinine’s precursor ion was 
observed at m/z 325 [M+H+], where R is a CH3O- group.  Cinchonine was observed at m/z 295 [M+H+], 
where R is a H- substituent.  C) Quinine was shown to elute at 18 minutes into collection plate well number 
19.  D) Cinchona bark extract in BH assay.  Compounds collected from LC separation of the Cinchona bark 
extract were also screend with the NP-40 mediated BH crystallization assay.  Quinine activity was 
observed in well 19 and is indicated by the cross-hair dotted line. 
 
and NP-40 assays were shown to selectively discriminate between bioactive hits, 
ultimately substantiating their potential use in future antimalarial drug screening.   
 
Conclusions 
 
 Despite almost universal resistance to chloroquine in Plasmodium falciparum, 
widespread mefloquine resistance and diminished efficacy of quinine, HZ remains a 
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uniquely suitable target for antimalarial drugs.  There is no compelling evidence for any 
change in HZ formation in resistant strains, and analogs of chloroquine retain activity 
against chloroquine resistant parasites 202-204.  However, the target pathway is 
complicated by the mystery of HZ’s in vivo formation.  Evidence for a lipid-rich 
biomineralization template was most recently acquired in the extraction of HZ-
surrounded neutral lipid droplets from P. falciparum infected red blood cells.  These 
extracted neutral lipids were shown to act as an effective scaffold for in vitro BH 
formation 29.  Herein, two optimized lipid-based assays were shown to provide a robust 
assay platform for the discrimination of BH inhibitors against both common chemical 
interferants and the complex milieu of natural product extracts.  In particular, the 
surfactant NP-40 is a newly used BH aggregation scaffold that requires less expensive 
materials than the specific blend of neutral lipids and expedites the processing time by 16 
hr.  Validation studies and application in a preliminary screen of NPEs confirmed both 
the neutral lipid and NP-40 mediated assays’ potential in future high throughput drug 
screens. 
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CHAPTER VI 
 
HIGH THROUGHPUT SCREENS FOR LEAD SMALL-MOLECULE INHIBITORS 
OF β-HEMATIN CRYSTALLIZATION 
 
 The international costs of malaria are estimated to balloon upwards $38-45 billion 
US dollars between 2006 and 2015.205  This increase is largely due to the decreasing 
efficacy of current drug therapies as they shudder under the pressures of parasite and 
vector resistance as well as distribution fraud and production costs.  The worldwide 
clinical and financial burden of malaria is third only to HIV and tuberculosis infections.  
Once easily treated by an oral dose of the fail-safe chloroquine, many areas are now 
inhabited by chloroquine-resistant strains of Plasmodium falciparum.   
 The resistance of the parasite to chloroquine treatment was slow to develop given 
the complexity of the DV and the invulnerable nature of released heme.206  Current 
resistance is primarily attributed to mutations in the gene that encodes for the parasite’s 
DV membrane protein, the Plasmodium falciparum chloroquine resistance transporter 
(PfCRT).207  The presence of PfCRT has been associated directly to a decrease of 
chloroquine concentration in the DV.  This change in the drug delivery system of the 
parasite has not altered the heme detoxification mechanism against which chloroquine is 
active, however.   
 In fact, many studies are directed at restoring chloroquine’s access to the DV by 
using chemosensitizers, or resistance-reversal agents, that act upon PfCRT.  The most 
recent successes of these agents are of the acridone chemotype.208  The acridone structure 
is designed to both promote π-π stacking with heme via a tricyclic aromatic core as well 
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as obtain DV access via acid trapping with hydrogen bond acceptors on its side chain 
nitrogen moieties.208  Preliminary studies were successful in synergy with chloroquine, 
amodiaquine, quinine and piperaquine in the P. falciparum Dd2 strain.208  This renewed 
access to the DV heme target reinforces the continued success of and interest in targeting 
the parasite’s heme detoxification system.   
 Specifically, the parasite is reliant on the biomineralization of heme into 
aggregates of dimeric ferriprotoporphyrin IX (Fe(III)PPIX), known as hemozoin (HZ).  
This process takes place along a neutral lipid scaffold in the acidic environment of the 
DV.  By mimicking this environment, several research groups have established in vitro 
models from which potential antimalarial activity can be measured against HZ’s synthetic 
analog, β-hematin (BH).23,29,35,174,185,189  As this synthetic analog is structurally, 
spectroscopically and crystallographically identical to HZ,35 the results of these assays 
are indicative of the heme and drug molecular interactions expected in vivo.  Few of these 
assays have been developed with true high throughput screening capabilities, however.  
Many are validated only to 96-well plates, contain centrifugation steps, extensive periods 
of incubation and costly radio-labeled substrates. 
 By introducing a pyridine reagent to the end step of the previously developed NP-
40 mediated BH crystallization assay,174 the centrifugation steps of the sodium 
bicarbonate washes were discontinued, reducing the assay’s processing time by 2 hours.  
Further optimization of this assay to a 384-well plate format and cross-validation in a 
high throughput screening facility has enabled the screening of 38,400 small molecules to 
date.  The development and validation of this assay are presented herein along with the 
analysis of its resultant 161 preliminary hits, and 136 of those further confirmed.      
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Experimental 
 
 NP-40 mediated BH crystallization assay.174  In a Corning 384-well clear plate, 
each assay was prepared with a series of substrates added by a CombiChem liquid 
dispenser.  The following order of distributions were added into each well:  14 µL of DI 
water, 30 µL of 222.2 µM heme in 2.0 M sodium acetate (pH 4.9), 5 µL of 0.0002 g/mL 
NP-40 and 15 µL of 100% acetone.  The final assay contained a 100 µM heme solution in 
1.0 M sodium acetate buffer with 30.5 µM NP-40 and 30% acetone.  The assay was 
incubated 4 hours under constant agitation in a reciprocating water bath at 37°C, 55 rpm.  
When plates were removed from incubation, 8 µL of 50% pyridine, 20 mM HEPES 
buffer (pH 7.5) was added, and the plates were shaken for 15 minutes prior to taking 
absorbance readings at 405 nm.  Amodiaquine and chloroquine stock controls were 
screened at an ICMAX of 100 µM.  Concentration response curves were designed at 0, 0.5, 
1.0, 5.0, 10, 15, 20, 30, 50, 80 and 110 µM doses of preliminary hit compounds (N=2).  
Data were fitted to sigmoidal dose response (variable slope) curves using GraphPad 
Prism v. 4.0 software.             
 Small molecule screens.  Small molecules were screened from the Vanderbilt 
University High Throughput Screening Facility and Institute of Chemical Biology.  All 
samples were dissolved in 100% dry DMSO at 10 mM stock solutions.  Molecules 
screened in the assay were screened at 19.3 µM, the approximate IC50 concentrations of 
amodiaquine and chloroquine in the assay.  To do this, 125 nL of the stock samples were 
added to each test well prior to assay substrate addition and the molecules’ absorbance 
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was read at 405 nm.  This initial absorbance reading was subtracted from the final assay 
reading in order to prevent a high false positive rate.       
 Drug properties of hits.  The preliminary assay hits were organized by their 
structural similarity to known antimalarial structures and their chemical properties as 
calculated using ChemAxon Marvin v.5.2.2 software.  The partition coefficients, pKa and 
solubility constants were determined for each hit.  Hits were labeled by their PubChem 
identification numbers. 
 
Results and Discussion 
 
The NP-40 BH assay was designed for its similarity to HZ formation in vivo, its low cost, 
robust nature and high reproducibility.  Previously, the assay was used to screen natural 
product extracts for potential BH inhibitors.174  Since then, the assay was reduced in 
volume to a 384-well plate compatible 60 µL, and its analysis changed from the 
quantification of BH produced to the absorbance of heme substrate remaining after 
incubation.  These changes required a complete re-validation of the assay and its 
parameters.  A checkerboard distribution of the drugs chloroquine and amodiaquine at 
ICMAX concentrations were prepared in the assay plates and their absorbance read at 405 
nm upon pyridine buffer addition (Figure 38).  The drift in the assays of both drugs was 
under 20%, indicating minimal variation between the wells across the plate.  The Z’ 
values for chloroquine and amodiaquine were 0.8824 and 0.7308, respectively.  These 
calculations were used to evaluate the quality performance of the assay in terms of 
reproducibility within the plate and between plates. 
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Figure 38  Calculation of Z’ values during assay cross validation.  Checkerboard plot of (A) 
chloroquine and (B) amodiaquine at ICMAX 100 µM (top line) and DMSO vehicle (bottom line).  The 99.7% 
confidence intervals of each line are plotted above and below the data lines.   
 
 Cross validation of the assay in a concentration response curve was carried out 
with amodiaquine (Figure 39).  The IC50 found for amodiaquine was 12.1 µM with a 
calculated Z’ value of 0.9430.  This calculated IC50 for amodiaquine was most likely 
lower than the expected 20 µM due to the decreased surface area in a 384 well plate as 
compared to a 96 well plate and hence an increase in molecular interactions between the 
  
 
Figure 39  Concentration response curve of amodiaquine in the NP-40 BH assay.  Increasing 
concentrations of amodiaquine were added to the BH assay and its IC50 determined.  The IC50 value of 
amodiaquine was 12.1 µM (error within ± 1.5 µM), and the assay calculated Z’ value was 0.9430.     
0 50 100 150
0
1
2
3
Vehicle
100 uM CQ
Alternating W ell #
A
40
5 
(n
m
)
0 50 100 150
0
1
2
3 Vehicle
100 uM AQ
Alternating Well #
A
40
5 
(n
m
)
A B
-7 -6 -5 -4 -3
0.0
0.5
1.0
1.5
2.0
2.5
IC50 12.11 μM
R2 = 0.7894
Z' = 0.943
-Log(Amodiaquine (M))
N
or
m
al
iz
ed
 A
40
5 
(n
m
)
  114
drug and the { }010  face of the heme moiety. 
 
Library screens were carried out in 384-well plates containing 320 test 
compounds and outer columns filled of amodiaquine controls.  Each plate contained a 
checkerboard of positive and negative controls from columns A1:P2 and A23:P24, while 
test samples were added to columns A3:P22.  The amodiaquine control was added at an 
ICMAX of 100 µM for maximum inhibition of BH formation.  The assay substrates 
without potential drugs were used as a negative control and background measurements.  
Collected data was plotted, containing linear regression averages with 99.7% confidence, 
at 3 standard deviations (Figure 40).   To date, a total of 38,400 compounds were 
screened with a 0.42% hit rate of 161 potential leads (Appendix D).  Of these hits, 15 
were found to express activity at the level of amodiaquine’s ICMAX, giving a 0.04% 
ICMAX hit rate (Scheme 6). 
 
 
Figure 40  Small molecule library screens in the NP-40 BH crystallization assay.  Library screens of 
320 small molecules were carried out per plate (green), and the outer columns were filled with positive and 
negative controls of potentiator and vehicle, respectively.  The potentiator was the amodiaquine at ICMAX 
(red), and the vehicle was the BH assay without inhibitor (blue).  Linear regressions were applied to each 
set of controls in order to calculate the drift across the plate as well as plot the 99.7% confidence interval 
from controls (dotted lines).  Outliers from vehicle standard deviation were considered hits, and hits within 
the potentiator interval were considered ICMAX hits, as marked with green rings.   
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PubChem identification and SMILES for the hits were obtained.  The PubChem 
records for these hits were searched June 15, 2009, and none of the hits were found to 
have known antimalarial activity.  The chemical properties (amine group pKa and log P 
values) of the hits were calculated using ChemAxon Marvin v.5.2.2 software.  As 
compared to the control amodiaquine and chloroquine values (Scheme 7), a clear trend 
was not distinguishable.   
The pKa values of compounds’ amine groups were considered for compatibility 
with the proposed acid-trapping mechanism of drugs entering and remaining in the acidic 
DV of the parasite.  There are two proton pumps in the P. falciparum DV:  a V-type H+-
ATPase and a H+-pyrophosphatase.209  Weakly basic compounds are thought to gain 
access to the DV and hence, the heme target by protonation and subsequent trapping in 
the acidic vacuole, unable to efflux.  While this route has been proposed as the means of 
drug access to the DV, it is not the sine qua non of antimalarial efficacy.  In fact, 
manipulations of the DV by ±1 pH unit were not found to result in significant changes in 
chloroquine accumulation as would be expected.209  DV permeability to charged species, 
however, has yet to be explored.  Ultimately though, amodiaquine’s moderately low pKa 
of 6.9 indicates that its nitrogen moiety can be protonated in an aqueous environment 
without high energy expenditures.  This was also the case for several of the hits. 
The move from potential leads to functioning drugs requires a number of 
considerations.  Early reports of these standards by Lipinski et al. gave way to ‘the rule of 
5’ well known in drug discovery and rational drug design.210  These rules state that lead 
compounds are more likely to suffer from poor absorption and permeation as drugs if  
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C16H13N3O4 C14H12ClFN4O2S C19H16N6OS
PubChem ID 773154 1085012 6810219
log P 3.66 2.7 3.09
MWT (g/mol) 311.29212 354.7870832 376.43494
amine pKA 2.5 ‐2.37 2.95, 0.65, ‐2.46, ‐9.2
C16H15N3O2S C21H19NO2 C14H16N2O
PubChem ID 676205 827956 661302
log P 2.18 3.2 2.57
MWT (g/mol) 313.3742 317.38106 228.28964
amine pKA 1.44, ‐8.19 2.26 16.19, 4.74
C18H13N5O4 C13H13NO3 C29H29N3
PubChem ID 1116129 776830 5721908
log P 1.66 1.62 7.26
MWT (g/mol) 363.32692 231.24722 419.56066
amine pKA 10.6, 9.81, 5.52, 4.92 5.16, 4.63, 4.05
C14H13ClN4O2S C23H19BrN2O3 C16H11FO3
PubChem ID 743083 15991225 5085883
log P 2.56 6.26 2.3
MWT (g/mol) 336.79662 451.31256 270.2551432
amine pKA ‐2.31 0.15, ‐4.61
C10H14N4O2S C25H18N4O4 C24H16N4O4
PubChem ID 708517 15998896 3799745
log P 1.01 5.95 5.45
MWT (g/mol) 254.30876 438.43482 424.40824
amine pKA ‐2.35 10.05, 0.90, ‐5.84 10.05, 0.90, ‐5.83  
Scheme 6  ICMAX hits identified in the preliminary screens of the NP-40 BH assay.  15 hits with the 
activity of amodiaquine at an ICMAX of 100 µM were identified.  The PubChem ID of each compound is 
provided along with calculated log P, molecular weight, pKa values and the structure’s chemical formula. 
   
 
they possess >5 hydrogen bond donors, >10 hydrogen bond acceptors, molecular weights 
>500 g/mol and log P values >5.210  Briefly, excessive hydrogen bond donors and 
acceptors lead to decreased membrane bilayer permeability.211  A molecular weight 
cutoff of 500 g/mol was established due to reported decreases in permeation rates through 
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Amodiaquine Chloroquine
PubChem ID 2165 2719
log P 4.53 3.93
MWT (g/mol) 355.86118 319.87214
amine pKA 6.9 7.73  
Scheme 7  The physicochemical properties of the BH assay controls amodiaquine and chloroquine.  
The log P and pKa values for the assay controls amodiaquine and chloroquine were calculated and used as 
a source of comparison with the preliminary hits identified.   
 
lipid bilayers212 and poorer permeability at the intestinal and blood brain barriers.213  The 
lipophilicity of the leads, as measured by the ratio (log P) of their solubility in octanol as 
compared to aqueous medium, accounts for the compounds’ absorption in vivo.214  
Fortunately, the majority of compounds in the Vanderbilt library screened heed these 
parameters.                 
The library of molecules screened was selected randomly, and upon inspection of 
the preliminary hit structures, they were organized structurally into 4 main groups for 
further evaluation:  1) Quinolines, 2) Azoles, 3) Perimidines and 4) Miscellaneous.  Of 
the 161 hits, 6% had quinoline-like structures, 44% contained azole cyclic rings, 2% had 
perimidine privileged structures and the remaining 47% were grouped as miscellaneous 
due to the lack of a recognizable trend in their structures (Figure 41A).  Of the 15 hits 
with ICMAX activity (Scheme 6), 1 was quinoline-like in structure, 8 contained azole rings 
and the remaining 6 were of miscellaneous trends (Figure 41B).  A large percentage 
(58%) of the 161 preliminary hits had structures containing joined, multi-cyclic rings and 
54% of those were resonant structures.  The strong presence of these resonant, multi- 
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 cyclic structures supports the drug-heme binding model of π-π stacking of the drug at the 
{ }010  heme face.  
 This π-π stacking with heme is most likely the activity of the perimidines 
observed in these screens (Structure in Scheme 9).  Perimidines are characteristically a 14 
π-electron system containing 1 electron that is not delocalized and hence yields a 
reduction in aromaticity.215  These molecules commonly form charge-transfer complexes 
with π-acids and have a high π-donor capacity.215  While not reported for their 
antimalarial activity until now (2% of hits), this family of compounds has been reported 
as effective anti-ulcer, neurotropic, fungicidal and anti-helminthic agents.215    
Similarly, the π-binding quinolines were expected to exhibit activity in this BH 
inhibition assay given the previous performance of the 4-aminoquinoline controls 
chloroquine and amodiaquine.  This family is also home to amopyroquine, tebuquine, 
mepacrine, pyronaridine, halofantrine, quinine, epiquinine, quinidine and bisquinoline.  
These drugs have been an effective source of BH inhibitors and consequently, 
antimalarials for over 300 years.  An understanding of their mode of action was slower in 
coming, however.  It is now thought that this group of antimalarials act by drug 
adsorption on the { }001  and { }011  crystal faces of BH, resulting in thinner crystal cross-
sections.31  Inhibition from π-π stacking at the { }010  heme face is also characteristic of 
the quinoline-heme complex.  These compounds accumulate in the parasite DV at 
concentrations reaching millimolar ranges.62  The quinoline-heme complex prevents the 
formation of Fe-O propionate bonds needed between the dimeric subunits of HZ, 
resulting in an accumulation of toxic heme at near 400 mM concentrations.87  The 
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buildup of free heme hinders metabolic function by generating oxidative free radicals, 
damaging DNA and inhibiting regulatory enzymes.62  
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Figure 41  Structural trends in the preliminary hits from the NP-40 BH assay screens.  Hits were 
organized structurally into 4 groups:  (yellow) Azoles, (blue) Quinolines, (red) Perimidines and (black) 
Miscellaneous.  The percent composition of these groups in (A) the 161 preliminary hits and (B) the 15 
ICMAX hits are shown.   
 
The structure-function relationship of the quinolines varies.  Compounds 
belonging to the 7-halo substituted 4-aminoquinolines are the most active 
antimalarials.216  In fact, activity declines when the halogen is replaced by 7-amino and 7-
chloro derivatives or when disubstitution at the quinoline nucleus occurs.  Quinolines 
lacking the 7-chloro group still bind heme, but HZ crystallization is not blocked.  When a 
Cl is substituted at the C-6 position, quinoline-heme binding is impeded.216  The 
dialkylaminoalkylamino side groups are also crucial for optimal activity.23  
Bisquinolines, compounds containing 2 quinoline nuclei bound by aliphatic or aromatic 
linkers, are reportedly more potent than chloroquine although higher concentrations are 
required both in vitro and in vivo.216,217  This potency is attributed to the compounds’ 
action as an antagonist against the heme sequestration process, possibly disrupting HZ’s 
lipid-rich biomineralization platform.217  
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Demonstrating a similar mode of BH inhibition are the azole-containing 
compounds.  A more recent family of compounds with antimalarial activity, this group 
includes ketoconazole, miconazole and clotrimazole.218  The antimycotic drug 
clotrimazole is the most potent of the group and exhibits antimalarial activity at low 
concentrations in P. falciparum cultures.219  Both clotrimazole and miconazole have high 
binding affinities to the heme monomer, even preventing heme binding to the parasite 
A CB
 
Scheme 8  Azole structures observed in preliminary hits of the NP-40 BH assay screens.  The azole-
containing compounds of the preliminary hits contained (A) pyrazole, (B) diazole and (C) triazole 
structures.    
 
histidine rich protein, an early recognized protein template for HZ biomineralization.220  
Clotrimazole’s potency has also been attributed to its large molecular size and 
hydrophobicity in the induction of hemolysis.221  Since HZ is thought to form along a 
scaffold of lipids, clotrimazole’s noted hydrophobicity may improve its access to the 
heme in a lipid network.   
A surprising number of the preliminary (44.7%) and ICMAX (53%) hits were 
identified as azole-containing structures.  Of these, there were three types of azoles 
observed:  1) pyrazoles, 2) diazoles and 3) triazoles (Scheme 8).  The aforementioned 
ketocon-, micon- and clotrim-azoles contain diazole structures.  A higher percentage 
(53%) of triazoles was observed in the preliminary hits than diazoles, yet 75% of the 
azoles in the ICMAX hits were diazoles (Figure 42).  The hydrophobicity, as evaluated 
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Figure 42  Azole structural trends in the preliminary hits from the NP-40 BH assay screens.  Azole-
containing hits were organized structurally into:  (red) pyrazoles, (green) diazoles and (blue) triazoles.  
The percent composition of these groups in (A) the 161 preliminary hits and (B) the 15 ICMAX hits are 
shown. 
 
with calculated log P values, of the azole-containing hits was observed to increase when 
the immediate azole ring contained an electron withdrawing substituent, like a benzyl 
ring.  
 The remaining hits of these preliminary screens likely inhibit BH in the assay 
similarly, as that is the property for which this assay selects.  While molecular trends 
were not recognized overtly in the miscellaneous group, this could change with further 
screening, potentially revealing a new privileged structure capable of inhibiting BH 
crystallization.  The miscellaneous compounds were surveyed for the BH inhibitor 
xanthone-, methylene blue- and isonitrile-like structures (Scheme 9), but these were not 
evident.  While the artemisinin derivatives are not noted primarily for their HZ inhibition 
activity, they have been implicated in the formation heme-adduct products incapable of 
aggregating to the dimeric Fe(III)PPIX biomineral.222  For this reason, the compounds 
were also searched for artemisinin-like structures, and while 2 bridged structures were 
found, they did not contain the endoperoxide bridge essential to artemisinin’s antimalarial 
activity.   
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Scheme 9  Structures searched in preliminary hits from NP-40 mediated BH assay screens.  (A) 
Perimidines were identified in 2% of the preliminary hits.  The hits were also searched for similar 
structures to the (B) isonitriles, (C) artemisinins, (D) xanthones and (E) methylene blue derivatives but 
were not found.  
 
    All preliminary hits were screened in follow-up concentration response curves 
where N=2 (Figure 43).  A complete list of these results is reported (Table 4).  A false 
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Figure 43  Concentration response curve of preliminary hit.  PubChem CID 676205 was screened in a 
follow-up concentration response curve (N=2) and confirmed as a hit to be screened further.  The 
compound’s IC50 was 7.78 ± 0.05 µM with a Z’ calculation of 0.1746.     
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positive rate of 16% was observed, distinguished by orange highlighting.  Curves were 
generated with 10 data points between 0 and 110 µM.  This range was sufficient for hits 
with IC50 values similar to the control amodiaquine.  Hits with higher IC50 values, and 
hence incomplete concentration response curves, were designated with yellow 
highlighting.  The 136 confirmed hits from these screens will be screened in P. 
falciparum maturation assays in the near future.         
 
Conclusions 
 
 Herein, a high throughput screening assay was developed that effectively mimics 
the lipophilic and acidic environment of the P. falciparum DV.  As such, the assay was 
applied to screen a library of 38,400 small molecules for inhibitors to the parasite’s heme 
detoxification pathway.  While parasite resistance continues to grow, the drug target of 
this screen has proven invulnerable to change.  These screens yielded a 0.42% 
preliminary hit rate, identifying 161 preliminary hits.  Further, these hits contained 15 
compounds with similar activity levels to the potentiator amodiaquine at ICMAX.  All hits 
were surveyed for structural trends, and 44% of the molecules were found to contain 
azole rings, a more recent addition to the antimalarial families.  The confirmed hit rate 
was 0.35% with 136 hits confirmed for secondary screening in P. falciparum maturation 
assays.  When it is demonstrated that the hits are in fact leads with drug potential, a closer 
evaluation of their ADME (absorption, distribution, metabolism and excretion) properties 
and performance in PBPK (physiologically based pharmacokinetic) models will follow. 
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Table 4  Results of Follow-Up Screen Concentration Response Curves 
PubChem CID Z' IC50 (µM) ± PubChem CID Z' IC50 (µM) ±
783797 0.677966 12.45 0.06 991474 0.7819967 20.87 0.04
805136 0.49651 10.77 0.03 2197254 ‐0.9730862 4.86 0.05
751934 0.471088 29.22 0.12 930671 0.9017011 5.03 0.09
2933614 0.505247 23.65 0.18 2947540 ‐0.3946032 46.43 0.26
706129 0.727289 9.88 0.07 1085012 0.2907878 6.22 0.07
2931719 0.808408 67.84 1.02 931717 0.2975118 7.48 0.06
2931787 0.628934 39.62 0.31 677540 0.2574554 7.33 0.06
873167 0.136354 12.39 0.04 5721523 0.2695838 10.09 0.05
2256655 676205 0.1745512 7.78 0.05
6742706 0.811165 15.03 0.04 95445 0.6792867 10.27 0.05
6800421 ‐0.204941 8.98 0.07 667526 0.4496272 9.09 0.04
2057602 820006 0.9309869 6.06 0.04
1356910 0.227747 7.87 0.08 689492 0.7462937 11.57 0.05
1587948 0.43769 25.72 0.07 366 ‐0.6814497 8.65 0.1
892241 0.821423 5.99 0.07 300848 0.6783625 10.95 0.09
731870 3557264 0.6086307 11.42 0.07
748069 0.670988 5.62 0.06 5414628 0.9680207 7.12 0.07
2941849 0.80042 22.12 0.05 6777892 0.1373502 6.15 0.08
892098 0.527199 6.65 0.05 707204 0.0928293 5.88 0.05
702457 660813 0.3591574 5.93 0.06
748044 0.765649 7.47 0.06 2253328 0.0933446 23.83 0.05
748042 0.773259 13.37 0.05 6810219 0.6677377 8.89 0.07
3455308 0.273602 29.22 0.23 708517 0.5157961 32.33 0.24
729843 0.881729 19.8 0.05 3490666 0.8612433 14.25 0.05
6273261 5721908 0.3041729 20.5 0.05
764330 0.850526 8.51 0.09 2884112 0.8321099 10.59 0.05
6800179 0.428089 18.68 0.12 5731584 0.8108231 29.14 0.05
725824 0.872773 12.98 0.09 986302 0.5120991 14.96 0.08
3131870 0.837197 13.71 0.04 6809875 0.5909079 8.94 0.05
764331 0.781692 5.83 0.04 150718 0.107777 11.67 0.06
4670755 683639 0.8580982 48.99 0.23
5066435 0.429261 5.71 0.06 5898619 0.668525 5.86 0.05
690371 0.087854 5.83 0.08 6803142 0.7966663 56.16 0.27
870599 0.371238 6.34 0.1 2831725 0.8230734 27.53 0.05
574330 0.822699 4.74 0.07 774193 0.8203441 55.33 1.28
2248254 0.419496 11.53 0.03 991453 0.8665602 26.33 0.06
1556024 ‐0.265293 20.46 0.08 5550271 0.9512268 43.41 0.17
773154 ‐0.237286 7.18 0.08 2947757 0.5138404 32.9 0.08
2901657 0.696329 7.5 0.06 975838
661205 0.853816 7.95 0.05 2947832 0.0224814 22.73 0.07
2897796 0.660458 66.27 0.41 830422
2898021 ‐0.024032 7.01 0.06 2948389 0.4409473 23.34 0.11
2896732 0.850494 8.7 0.05 2949870 0.7335094 13.59 0.04  
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PubChem CID Z' IC50 (µM) ± PubChem CID Z' IC50 (µM) ±
5739057 0.878833 15.3 0.06 555190 ‐1.590492 12.64 0.11
3799887 776836 0.738555 15.85 0.04
6796866 0.747734 28.06 0.05 3534454 0.766656 10.3 0.04
943060 0.643584 16.07 0.03 827956 ‐1.656443 8.77 0.24
757553 5724276 ‐3.219821 12.81 0.16
743083 0.534358 6.54 0.06 94022 0.787786 9.18 0.04
704537 0.520353 20.15 0.09 741829 0.538595 9.61 0.1
5336686 0.584344 11.23 0.06 2859344 0.357035 8.09 0.05
1226086 0.008623 8.42 0.08 661302 0.84382 12.34 0.17
3121854 0.679529 8.42 0.08 2858149 ‐0.8013 12.52 0.16
4365930 0.474188 21.16 0.13 3829096 0.258711 18.67 0.06
2918158 0.587352 16.97 0.06 695277 0.503433 14.53 0.04
2766102 0.802168 30.08 0.18 2888260 0.754397 8.17 0.06
15998154 0.007659 27.16 0.08 5085883
3671746 0.249987 18.68 0.02 2158438
6024818 0.901384 29.52 0.1 683639 0.682825 7.88 0.06
5740675 4435441 0.798934 13.66 0.02
6617298 0.707565 7.16 0.05 6751296 ‐0.798021 4.6 33.32
2761386 0.298912 6.11 0.05 15991628 0.936469 19.82 0.02
6824199 0.500856 49.36 0.21 3113707 0.884736 13.01 0.05
3762472 0.965874 8.38 0.07 3131467 0.867685 15.05 0.02
15991225 0.775061 7.25 0.06 15993120 0.512896 12.1 0.03
3275143 3134422 0.885663 50.81 0.2
4377684 0.380518 30.07 0.15 3109159
2295553 5101675 0.8748 12.06 0.03
3746677 0.857208 9.43 0.07 1368402 0.525012 59.53 0.33
5189170 0.105935 9 0.09 2731017
15998896 0.771507 12.4 0.13 211447
5978130 0.229182 11.59 0.03 997968 0.86518 9.95 0.03
1098314 Unknown
4436435 2337316
6815125 0.606887 8.87 0.06 2921452
3287443 0.872562 8.41 0.03
15998274 0.778275 22.99 0.06
3799745
4104558
4403626 0.428894 10.24 0.05
3121968 0.679991 18.43 0.21
3427810 0.064597 10.29 0.06
4101678 0.046426 16.31 0.05
3698429 0.328546 41.95 0.31
Unknown ‐0.125463 9.48 0.13
1716517 ‐0.349886 11.47 0.05  
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APPENDIX A 
 
Cell and Tissue Culture Protocols and Assays 
 
Cell Culture, Counting and Plating 
Cell cultures were maintained in a Biosafety Level 2 laboratory.  Biosafety hoods 
with two-way venting were used to prevent contamination of cell stocks and lab 
personnel.  Hoods were sprayed with 70% isopropanol (IPA) and wiped down prior to 
and following use.  Standard personal protective equipment was used, and gloves were 
sprayed with 70% IPA prior to contact with cell flasks (within incubator or hood).  All 
bottles were sprayed with 70% IPA before placement in hoods.  To avoid contamination 
of cell stocks, containers were not allowed to touch when transferring solutions or media, 
and all flask or bottle tops were placed top-up when sitting in the hood.   
Three cell cultures were maintained in this work:  Clone 15 HL-60 lymphoblast 
cells (ATCC CRL-1964), J774A.1 macrophage cells (ATCC TIB-67) and RAW 264.7 
macrophage cells (ATCC TIB-71).  Cells were incubated at 37°C, 5% CO2.  All cell lines 
were grown in RPMI complete media:  10% fetal bovine serum (FBS), 90% RPMI 1640, 
100 U/mL penicillin and 100 U/mL streptomycin.  Specifically, to every 1 L of RPMI 
1640, 100 mL of FBS and 10 mL of a 10,000 U/mL stock of penicillin and streptomycin 
were added.  This growth media was filtered through 0.45 µm pore size Nalgene filters to 
remove any contaminant bacteria or flora and stored at 4°C.   
The murine macrophage-like J774 and RAW cell lines were maintained in a 
similar fashion.  A freezing medium of 95% culture medium and 5% DMSO was used to 
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freeze down cells at a density of 6 x 106 cells/mL and volume of 1.5 mL.  The HL-60 
cells, however, were frozen down in 90% FBS and 10% glycerol.  In general, if a sample 
has been pulled up from freeze, is growing healthily in a T75 flask and is at a low 
passage, more cells should be frozen down from these.  Cells are frozen down in 2 mL 
cryogenic vials.  The filled vials are placed in a Nalgene Cryo 1°C Freezing container 
(VWR 5100-0001) filled with 250 mL of 100% IPA.  The container is placed in a -80°C 
freezer ≥4 hours undisturbed; the frozen vials are stored in a liquid nitrogen canister at     
-196°C.   
To pull the cells up from freeze, thaw them rapidly (40-60 seconds) in a 37°C 
water bath.  The neck of the vial should not be submerged in the water in order to prevent 
contamination.  When removed from the water bath, the vials were sprayed thoroughly 
with 70% IPA.  Cells were transferred via a 10 mL RPMI complete media suspension in 
a 15 mL Falcon centrifuge tube.  Tubes were centrifuged at 430 x g for 5 minutes.  The 
supernatant was discarded, and the cell pellet was resuspended in 10 mL RPMI complete.  
The cells were centrifuged again, the supernatant removed and the pellet resuspended in 
10 mL RPMI complete.  The cell suspension was transferred to a T-25 flask and placed in 
the incubator.  J774 and RAW cells should be brought up from freeze every ~45 
passages while HL60s should be brought up every ~26 passages (or 52 population 
doublings). 
All cell lines can be split 2 to 3 times a week as desired.  Visual inspection of the 
cell medium color and cell-to-cell confluency will indicate the need for splitting.  The 
medium contains phenol red which acts as a pH indicator.  When the media is “salmon 
pink” in color, the pH is near 7.4, but as the nutrients from the growth media are 
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consumed and cell waste accumulates, the color changes to orange.  If allowed to persist, 
the media will turn yellow from the acidity of cell waste and cause cell stress and 
eventually death.  To split the adherent J774 and RAW cells and exchange their media, 
RPMI complete should be warmed at 37°C (15-20 minutes), the old media 
poured/aspirated away and enough fresh media added to cover the bottom of the flask (5 
mL T25, 10 mL T75 and 20 mL T150) in order to scrape the cells loose from the flask 
bottom.  Then, pipet off the loosened cells and transfer 1-2 mL of these to a new flask 
with ample fresh media (10 mL T25, 25-30 mL T75 and 50 mL T150).  Under the 
inverted light microscope, these cells will appear as a floating suspension.  The remaining 
cells may be discarded unless they are needed for plated experiments.  Since HL-60 cells 
are non-adherent, 1-2 mL of these non-differentiated cell stocks may simply be 
transferred to a flask of fresh media as described for the RAWs and J774s but without the 
need for scraping.  A non-differentiated stock of HL-60s must be maintained because 
they cannot be cultured long-term in their differentiated (neutrophil-like) state.   
To differentiate the HL-60 cells, a similar process to splitting is used with the 
exception that the culture medium in the flask would be 98.7% RPMI complete media 
and 1.3% sterile, cell-tested DMSO (Sigma).  Specifically, 5 mL of cells should be added 
to a T75 flask containing 25 mL RPMI complete media and 390 µL DMSO followed by 
incubation.  Literature differentiation time is 5-7 days, but no difference was noted 
between 5 and 7 days for my experiments. 
All cell lines were plated similarly.  Once cells have been removed in a Falcon 
tube during splitting, the cells were centrifuged at 430 x g for 5 minutes, the supernatant 
was discarded and the cells were resuspended in desired media.  Twenty microliters of 
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this cell suspension was placed in an autoclaved microcentrifuge tube (1.5mL) along with 
20 µL trypan blue and mixed by pipetting.  The trypan blue is pumped out of live cells, 
but dead cells retain the dye and appear blue under a light microscope.  A hemacytometer 
with two cell platform grids was used to count these cells (Figure 44).   
 
 
Figure 44  Hemacytometer grid.  Live cells were counted in the four corner and center 1x1 mm quadrants 
of blocks.  When cells came to rest on quadrant edges, they were only counted on the top and leftmost 
border lines.         
 
Ten microliters of the trypan blue and cell mix were added to each platform.  The 
hemacytomer was placed under a light microscope, and live cells were counted in the 
corner and centermost 1x1 mm grid quadrants.  Cells resting along the borders of these 
quadrants were only counted when they were on the top- and left-most quadrant borders.  
The total number of cells for the two grids was then used to calculate the cell density of 
the suspension.  For instance, a total of 92 cells would be divided by two (# of grid 
plates), equaling 46.  This number would indicate a density of 4.6x106 cells/mL.  To 
dilute this density to say 1x106, simply use the M1V1=M2V2 for common dilutions:   
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4.6x106 cells/mL (5 mL cell suspension) = 1x106 cells/mL (V2).  The final volume of the 
diluted solution would be 23 mL; therefore, 18 mL of media would be used to dilute the 5 
mL suspension of cells giving the desired 1x106 cells/mL density. 
Four types of tissue culture plates were used for experiments:  6-well, 24-well, 
96-well plates and 14 mm microwell dishes.  The 6-, 24- and 96-well plates were used for 
cellular assays while the 35 mm MatTek-glass bottom 14 mm microwell dishes were 
used for cell studies with the confocal microscope.  Cell plating for each of these plate 
types differed in obtaining the optimal cellular confluency (Table 5). 
 
Table 5  Cell Plating Values for Optimal Cell Confluence. 
Plate Type Total Volume (mL) Cell Density (cells/mL) Total Cells (cells/well)
6-well 2.0 5x105 1x106
24-well 0.5 1x106 5x105
96-well 0.2 5x105 1x105
14 mm 3.0 5x105 5x104  
 
 Cell suspensions were added to each plate by lightly resting the pipet tip along the 
side of each well so that the transfer process had a softer impact on the cells.  Cell 
transfer to the MatTek 14 mm microwell dishes was different in that only 100 µL of a 
5x105 cells/mL suspension was added to the center of the 14 mm microwell, incubated for 
90 minutes and then diluted with 2.9 mL fresh media.  This ensures that the cells are 
concentrated over the coverslip during confocal imaging.  Stimulant treatments of plated 
cells are possible.  When adding new stimulants, it is important that the stimulant dose be 
mixed thoroughly in the media to be applied and that the addition is made along the side 
of the plate well, avoiding direct impact on the cell layer.  Likewise, the pipet tip used to 
aspirate off media should not make contact with the cell layer.      
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Griess Assay 
 The Griess assay is a standard assay63 used to monitor the cellular production of 
nitric oxide (NO).  This measurement is an indirect one since the Griess reaction actually 
quantifies the concentration of nitrite (NO2-), the stable byproduct of NO in the presence 
O2.  The amine group of the sulfanilimide reagent is converted to a diazonium ion upon 
nitrite addition and loss of a water molecule (Scheme 10).  The diazonium ion quickly 
couples to the naphthylethylenediamine reagent to form an azo derivative that absorbs at 
540 nm.   
 
 
Scheme 10  Griess reaction scheme.  Nitric oxide is measured in biological systems by measuring the 
amount of nitrite present.  In reaction with sulfanilamide and naphtylethylenediamine, the presence of 
nitrite leads to the production of an azo compound that can be monitored at λ=540 nm.      
 
 This assay was used herein to measure the effects of HZ and polyunsaturated fatty 
acids on macrophage-like cells’ inducible nitric oxide synthase (iNOS) activity.  The 
assay can be used with the macrophage-like RAW and J774 cell lines but not with the 
neutrophil-like differentiated HL-60s since they are not a significant producer of nitric 
oxide.  To set up this assay, Griess reagents were prepared.  A solution of 0.1% 
naphthylethylenediamine dihydrochloride (NED) was prepared by dissolving 0.1 g of 
NED (Sigma N-9125, 259.2 g/mol) in 100 mL DI water, and 1.0% sulfanilimide in 5% 
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phosphoric acid was prepared by dissolving 1.0 g of sulfanilimide (Sigma S-9251, 172.21 
g/mol) in 100 mL of 5% phosphoric acid (5 mL concentrated phosphoric acid in 95 mL 
DI water).  Reagents were stored at 4°C in amber bottles for up to 6 months.   
 RAW cells were plated in 24-well plates at 1x106 cells/mL and allowed to 
incubate overnight.  The media was aspirated, cells were washed lightly with 300 µL 
phosphate buffer saline (PBS) containing Ca2+ and Mg2+, followed by the addition of 
390µL media and 10 µL lipopolysaccharide (LPS) to activate the cells and another 100 
µL of stimulant dosed media.  Note: It is important to prepare stimulant doses at 5 times 
their desired concentration since the final volume in the well will be 5 times that of the 
dose volume added.  Plates were incubated at least 8 hours and the supernatants removed 
into autoclaved 1.5 mL microcentrifuge tubes and centrifuged at 16.1 x 103 g for 5 
minutes to remove any cellular debris.  Of the resultant supernatants, 100 µL was added 
to clear 96-well plates along with the sequential additions of 50 µL of sulfanilimide and 
50 µL of NED.  After 5 minutes, the plates were read at λ=540 nm.       
 A standard curve of sodium nitrite (NaNO2) was used to quantify the 
concentration of nitrite in the cell supernatants.  A serial dilution of NaNO2 was prepared 
from a stock solution of 100 mM (6.9 mg in 1.0 mL DI water) and diluted to ranges of 0-
100 µM.      
 
Cytochrome C Superoxide Assay 
 The cytrochrome c superoxide assay measures the classic reduction of 
cytochrome c by superoxide reactive oxygen species (ROS) in the presence and absence 
of anti-oxidant superoxide dismutase (SOD).102  The addition of SOD enables the 
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scavenging of extracellular superoxide when oxidative stress is induced.  Differentiated 
HL-60 (neutrophil-like) cells were used in order to monitor the effects of a pro-oxidant 4-
hydroxy-2-nonenal (HNE) on the nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase pathway of activated phagocytes.  NADPH complexes within the 
mitochondrial membrane act as the major sources of ROS production during oxidative 
stress, serving as electron donors to cellular oxygen.  In the presence of superoxide, ferric 
cytochrome c can be reduced to its ferrous state therefore oxidizing the ROS back to 
molecular oxygen (Scheme 11). 
 
 
Scheme 11  Cytochrome c reduction by superoxide.  Superoxide generated during phagocyte activation 
acts as an electron donor, reducing ferric cytochrome c to its ferrous state.  The ferrous state absorbs at 
λ=550 nm and can be monitored spectroscopically as a measure of oxidative stress.    
 
 It is the ferrous form of the cytochrome c that can be monitored spectroscopically 
at 550 nm.  Therefore, when SOD is added to solution, the extracellular superoxide is 
scavenged by the SOD and ferric cytochrome c is not reduced resulting in minimal 
absorbance change.  The use of SOD in this assay ensures that the reduction of the 
cytochrome c observed is in fact due to superoxide.   
 This assay was carried out in sterile black 96-well clear bottom plates.  A series of 
HNE dilutions were prepared from a 64 mM stock and added to each well to produce a 
concentration response curve ranging from 0-1 mM.  The appropriate HNE dilutions 
were prepared in RPMI phenol red-free media and added to each well (x8).  These 
additions were followed by a 50 µL volume of 2x106 cells/mL in phenol red-free media 
to each well ensuring a total cell count of 1x105 cells/well and incubated 3 hours.  SOD 
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treated and SOD deprived reaction mixtures were then added to the wells (4 each of the 8 
HNE doses).  A 320 µM cytrochrome c solution (64 mg in 16 mL Hank’s Buffer Saline 
Solution (HBSS)) was made and 60 µL of 8.1 mM (5 mg/mL stock in 20 µL DMSO 
stored at -40°C) phorbol 12-myristate-13-acetate (PMA) added for a final solution 
concentration of 32 µM.  PMA is a preferred pharmacological stimulant because it 
bypasses cell surface receptors and induces direct activation of NADPH oxidase, 
generally making stimulation quicker and more prominent.  This 16 mL solution was then 
divided in two, and to one solution, 80 µL of 10,000 U/mL SOD (4 mg SOD in 500 µL 
HBSS) was added.  Each HNE concentration then received 150 µL of each of these 
reaction mixtures (4x).  The plate was incubated 37°C for 30 minutes, read at λ=550 nm 
and the concentration of superoxide calculated using a molar absorptivity constant of 
2.1x104 M-1cm-1.  
 Physiological stimulants were also attempted with this assay; including zymosan 
(protein-carbohydrate complexes from the Saccharomyces cerevisae cell wall), zymosan 
activated serum (ZAS, or zymosan incubated with FBS), opsonized zymosan particles 
(OZP, particulate from ZAS preparation) and N-formyl-methionyl-leucylphenylalanine 
(fMLP, oxidase activation via formyl-peptide receptors).  These stimulants were prepared 
as follows and added to the 16 mL reaction mixture in the place of PMA.  Zymosan was 
prepared at 2 mg/mL, or 32 mg per 16 mL solution.  ZAS and OZP were prepared by 
incubating zymosan in FBS at 10 mg/mL 1 hour at 37°C and centrifuged at 2,000 x g for 
10 min.  The supernatant and pellet were separated and heated at 56°C for 1 hour to 
inactivate endogenous alkaline phosphatase.  The supernatant was the 10 mg/mL ZAS, 
and 3.2 mL of this was added to the 16 mL reaction solution for a final 2 mg/mL density.  
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The 150 mg pellet was OZP and was further washed in HBSS twice before resuspending 
in 5 mL of HBSS.  A 2 mg/mL reaction solution was prepared by adding 1.07 mL of the 
OZP mixture.  The fMLP was used at 32 µM by adding 0.22 mg of the powder to the 16 
mL reaction solution.          
 
Amplex Red Hydrogen Peroxide Assay 
 The amplex red assay is a sensitive fluorescence assay used to measure hydrogen 
peroxide.223  The 96-well microplate assay is capable of detecting 5 pmol of hydrogen 
peroxide per 100 µL sample.  This assay was used herein to measure extracellular levels 
of hydrogen peroxide produced by differentiated (neutrophil-like) HL-60 cells upon 
stimulation with PMA and inhibition with HNE.  In the assay, horseradish peroxidase 
(HRP) catalyzes the de-N-acetylation and oxidation of Amplex Red.  In the presence of 
hydrogen peroxide, Fe(III)-HRP is oxidized to its Fe(IV) state as seen in the equation:  
Fe(III)-HRP + 2H2O2 → 2H2O + O2 + HRP•-Fe(IV) + 2e-.  In turn, the reductant 
substrate, amplex red, is oxidized to its fluorescent derivative, resorufin (Scheme 12). 
 
Scheme 12  Amplex red oxidation to fluorescent resorufin.  In the presence of hydrogen peroxide, 
horseradish peroxidase catalyzes the de-N-acetylation and oxidation of amplex red to resorufin.  This 
fluorescent product excites at 530/25 nm and emits at 590/35 nm, enabling an indirect measurement of 
hydrogen peroxide levels.   
    
This fluorescence assay provides a sensitive method to monitor ROS production 
during oxidative stress and specifically, the measurement of hydrogen peroxide levels.  
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Coupled with the cytochrome c superoxide assay described previously, these assays 
provide a precise means of evaluating the effects of HNE on phagocyte function through 
the NADPH oxidase pathway.  The assay was conducted on 5-day differentiated HL-60 
cells.  To sterile, black 96 well clear bottom plates, 20 µL of 7.5x105 cells/mL were added 
in phenol red-free RPMI 1640 for a total cell count of 1.5x104 cells/well.  HNE 30 µL 
serial dilutions were added resulting in a final concentration range of 1 nM-100 µM and 
incubated 3 hours.  A 10 mL reaction mixture was prepared in Krebs Ringer phosphate 
buffer (KRPB) of  20.5 µL of 7.81 mM PMA (final 16 µM), 50 µL of 10 mM amplex red 
(final 50 µM) and 100 µL of 10 U/mL HRP (1.68 mg in 50 mL KRPB) (final 0.1 U/mL).  
This mixture was added to each reaction well at a volume of 100 µL and incubated 30 
minutes.  Samples were excited at 530/25 nm and their fluorescence read at 590/35 nm.  
A 0-5 µM standard curve of hydrogen peroxide was prepared for quantitation.       
 
Alternatively Activated Macrophages 
 Alternatively activated macrophages (AAMs) were attempted in murine RAW 
264.7 cells.224,225  Activated macrophages are used to study innate immune responses 
while AAMs provide a model to study humoral immunity including repair processes.  
Macrophages possess two inducible enzymes, arginase and nitric oxide synthase-2 (NOS-
2) (Scheme 13).  Nitric oxide from the NOS-2 pathway was measured as described by the 
Griess assay when cells were challenged with LPS, a potent endotoxin that elicits the 
secretion of several pro-inflammatory cytokines.  To study the arginase pathway, RAW 
cells were plated in 6-well plates at 1x106 cells/well (2 mL of 5x105 cells/mL RPMI 
complete media) and incubated overnight.  Media was then aspirated and replaced by  
  137
 
Scheme 13  Th1 and Th2 stimulant response pathway in macrophage cells.  Macrophages have two 
inducible enzymes where arginine is the substrate:  arginase and NOS-2.  Measurements were attempted of 
products highlighted by square borders.  The top-most Th1 response was induced by LPS challenge and the 
bottom-most Th2 response was induced by ILs-4, 13 and 21.   
 
Dulbecco’s modified eagle medium (DMEM), low glucose 1X, 1 g/L D-glucose, L-
glutamine, 110 mg/L sodium pyruvate, 1% FBS and 1% penicillin, streptomycin.  Cells 
were incubated 20 hours.  Media was aspirated and washed twice with PBS (without 
Ca2+/Mg2+).  DMEM (2 mL) was added again but without FBS supplement.  Cells were 
dosed with interleukins 4, 13 and 21 (IL-4, 13, 21) from 1-40 ng/mL, rotated by hand and 
incubated 48 hours.  Measurements of arginase activity were attempted by monitoring the 
conversion of arginine to ornithine.   
Cells were harvested and lysed with lysis buffer containing 0.5% triton solution 
with trypsin-chymotrypsin inhibitor (0.1 mg/mL), leupeptin (0.05 mg/mL), aprotinin 
(0.05 mg/mL) and pheynylmethonylsulfonyl fluoride (PMSF, 0.2 mM).  After lysis, 25 
µL of 10 mM MnCl2 was added to 25 µL of lysate from each IL sample.  Samples were 
incubated at 55°C for 20 minutes.  Carbonate buffer (150 µL of 0.1 M) was added to each 
sample.  Half of the samples received 50 µL of 100 mM L-arginine, incubated at 25°C 1 
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hour and the reaction stopped with addition of 750 µL of glacial acetic acid.  A 250 µL 
aliquot of 2.5 g/L ninhydrin solution (in ethanol) was added to all samples and brought to 
a boil for 1 hour.  Ornithine production was measured at 560 nm.  Significant distinction 
between control and experimental samples was not established.   
Measurement of urea levels was then attempted as previously described.226,227  In 
these experiments, RAW cells were plated in 96-well plates at 5x105 cells/well (200 µL 
of 2.5x106 cells/mL).  Cells were incubated overnight.  IL-21 was added to each well (0.4 
µL of 10 µg/mL stock, final density of 20 ng/mL) and incubated 6 hours.  ILs-4 and -13 
were added to the appropriate wells and incubated 6 hours.  Cells were washed 3 times 
with PBS and lysed with 50 µL 0.1% Triton X-100 (15 µL of 10% Triton X-100 in 1.5 
mL PBS, 1 protease inhibitor cocktail tablet).  The plates were rotated 15 minutes at 4°C.   
Aliquots of 50 µL of 10 mM manganese chloride and 50 mM TrisHCl, pH 7.5 
(1.5 mL and 750 µL) were added to each well and incubated at 55°C for 10 minutes.  
Afterwards, 25 µL lysate was added to a new plate and wells already containing 25 µL of 
0.5 M arginine (0.13065 g Arg in 1.5 mL 0.1 M sodium bicarbonate), pH 9.7.  The plates 
were incubated at 37°C for 1 hour.  A 100 µL solution of 1 sulfuric acid: 3 phosphoric 
acid: 7 water (v:v:v) was added to stop the reaction.  An aliquot of 25 µL 9% (w/v) ISPF 
(α-isonitrosopropiophenone) in ethanol was added and incubated at 95°C for 3 hours.  
The absorbance of the samples was measured at 540 nm after cooling for 10 minutes.  A 
0-12 mM calibration curve of urea was treated in the same manner.  Again, no significant 
distinction between control and sample wells was observed. 
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APPENDIX B 
 
Schistosomiasis Study Protocols 
 
Murine Model Infection 
 All stages of the Schistosoma mansoni life cycle are maintained at the Biomedical 
Research Institute in Rockville, Maryland, USA.61  There, cercariae were collected from 
Biomphalaria glabrata snail hosts and counted.  Desired dilutions were made within 5 
hours, and Swiss Webster mice were infected with 150 cercariae per mouse.  To do this, 
mice were placed in individual plastic restraining tubes (Figure 45A).  Their tails were 
positioned through the tube bottom and taped securely (Figure 45B).  The restraining  
 
 
Figure 45  Percutaneous tail infection of Swiss Webster mice with S. mansoni cercariae.  (A) Mice 
were placed in plastic restraining tubes.  (B) Mouse tails were extended from the restraining tube bottoms 
and held in place by adhesive tape.  (C) Mice restraining tubes were inverted over an exposure rack with S. 
mansoni cercariae dilution test tubes.  The mice were infected via painless percutaneous tail exposure for 1 
hour.    
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tubes were then inverted over an exposure rack containing 12 x 75 glass test tubes with 
the cercariae dilutions (Figure 45C).  An absorbent kimwipe in each tube prevented 
mouse urine from reaching and killing the cercariae in the test tubes below.  Mouse tails 
were wiped clean with water and then inserted into the cercariae dilutions for a 1 hour 
exposure time.  Mice were removed from their tubes and placed back in their cages until 
desired time of schistosome collection.  Cercariae infection numbers were estimated by 
staining the cercariae remaining in the test tubes with iodine and counting the stray 
bodies and tails under a light microscope. 
 
Observed Disease Progression 
 Mice were evaluated at weeks 4, 5, 6, 7 and 8 p.i. and compared to uninfected 
controls.  The abdomens of infected mice were observed to grow rotund as expected with 
the progression of the disease.  A distended abdomen is characteristic of schistosomiasis 
infection.  In severe chronic cases, portal shunts can be seen from the chest cavity to the 
abdomen as liver function and hence blood flow is dangerously reduced.  Although, 
abdominal circumference was visually estimated to grow 23% (3.5 in. to 4.5 in.), mouse 
weight remained constant at ~30 g.  Upon dissection, uninfected controls were found to 
contain healthy pink tissue, but infected mice were found to have larger, darker livers and 
spleens.  Furthermore, the abdominal cavity was primarily taken up by the infected liver 
and spleen by weeks 7 and 8 p.i. (Figure 46).            
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Figure 46  Increase in abdominal circumference in disease progression.  Abdominal circumference of 
mice was observed to increase 23% progressively from (A) uninfected mice through weeks (B) 4, (C) 5, 
(D) 6, (E) 7 and (F) 8 p.i.  Black scale bars are 5 cm.   
 
Schistosome Perfusion 
 Schistosoma mansoni reach sexual maturity at 5½ to 6 weeks post-infection.  
Therefore, adult schistosomes are generally collected 6 to 7 weeks post-infection.  The 
adult schistosomes reside in the hepatic portal vein, and perfusion of the descending aorta 
is used to extract them.  First though, mice were weighed and euthanized with a 65 
mg/mL sodium pentobarbital solution prepared from a 260 mg/mL stock of the controlled 
A B C 
D E F 
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substance Sleepaway.  A 25 mL solution was prepared for the euthanasia of 60 mice.  
This solution included 2.5 mL of 260 mg/mL Sleepaway, 0.5 mL of 10 kU/mL heparin 
and 22 mL of sterile water.  Each mouse received a 0.3 mL intraperitoneal injection of 
the pentobarbital solution with a 25G⅝ syringe.  After 30 minutes, mice were confirmed 
dead by toe pinch.  The mice were then dipped in warm water and their coats smoothed.  
Scissors were used to make an incision through the abdomen coat, and the fur was 
removed from the abdominal and thoracic cavities.  Mice were again submerged in warm 
water and another cut made to open the abdomen.  The diaphragm was cut, and the ribs  
 
 
Figure 47  S. mansoni collection from infected Swiss Webster mice.   (A) A 20G needle was used to 
perfuse the descending aorta.  (B) Adult schistosomes were collected on a mesh screen in order to wash 
away red blood cells.  (C) Worms were counted in a grid-laden Petri dish and separated by gender. 
 
of the left half thoracic cavity were severed.  Below the liver, the hepatic portal vein was 
severed, and a 20G needle attached to a peristaltic perfusion pump was inserted in the 
descending aorta, carefully avoiding completely puncturing the aorta and losing pressure 
(Figure 47A).  Perfusion fluid (7.5 g trisodium citrate dihydrate and 8.5 g sodium 
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chloride per 1 L sterile water) was used to perfuse the schistosomes from the hepatic 
portal vein.The abdomen and intestines were carefully washed to ensure that all 
schistosomes were collected in the designated pan.   
The infected livers and spleens were collected, weighed, wrapped in labeled 
aluminum foil, frozen in liquid nitrogen and stored at -80°C.  The worms collected were 
washed onto a construction grade mesh screen and washed with perfusion fluid until no 
tissue, fur or red blood cells were visible (Figure 47B).  Finally, the worms were placed 
in a gridded Petri dish (Figure 47C), separated by gender, counted, placed in cryo-tubes, 
frozen in liquid nitrogen and stored at -80°C.   
 
Hemozoin Isolation 
 SmHZ was isolated from adult schistosomes by thawing frozen worms and adding 
them to an autoclaved 15 mL glass homogenizer and homogenizing into a homogenous 
mixture.  The mixture was centrifuged at 1000 x g for 1 minute and the supernatant 
containing the HZ removed.  This process was repeated twice.  The final supernatant was 
centrifuged at 5445 x g for 2 hours.  This supernatant was discarded and the precipitate 
resuspended in 10 mL of 150 mM phosphate buffer, pH 7.4.  The mixture was 
centrifuged at 5445 x g for 1 hour.  The supernatant was discarded, and the dark brown 
precipitate was purified as described below.   
SmHZ was also isolated from the livers and spleens collected.  Organs were 
homogenized using hand-held electric homogenizer in a total of 50 mL deionized water.  
The solutions were centrifuged at 1,000 x g for 2 minutes to remove some of the cellular 
debris.  The supernatant was centrifuged at 5445 x g for 2 hours.  The supernatant was 
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discarded, and 1 mL of 150 mM phosphate buffer was added lightly.  The pellet (two 
shades: lighter is tissue and darker is HZ) was vortexed gingerly to loosen the lightly 
colored tissue from the dark bottom pellet, and the supernatant was poured away.  A 
series of 1:1 phosphate buffer and ethyl acetate washes (1 minute centrifugations at 1,000 
x g) were repeated until the supernatant was clear.  The HZ was further purified and 
quantified as described by Chen and coworkers.114  
Briefly, the precipitate was resuspended in 5 mg/mL Proteinase K buffer (as 
purchased in Vanderbilt Core) and incubated at 37°C overnight.  The pellet was washed 3 
times with 2% SDS.  The final pellet was resuspended in 6.0 M urea and incubated 3 
hours at 37°C in a shaking water bath set at 80 rpm.  The sample was again washed 3 
times with 2% SDS, followed by 8 DI water washes.  All purification washes as 
described were centrifuged at 16.1 x 103 g for 5 minutes. 
The water suspension of the final wash was used to quantify the amount of HZ 
isolated by removing 10 µL of the suspension and adding it to 990 μL of 20 mM NaOH, 
2% SDS.  This solution sat at room temperature for 1 hour and its absorbance was 
measured at 400 nm, 5101×=ε M-1 cm-1.  Beer’s law was used to calculate the 
concentration of HZ in solution, and the final mass was determined by using the molar 
ratio of heme and HZ reported previously (25 µg HZ/ 20 nmol heme).62  The final HZ 
pellet was blown dry under argon gas and stored under dessicant at -20°C.   
 
Thromboxane Assay for Mouse Urine 
 Mouse urine was collected by bladder massage from uninfected (C), 4-, 5-, 6-, 7- 
and 8-weeks post-infection mice.  Thromboxane levels in the urine samples were 
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measured as another measure of oxidative stress during infection.  The assay measured 
the presence of 11-dehydro thromboxane B2 (TxB2) (Figure 48) using an internal  
 
 
Figure 48  Structure of 11-dehydro-thromboxane B2 (TxB2). 
 
standard of D4-11-dehydroTxB2.  TxB2 is the stable metabolite of the deleterious 
proaggregatory vasoconstrictor, thromboxane A2 (TxA2).  Elevated levels of TxA2 and 
hence TxB2 have been found in tissues where arachidonate and its metabolites are 
upregulated, such as in inflammation and endotoxic shock.228  Therefore, an assay for 
TxB2 was carried out as a measure of inflammation as it correlates to the lipoxidation of 
arachidonic acid.  The assay was carried out as follows.  A separate sample (100 µL urine 
and 150 µL DI water) from the assay was sent to the Vanderbilt comparative lab for 
creatinine levels.  The internal standard D4-11-dehydroTxB2 (3 ng) was added to a tube 
of 3 mL pH 3.0 water and vortexed.  A sample of urine (840 µL) was then added and 
vortexed.  The sample acidity was adjusted to pH 3.0 with 1 N HCl (250 µL).  A C18 
SepPak column was preconditioned with 5 mL methanol followed by 5 mL of pH 3.0 
water.  The sample was loaded onto the column, rinsed with 10 mL of pH 3.0 water, then 
10 mL 20% methanol (in pH 3.0 water) and finally eluted with ethyl acetate into a 
scintillation vial.  The sample was dried over 1 scoop of sodium sulfate, transferred to a 
reactivial and dried under nitrogen gas.  Methanol (25 µL) was added and vortex.  The 
residue is not soluble.  An addition of 400 µL pH 3.0 water and 5 µL 1 N HCl was made, 
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vortexed and the pH kept below 3.0.  The sample was allowed to sit at room temperature 
for 30 minutes. 
 Extraction was made with 1 mL of ethyl acetate, transferred to a microcentrifuge 
tube, dried and reconstituted in 50 µL ethyl acetate.  A TLC plate was run in 97 ethyl 
acetate: 3 acetone: 2 acetic acid using 5 µL prostaglandinD2 (PGD2) free acid as a 
standard.  Bands were run to 13 cm (reference should be 0.40 cm) and scraped 1 cm on 
each side.  Another 1 mL extraction of ethyl acetate was made.  The extract was 
transferred to a glass vial and dried under nitrogen and pentafluorobenzylbromide 
(PFBB) at 37°C for 20 minutes.  An addition of 40 µL PFBB (in 10% acetonitrile) and 20 
µL of diisopropylethylamine (DIPE) (in 10% acetonitrile) was made, evaporated under 
nitrogen and reconstituted in 50 µL ethyl acetate.  Another TLC plate was run in 60 ethyl 
acetate: 40 heptane using 5 µg PGD2-PFBB ester as a standard.  Bands were run 13 cm 
(reference should be 0.23 cm) and scraped 1.3 cm below center of band to 0.7 cm above 
center of band.  
 A 1 mL ethyl acetate extraction was made, dried and silated with 20 µL 
bis(trimethylsiliyl)trifluoroacetamide (BSTFA) and 10 µL of dimethylformamide (DMF).  
Samples were incubated at 37°C for 10 minutes.  The samples were then dried and 
reconstituted in 10 µL undecane when ready to run GC-MS analysis.  Injections of 1-2 
µL were made and tracings were smoothed x1.  A 15M DB 1701 column was used, 
monitoring 511-515, 190°-300°C, 20°C per minute, and a retention time of 9-10 minutes 
was seen.  Normal human urine TxB2 levels are 370 ± 137 pg/mg of creatinine.         
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 The TxB2 levels for each week of the time study were measured, where N=1 
(Figure 49).  Small sample volumes and the lack of uniform sampling per mouse limited 
the accuracy and precision achieved with this assay.  As schistosomes matured during 
 
 
Figure 49  Mouse urine 11-dehydro-thromboxane B2 levels during S. mansoni infection.  Urine 
samples were collected from uninfected (C), 4-, 5-, 6-, 7- and 8-week post-infection mice.  TxB2 levels 
were measured (N=1) using a D4- internal standard in GC-MS analysis and normalized to urine creatinine 
levels.    
 
 
infection, more eggs would be expected to accumulate in the liver, causing the formation 
of fibrotic granulomas and an increase in tissue inflammation.  HZ formed by adult 
worms would also be expected to accumulate over time, contributing to the lipoxidation 
of fatty acids and the upregulation of arachidonate metabolites.            
 
Anti-HNE Immunostaining of Thin Tissue Sections 
 Thin tissue sections (5 µm thick) were taken of the livers and spleens collected 
from uninfected, 4-, 5-, 6-, 7- and 8-weeks post-infection mice.  The sections were made 
by the Vanderbilt University Immunohistochemistry Core.  Hemotoxylin and eosin 
(H&E) stains of these tissues were made by the core.  Anti-HNE stains were made in my 
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lab using a similar method as referenced in previous literature.149  Each slide obtained 
from the core had 2 tissue sections.  For each sample treatment, a coverslip was used to 
uniformly cover the entire section (liquid tended to bubble over the paraffin-section).  
The R&D systems HRP-AEC System Cell and Tissue Staining kit was used, along with 
the R&D systems monoclonal anti-4-hydroxynonenal primary antibody.  A 100 µg order 
of antibody was placed and was reconstituted in 4 mL sterile PBS (without Ca2+ or Mg2+) 
and then stored in 100 µL aliquots at -40°C.  These aliquots are stable for 6 months.  
Specifically, the staining procedure was as follows: 
 Samples were covered with 2 drops of peroxidase blocking reagent for 5 minutes.  
The samples were rinsed with PBS (without Ca2+ or Mg2+) and then washed in PBS for 5 
minutes.  Washes must be gentle since hydrogen peroxidase may loosen the tissue 
sections from the slide.  Samples were incubated with 2 drops of serum blocking reagent 
for 15 minutes.  Slides were drained and excess blocking reagent was wiped away (no 
PBS rinse here).  Samples were incubated with 2 drops of avidin blocking reagent for 15 
minutes.  Samples were rinsed with PBS, the slides drained and excess buffer wiped 
away.  Samples were incubated with 2 drops of biotin blocking reagent for 15 minutes.  
Slides were rinsed again with PBS, drained and excess buffer wiped away.  Samples were 
incubated at 37°C with primary antibody (25 µL of the 25 µg/mL stock) for 1 hour.  The 
sample was rinsed with PBS and washed 3 times at 15 minute increments.  Slides were 
drained and excess buffer was wiped away.  Samples were then incubated at 37°C with 2 
drops of biotinylated secondary antibody for 1 hour.  The sample was rinsed with PBS 
and washed 3 times at 15 minute increments.  Slides were drained and excess buffer was 
wiped away.  Samples were incubated at 37°C with 2 drops of HSS-HRP for 30 minutes.  
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Slides were rinsed with PBS and washed 3 times at 2 minute increments (used pipet tip 
box lid and rotator to do this).  Slides were drained and excess buffer removed.   
The total volume of AEC chromagen needed for the entire reaction was calculated 
(20 µL AEC chromagen in 480 µL chromagen buffer, vortex).  Two drops of freshly 
prepared AEC chromagen was added to the slides using small transfer pipets and 
incubated at 37°C for 1½ hours.  The slides were rinsed with DI water and washed for 5 
minutes (used pipet tip box lid and rotator to do this).  Aqueous mounting medium (2 
drops) was used to slowly and evenly position new coverslips over stained section, 
paying careful attention not to trap air bubbles over the samples.  The slides were allowed 
to dry extensively.  Samples were imaged on an Olympus BH2-RFCA light microscope 
with Olympus DP70 camera and DP controller software. 
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APPENDIX C 
 
β-Hematin Assay Protocols 
 
Dehydrohalogenation β-Hematin Synthesis 
 BH was prepared according to the dehydrohalogenation Bohle-Madsen method.35  
In three 240 mL round bottom flasks, 0.3 g of hemin chloride (Fluka ≥99.8%) was 
weighed out and a stir bar added.  The flask neck was covered with a kimwipe held in 
place by a rubber band.  Flasks were taken into a glovebox along with 3 24/40 glass 
stoppers, 3 pieces of 6 in. electrical tape and 3 pieces of aluminum foil to cover flasks 
completely.  While stirring, 5.0 mL of 2,6-lutidine was added.  In a graduated cylinder, 
25 mL of DMSO and 25 mL of anhydrous methanol were mixed and added to the stirring 
flask.  After 1 minute, stirring was stopped, and the flask was stoppered.  The stopper was 
sealed with the electrical tape, and the flask was covered with aluminum foil.  The flasks 
were stored in the glovebox 3 months.   
Final products were removed from the glovebox and filtered on 0.45 µm filter 
paper.  Samples were rinsed with methanol until filtrate was clear.  Rinses continued with 
DI water.  The sample was scraped from the filter paper and placed in a 50 mL centrifuge 
tube along with 25 mL of methanol, vortexed and centrifuged at 5445 x g for 30 minutes.  
Alternating washes of DI water and 0.1 M bicarbonate buffer, pH 9.0 were repeated until 
the absorbance of water supernatants were <1x10-2 at λ=400 nm (generally 3 months of 
daily washes following glovebox removal).  Bicarbonate washes were rotated at room 
temperature for 1 hour while DI water washes were immediately centrifuged.  Final 
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products were characterized by XRD, FT-IR and SEM and stored in the dark, under 
vacuum and dessicant.  Since the faces of the crystal may degrade over time, the integrity 
of the stored sample may be tested by reading the absorbance of the sample in 
bicarbonate buffer.  If an absorbance is observed, the crystal has degraded and should not 
be used for experiments. 
 
Crystal Extension Assay 
 A BH crystal growth assay is used in which preformed BH seeds the extension of 
the BH aggregate with addition of hemin.189  Since BH is used to seed further crystal 
growth, quantification of assay-formed BH requires a mass balance adjustment for the 
BH initially added to the assay.  Drug concentrations in the range of 0-10 μM were 
effective in inhibiting the assay’s aggregation of BH formation (Figure 50).  
Concentration-response curves were used to plot data from the assay, and IC50 values of 
1.58 μM amodiaquine and 3.29 μM chloroquine were obtained, similar to those reported 
previously.189  The Z΄ values for this assay range from 0.792 to 0.872, indicating its 
potential for use as a high throughput screen. 
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Figure 50  Concentration response curves from the BH crystal extension assay.  (A) Chloroquine and 
(B) amodiaquine were evaluated for their IC50 concentrations in an assay of extension of BH growth from a 
preformed crystal.  
 
  152
 A BH crystal extension assay was adapted from previous description.189  A 25 
mM hematin stock solution was prepared by dissolving hemin in DMSO and filtering 
through a 0.22 μm PVDF membrane syringe driven filter unit.  From this solution, a 
222.2 μM hematin stock solution was prepared in 0.1 M ammonium acetate solution.  To 
each well, final concentrations of 50 μM hematin stock solution, 10 nmol preformed BH 
190 and 0-10 μM antimalarial were incubated in clear, 384-well plates at 37 °C in a 
Thermo water bath and shaken at 40 rpm for 16 h.  The plates were centrifuged in a 
Beckman Coulter AllegraX 22R, S2096 rotor, at 25 °C for 1 h at 1100 x g.  Supernatant 
was removed and 0.15 M sodium bicarbonate, 2% SDS was used to dissolve free heme in 
the mixture.  The plate was centrifuged again for 1 h and the supernatant removed.  The 
remaining BH pellet was dissolved using 0.36 M NaOH, 2% SDS and its absorbance read 
at 400 nm. 
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Figure 51  Cross validation of the BH crystal extension assay.  The BH crystal extension assay was 
cross validated with checkerboard controls of (red) potentiator of amodiaquine at 10 µM and (blue) vehicle 
assay substrates.  The assay had a strong Z’ value of 0.8409. 
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Checkerboard cross validation experiments were carried out with this assay in 
order to provide a secondary assay for follow up confirmation of the preliminary hits 
from the NP-40 mediated BH crystallization assay (Figure 51).  Confirmation of hits in 
this assay would ensure that the hits from the NP-40 assay were in fact targeting the heme 
surface rather than generating potential false positives from stronger interactions with the 
lipophilic detergent NP-40. 
 
Lipid-Mediated Crystallization Assay 
 While the precise in vivo mechanism of HZ biomineralization is unknown, new 
evidence suggests that lipid-rich environments can act as templates for Hz crystallization.  
In vitro lipid-initiated BH crystallization was reported by Egan and coworkers using 
various glycerols.229  In a recent study, transmission electron microscopy (TEM) showed 
the localization of SmHz at the hydrophilic-hydrophobic interface of lipid droplets in the 
S. mansoni gut lumen.64  Similarly, Pisciotta and coworkers proposed that neutral lipid 
nanospheres were the sites of Hz formation within the digestive food vacuole of P. 
falciparum.230  In both cases, lipid extracts from each organism provided a competent 
scaffold for Hz formation in vitro.64,230  Using the individual as well as the ratio of 
glycerols with the BH assay reported by Pisciotta et al., we repeated the assay with a 
similar IC50 value of 21.9 μM for chloroquine.  We also tested amodiaquine and found an 
IC50 of 27.3 μM (Figure 52).  The resultant BH product was measured.  This assay’s Z΄ 
factor range of 0.602-0.755 demonstrates its suitability for high throughput screening. 
 Lipid mediated BH formation was adapted from previous description.231  A 25 
mM hematin stock solution was prepared by dissolving hemin (≥98%, Sigma-Aldrich, St. 
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Louis, MO) in DMSO and filtering through a 0.22 μm PVDF membrane syringe driven 
filter unit.  From this solution, a 222.2 μM hematin stock solution was prepared in 0.2 M 
ammonium acetate solution.  Lipids (1-Stearoyl-rac-glycerol [MSG]; 1,2-Dipalmitoyl-
rac-glycerol [DPG]; 1,2-Dioleoyl-rac-glycerol [DOG]; 1,3-Dilinoleoyl-rac-glycerol 
[DLG]; or 3-Palmitoyl-sn-glycerol [MPG]; Sigma-Aldrich, St. Louis, MO) were 
dissolved in ethanol prior to addition to the assay.  Final concentrations of 100 μM  
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Figure 52  Inhibition studies of neutral lipid blend mediated BH assays.  (A) BH production was 
measured by the individual glycerols of the neutral lipid blend (blue) without inhibitor, (red) with 
chloroquine at IC50 and (green) with amodiaquine at IC50.  (B) Specifically, the neutral lipid blend was 
found to form 3 nmol of BH at 50 µM hematin substrate and was inhibited 2-fold with the addition of 
chloroquine and amodiaquine at IC50.  (C) and (D) Concentration response curves of amodiaquine and 
chloroquine, respectively, in the NP-40 mediated BH assay. 
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hematin stock solution, 100 μM lipid solution (a ratio of 4:2:1:1:1 monostearoyl-, 
monopalmitoyl-, dipalmitoyl-, dioleoyl-, and dilinoleoyl glycerols, respectively), and 0-
100 μM antimalarial (chloroquine or amodiaquine, Sigma-Aldrich, St. Louis, MO) were 
incubated in clear, 384-well plates at 37 °C in a Thermo water bath and shaken at 40 rpm 
for 20 h.  The plates were centrifuged in a Beckman Coulter AllegraX 22R, S2096 rotor, 
at 25 °C for 1 h at 1100 x g.  Supernatant was removed and 0.15 M sodium bicarbonate, 
2% SDS was used to dissolve free heme in the mixture.  The plate was centrifuged again 
for 1 h and the supernatant removed.  The remaining BH pellet was dissolved using 0.36 
M NaOH, 2% SDS and its absorbance read at 400 nm. 
 
Detergent-Mediated Crystallization Assay 
 The detergent-mediated crystallization assay was designed to serve as a primary 
screen in the identification of potential antimalarials.  The acidic and lipid-rich 
environment of the digestive food vacuole was mimicked in vitro and tailored to a 384-
well plate format for high throughput screening.  This assay uses an inexpensive 
detergent as an alternative to the more expensive lipid blend native to the parasite’s 
digestive food vacuole, saving ~$0.05/well.  This assay also only requires an incubation 
time of 4 hours as compared to previously published ≥ 20 hour reactions.29,189  Several 
detergents are reported herein, but the detergent NP-40 was found to provide the growth 
platform that yielded the closest drug IC50 values as those obtained by the native neutral 
lipid blend (Figure 53). 
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To set up the assay, a 2.0 M sodium acetate buffer, pH 4.9 was prepared (13.4039 
g sodium acetate trihydrate and 5.799 mL glacial acetic acid in 100 mL deionized water).  
A 0.0002 g/mL NP-40 stock was prepared by adding 84.9 µL of 10% NP-40 to 45 mL of 
deionized water and vortexed.  Both of these solutions have been scaled-up for large  
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Figure 53  Concentration response curves of NP-40 mediated BH assays.  The IC50 values of (A) 
amodiaquine and (B) chloroquine were calculated as 25 µM and 50 µM, respectively. 
   
screens.  A 25 mM heme solution was prepared by weighing out 16.3 mg of hemin (Fluka 
≥99.8%) in a microcentrifuge tube and dissolving it in 1 mL DMSO.  This solution was 
vortexed and sonicated before filtering through a 0.22 µm PVDF Millex filter.  A 177.8 
µL aliquot of the filtrate was added to 20 mL of the 2.0 M sodium acetate buffer for a 
final 222.2 µM heme buffer solution.  This solution was kept stirring during plate 
delivery; this is especially important when scaling up to volumes of ≥500 mL.   
Control drug stocks (amodiaquine) were prepared at 51.6 mM in 100% DMSO.  
These additions resulted in a 100 µM final concentration (ICMAX) of drug in the final 
assay.  Aliquots of 125 nL were made to designated wells, followed by 14 µL of 
deionized water.  The two outer columns of the plate A1:P2 and A23:P24 contained a 
checkerboard distribution of positive control amodiaquine and drug vehicle DMSO 
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(Figure 54).  Library compounds (10 mM) were added (125 nL) to desired wells followed 
by 14 µL of deionized water, resulting in a 19.3 µM final concentration (the control 
drug’s IC50).   
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Figure 54  HTS plate layout of the NP-40 mediated BH assay.  The assay plate is organized by controls 
of (red) potentiator amodiaquine at ICMAX 100 µm and (blue) vehicle DMSO, and the orange wells contain 
19.3 µM test compounds. 
 
To the plate containing drug and library compounds, 30 µL of heme buffer 
solution was added, followed by 5 µL of 0.0002 g/mL NP-40 stock and 15 µL of acetone.  
Plates were incubated in a 37°C reciprocating water bath (55 rpm) for 4 hours.  
Meanwhile, a 20 mM 4-(2-hydroxyethyl)-1-piperzineethanesulfonic acid (HEPES) 
buffer, pH 7.5 was prepared by dissolving 2.383 g HEPES enzyme grade in 500 mL of 
deionized water.  This buffer was used to prepare a 1:1 (v:v) solution of HEPES buffer to 
pyridine and was added (8 µL) to plates following incubation.  Plates were shaken 15 
minutes and their absorbance read at 405 nm.  The raw absorbance data was plotted 
against a logarithmic scale of drug in GraphPad Prism 5.0.  Hits were identified as those 
data points lying three standard deviations outside of the control antimalarial in the 
screen.           
  158
BH Assay Development and Optimization 
 Several steps were undertaken in the optimization of each BH assay presented 
herein.  One of the first inquiries was into the reaction buffer of each assay.  The buffer of 
the neutral lipids was 0.1 M ammonium acetate while the buffer of the NP-40 assay was 
1.0 M sodium acetate.  Therefore, a series of experiments varying in pH and ionic 
strength were carried out (as summarized in Tables 6-8).  A final reaction pH of 4.9 was 
 
Table 6  Chloroquine-Inhibited Neutral Lipid BH Assay’s Response to pH and Ionic Strength. 
0.66550.966819.3160
0.71470.973024.51575.6
0.61470.990543.8160
0.72710.991141.31395.4
0.80620.995099.3160
0.69010.995592.71175.1
0.87660.9970297.5160
0.71450.9541190.4934.9
0.80280.9936484.1160
0.74420.9950472.4704.7
0.60430.9573975.3160
0.67660.9837748.2504.5
0.84340.98633,153160
0.69110.97411,460344.3
0.76570.91622,076160
0.70260.80112,020224.1
Z´R2IC50 (μM) 
of CQ
Buffer Ionic 
Strength (mM)
pH of Reaction 
Mixture
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Table 7  Amodiaquine-Inhibited Neutral Lipid BH Assay’s Response to pH and Ionic Strength. 
0.84870.988010.70160
0.71630.983111.551575.6
0.77330.996812.62160
0.80410.990914.781395.4
0.86790.997320.41160
0.86200.983420.961175.1
0.78040.990340.73160
0.84570.990634.47934.9
0.77400.993072.93160
0.80260.965159.79704.7
0.69650.8556169.1160
0.87240.9849136.1504.5
Z´R2IC50 (μM) 
of AQ
Buffer Ionic 
Strength (mM)
pH of Reaction 
Mixture
 
 
maintained for all future assays.  The ionic character was not found to cause significant 
change in the assay BH production as demonstrated in the neutral lipid mediated assay 
 
Table 8  Chloroquine-Inhibited NP-40 BH Assay’s Response to pH and Ionic Strength. 
0.48830.94759.721.575.6
0.81730.98648.901.405.4
0.65680.964719.451.205.1
0.75970.962630.080.9854.9
0.63460.977566.160.7674.7
0.70750.9756102.10.5654.5
0.82040.9514182.90.3954.3
0.61380.9532217.00.2634.1
Z´R2IC50 (μM) 
of CQ
Buffer Ionic 
Strength (M)
pH of Reaction 
Mixture
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BH product (Figure 55A).  The change in buffer concentration, however, between the 
NP-40 and neutral lipid assays was found to be of significance (Figure 55B).  The BH 
produced from 4, 16, 20 and 24 hours in the various buffers were monitored, and the 1.0 
M acetate buffers were found to consistently produce greater amounts of BH at 4 h, 
compared to the 0.1 M acetate buffers.  It is possible that the greater salt concentration in 
the 1.0 M buffers provides a system with superfluous molecular interactions, supporting a 
faster formation time between substrates or even a faster sequestration of lipophilic 
mediator in the aqueous medium.   
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Figure 55  Quantification of BH formed at varying pH and buffer ionic strength.  (A) The effects on 
BH production of varying ionic strength in the 0.1 M ammonium acetate, neutral lipid mediated BH assay 
were measured.  These were minimal as observed between the buffers of (red) 160 mM and (blue) 22-157 
mM ionic strengths.  (B) The NP-40 assay was applied to varying concentrations of acetate buffer, where 
the 0.1 M buffers had an ionic strength 93 mM and the 1.0 M buffers are 985 mM.  The 1.0 M buffers were 
found to support faster BH aggregation at the intervals:  (red) 4, (green) 16, (blue) 20 and (yellow) 24 h.      
 
Increasing concentrations of heme substrate at 16, 20 and 24 h intervals were also 
considered in each assay.  Time was not found to be a factor in BH formation; product 
increased as substrate did.  In the BH crystal extension assay (Figure 56A), an increase in 
BH was not observed because the quantity of preformed BH was not increased in the 
  161
 
assay.  The lipophilic neutral lipid and NP-40 BH crystallization assays (Figure 56B&C), 
however, were found to mediate the formation of BH as the amount of heme was 
increased. 
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Figure 56  Kinetic and heme-dose response studies in the BH crystallization assays.  The quantity of 
BH produced in the (A) BH crystal extension, (B) neutral lipid mediated and (C) NP-40 mediated BH 
assays was measured at (red) 16, (green) 20 and (blue) 24 h intervals as the concentration of heme 
substrate was increased.   
 
Hydrogen Peroxide Degradation Assay41,100 
 H2O2 degradation studies were carried out on Bohle, neutral lipid, extension and 
NP-40 prepared BH, similar to the studies used in chapter 3, but adapted to a 96-well 
plate format and with consideration of the various products of BH preparation.  Prior to 
assay measurements, stock solutions were prepared and standardized.  The 5 mM KMnO4 
(0.7902 g in 1 L DI water), 0.015 M Na2C2O4 (0.5025 g in 250 mL DI water), 3 M 
sulfuric acid (16.7 mL 18 M H2SO4 in 100 mL DI water) and 4.5 M sulfuric acid (25 mL 
18 M H2SO4 in 100 mL DI water) stocks were prepared.  The standardization of KMnO4 
(Scheme 14) was began by preparing the analyte (25 mL of 0.015 M Na2C2O4 
 
Scheme 14  KMnO4 Standardization 
5Na2C2O4 + 2KMnO4 + 8H2SO4 → 2MnSO4 + K2SO4 + 5Na2SO4 + 10CO2 + 8H2O  
  162
Scheme 15  H2O2 Standardization 
5H2O2 + 2KMnO4 + 3H2SO4 → 2MnSO4 + K2SO4 + 5O2 + 8H2O  
 
and  15 mL of 3 M H2SO4 in 50 mL of DI water) and filling the buret with 5 mM KMnO4 
titrant.  The H2O2 stock was standardized (Scheme 15) by preparing the analyte (15 mL 
of 4.5 M H2SO4, 50 mL of DI water and 25 µL of 30% H2O2 [newly opened]) and filling 
the buret with standardized KMnO4 titrant. 
 Neutral lipid, extension and NP-40 BH assays were prepared as previously 
described (at 166 µL reactions volumes in round bottom 96-well plates).  All assays were 
incubated at 37°C, 55 rpm for 20 h.  The plates were centrifuged at 1100 x g for 1 hr at 
25°C in a Beckman Coulter AllegraX 22R, S2096 rotor.  The supernatant was removed, 
and HZ precipitate was washed with 200 µL of DI water, centrifuging again for 1 h.  The 
supernatant was discarded, and the assay BH product (as well as a new plate of 2.0 
mg/mL suspension of Bohle) was suspended in 100 mM sodium acetate buffer pH 4.8 
with the appropriate concentration of standardized H2O2.  These plates were incubated at 
37° for 20 h.  They were centrifuged 1 h and HZ precipitate was washed with 200 µL of 
DI water, centrifuging again for 1 h.  To the remaining precipitate, 200 µL of 0.36 M 
NaOH, 2%SDS was added to each well.  The absorbance of the plates’ contents was 
measured at 400 nm on a BioTek SynergyHT plate reader.  A molar extinction coefficient 
of 1x10-5 M-1cm-1 was used to calculate the BH remaining.  These calculations were used 
to determine the EC50 values of H2O2 in the degradation of BH.       
 The resultant dose response curves of Bohle BH, extension BH, lipid blend BH 
and NP-40 BH revealed stability strengths of the formed BH (Figure 57).  As expected, 
the Bohle synthesis of BH had the highest EC50 of 7.68 mM, followed by the neutral 
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blend BH at 5.95 mM, the NP-40 mediated BH at 4.13 mM and the extension formed BH 
at 3.37 mM.  The BH formed in just acetate buffer was weaker and had EC50 values of 1 
mM.   
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Figure 57  H2O2 Degradation of BH produced from varying templates.  Concentration response curves 
of BH’s degradation by H2O2 were generated for BH prepared from (A) the Bohle dehydrohalogenation 
method, (B) the BH crystal extension assay, (C) the neutral lipid blend mediated BH assay and (D) the NP-
40 mediated BH assay.  These plots generated H2O2 EC50 values of 7.68 mM, 3.37 mM, 5.95 mM (1.84 
mM) and 4.13 mM (1.38mM), respectively.  In C and D, the -□- symbols represent assays where lipophilic 
mediator (whether glycerols or NP-40) were absent.  The EC50 values of these plots are given in the earlier 
parentheses. 
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APPENDIX D 
 
HTS Preliminary Hits of the NP-40 Mediated BH Crystallization Assay 
 
 This appendix contains the graphical representation of the structural trends of the 
hits identified in the preliminary screens of the NP-40 mediated BH crystallization assay 
(Figure 56).  The following pages of Scheme 16 contain the 161 hits (15 per page), 
labeled with their PubChem ID, calculated log P, molecular weight and amine pKa 
values.  The compounds outlined with a black border are ICMAX hits.  Log P and pKa 
values were calculated using ChemAxon Marvin v.5.2.2 software. 
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Figure 58  Graphical representation of the structural trends identified from the preliminary screens 
of the NP-40 mediated crystallization assay.  (solid green) The total preliminary hits belonging to each 
structure category.  (checker green) The number of ICMAX hits belonging to each structure category. 
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Scheme 16  Complete list of preliminary hits identified in the NP-40 mediated BH crystallization 
assay small molecule library screens. 
 
 
PubChem ID 783797 2931719 6800421
log P 1.08 3.37 4
MWT (g/mol) 209.22508 348.19126 344.36664
amine pKA 0.45 4.48 1.23, ‐2.47, ‐7.13
PubChem ID 805136 2931787 2057602
log P 2.31 3.21 5.83
MWT (g/mol) 331.39278 303.74026 332.46036
amine pKA 1.75 4.45 ‐3.95
PubChem ID 751934 873167 1356910
log P 1.9 3.28 4.19
MWT (g/mol) 277.3205 308.41904 386.44476
amine pKA 1.68, 5.95 6.4 14.39
PubChem ID 2933614 2256655 1587948
log P 4.04 4.67 3.06
MWT (g/mol) 326.43586 356.82602 410.48938
amine pKA 0.20, ‐9.91 7.57 1.18, ‐0.54
PubChem ID 706129 6742706 892241
log P 2.2 2.79 3.75
MWT (g/mol) 207.25226 282.29726 313.3742
amine pKA 8.88, ‐5.34 1.25, ‐2.79, ‐7.13 9.10, ‐5.51  
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PubChem ID 731870 748044 3131870
log P 2.15 3.11 2.68
MWT (g/mol) 251.32144 341.42736 314.42194
amine pKA 15.17 1.34, ‐8.25 7.31
PubChem ID 748069 748042 764331
log P 1.51 3.62 1.84
MWT (g/mol) 272.3007632 301.4297 268.33688
amine pKA 3.78, 0.42, ‐8.91 1.83, ‐7.81 3.78, 0.42, ‐8.91
PubChem ID 2941849 764330 690371
log P 2.73 4.19 2.63
MWT (g/mol) 384.22666 336.23894 191.25286
amine pKA 2.44, 12.9 1.23, ‐8.21 ‐2.94
PubChem ID 892098 6800179 870599
log P 0.87 3.44 3.14
MWT (g/mol) 314.36226 331.34642 231.31672
amine pKA 3.77, 0.41, ‐8.96 19.77, 1.24, ‐8.23 9.37, ‐2.56
PubChem ID 702457 725824 574330
log P 2.77 3.3 0.71
MWT (g/mol) 297.3748 252.35578 290.27466
amine pKA 1.43, ‐8.14 6.45 ‐2.31  
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PubChem ID 2248254 2897796 930671
log P 1.82 3.43 5.07
MWT (g/mol) 296.27748 363.3817064 302.41446
amine pKA 3.65 13.97, 13.91, 13.03, 1.44 5.41
PubChem ID 1556024 2898021 2947540
log P 3.7 4.81 1.73
MWT (g/mol) 356.41878 311.44444 306.40646
amine pKA 13.5 9.01, ‐5.4 ‐1.57
PubChem ID 773154 2896732 1085012
log P 3.66 2.76 2.7
MWT (g/mol) 311.29212 353.37186 354.7870832
amine pKA 2.5 13.91, 13.2, 12.29, 1.44 ‐2.37
PubChem ID 2901657 991474 931717
log P 3.62 2.65 1.92
MWT (g/mol) 323.36902 444.22589 253.34714
amine pKA       ‐   1.21, ‐2.61 10.51, 9.58, 5.22, 3.5 9.1, 3.87, ‐4.5
PubChem ID 661205 2197254 677540
log P 2.29 5.03 2.68
MWT (g/mol) 295.35738 376.27086 253.32224
amine pKA ‐3.1 9.18, ‐5.73 1.43, ‐8.14  
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PubChem ID 676205 827956 661302
log P 2.18 3.2 2.57
MWT (g/mol) 313.3742 317.38106 228.28964
amine pKA 1.44, ‐8.19 2.26 16.19, 4.74
PubChem ID 95445 5724276 2858149
log P 1.6 3.66 3.24
MWT (g/mol) 232.23528 409.43512 276.76128
amine pKA 9.18 1.97 14.76, 4.48
PubChem ID 667526 94022 5414628
log P 2.87 2.86 2.78
MWT (g/mol) 267.34882 241.2851 296.34698
amine pKA 1.95, ‐8.11 3.72 0.68, ‐0.99, ‐9.20
PubChem ID 820006 741829 6777892
log P 1.74 1.43 4.45
MWT (g/mol) 237.27824 242.25984 335.37972
amine pKA ‐2.93  ‐   0.35, ‐ 2.28, ‐ 9.62 9.16, ‐5.49  
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PubChem ID 707204 3490666 1116129
log P 1.89 4.33 1.66
MWT (g/mol) 288.75536 367.39998 363.32692
amine pKA 3.77, 0.41, ‐8.92 2.11 10.6, 9.81, 5.52, 4.92
PubChem ID 660813 776830 5731584
log P 4.12 1.62 5.21
MWT (g/mol) 293.34304 231.24722 400.26582
amine pKA 8.62, ‐7.41 3.37
PubChem ID 2253328 5721908 6809847
log P 2.68 7.26 4.77
MWT (g/mol) 316.39476 419.56066 297.73568
amine pKA 14.11, 4.22 5.16, 4.63, 4.05 3.37
PubChem ID 6810219 2884112 986302
log P 3.09 4.94 3.67
MWT (g/mol) 376.43494 389.3791432 415.44124
amine pKA 2.95, 0.65, ‐2.46, ‐9.2 1.57 3.55, ‐2.3
PubChem ID 1207571 963506 6809875
log P 4.44 3.1 4.87
MWT (g/mol) 393.23672 337.3989 342.18668
amine pKA 10.82, 1.89, 0.85, ‐5.84 4.95, 1.75, ‐5.87 3.37  
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PubChem ID 5406135 2829105 991453
log P 0.4 2.8 3.39
MWT (g/mol) 221.2557 308.33124 381.81234
amine pKA 9.93, 4.16, 1.9 7.79, 3.32 11.63, 9.94, 5.21
PubChem ID 777097 2831725 5550271
log P 3.31 2.43 3.7
MWT (g/mol) 259.30522 228.28964 302.3714
amine pKA 5.88, 3.04 15.73, 4.6 7.48, 1.75, ‐5.66
PubChem ID 5898619 1070499 1306410
log P 3.21 4.2 3.15
MWT (g/mol) 215.24782 361.52304 354.44926
amine pKA 5.07 8.57, 4.62, 4.01 ‐1.73
PubChem ID 5717183 774193 2947757
log P 0.76 3.52 3.39
MWT (g/mol) 238.23986 238.32752 415.4843
amine pKA 0.53 5.17 6.68, ‐9.59
PubChem ID 6803142 6796866 975838
log P 5.99 4.54 3.46
MWT (g/mol) 717.63026 327.76166 273.30704
amine pKA 7.27, ‐1.24 3.37  
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PubChem ID 2947832 3799887 939004
log P 1.45 1.38 2.8
MWT (g/mol) 378.49556 270.32632 346.40566
amine pKA 0.45, ‐0.54, ‐8.57 6.62 3.94, 0.86, ‐8.21
PubChem ID 830422 6801973 757553
log P 2.41 4.04 1.48
MWT (g/mol) 223.31786 308.28818 239.33718
amine pKA 16.22, 0.1, ‐9.4 3.37 13.97, 8.22
PubChem ID 2948389 6845036 743083
log P 4.41 4.71 2.56
MWT (g/mol) 370.23984 372.21266 336.79662
amine pKA 19.95, 2.19 3.38 ‐2.31
PubChem ID 2949870 1592012 704537
log P 3.69 7.16 1.38
MWT (g/mol) 403.4487832 457.69479 273.31034
amine pKA 6.62, ‐5.22 15.94, 4.2, ‐1.51, ‐6.3 0.51, ‐9.81
PubChem ID 5739057 943060 5336686
log P 3.67 2.31 2.69
MWT (g/mol) 338.7909 282.36346 268.32874
amine pKA 17.87, 2.78, ‐6.56, ‐5.81 3.94, 0.86, ‐8.44  
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PubChem ID 1226086 15998154 2761386
log P 4.23 1.519663 2.21
MWT (g/mol) 319.42176 412.4622 240.32194
amine pKA ‐2.58 18.8, 7.98, ‐7.84
PubChem ID 3121854 3671746 6824199
log P 4.49 0.019000 2.14
MWT (g/mol) 348.43816 206.28738 311.16658
amine pKA 3.13 19.94, 4.74, 2.26, ‐7.4
PubChem ID 4365930 6024818 3762472
log P 3.13 3.468510 5.57
MWT (g/mol) 366.43682 388.3432096 334.43472
amine pKA 13.91, 13.12, 10.47, 1.44 15.4, 13.42
PubChem ID 2918158 5740675 15991225
log P 3.73 4.2 6.26
MWT (g/mol) 438.3441992 434.8237864 451.31256
amine pKA 19.82, 10.33 9.99, ‐5.94 0.15, ‐4.61
PubChem ID 2766102 6617298 3275143
log P 2.39 3.34 2.36
MWT (g/mol) 276.31428 435.49884 283.36814
amine pKA 10.03, ‐3.38 7.01, 1.46, ‐0.15, ‐6.34, ‐6.93 3.88, 0.49  
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PubChem ID 4377684 5066435 3698429
log P 4.34 5.15 4.07
MWT (g/mol) 499.53774 420.88814 422.56628
amine pKA 6.31, 2.18 1.78 14.76, 9.3, ‐0.95, ‐5.98
PubChem ID 3455308 4403626 Unknown
log P 4.44 5.09 4.59
MWT (g/mol) 396.48272 382.88322 409.77938
amine pKA 4.49, ‐2.06, ‐7.83 2.51 12.19, 0.02
PubChem ID 729843 3121968 1716517
log P 2.36 5.17 6.38
MWT (g/mol) 301.2956232 358.88496 491.4498792
amine pKA 15.24, 9.76, ‐8.89 1.47 14.12, 10.12
PubChem ID 6273261 3427810 555190
log P 3.71 4.4 4.86
MWT (g/mol) 392.45096 293.42432 326.39112
amine pKA 18.02, 2.78, ‐5.99, ‐6.14 7.73 3.07
PubChem ID 4670755 4101678 776836
log P 4.24 3 2.37
MWT (g/mol) 291.756 375.4851 229.2744
amine pKA 8.65, ‐8.12 ‐2.03  
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PubChem ID 3534454 366 683639
log P 1.42 1.67 2.39
MWT (g/mol) 259.25732 218.2054 208.23702
amine pKA 8.67, ‐0.54, ‐1.97
PubChem ID 3829096 300848 2295553
log P 1.53 3.81 4.25
MWT (g/mol) 356.33274 282.2509 418.22837
amine pKA 13.91, 13.14, 11.76, 1.44 ‐2.19 18.90, 1.57, 0.36
PubChem ID 695277 3557264 3746677
log P 4.31 3.26 3.96
MWT (g/mol) 323.38564 431.35452 360.4058
amine pKA 19.26, 4.14 12.23 0.26
PubChem ID 2888260 708517 5189170
log P 4.04 1.01 4.2
MWT (g/mol) 296.40666 254.30876 430.45258
amine pKA 15.75, 4.56 ‐2.35 1.95
PubChem ID 5085883 150718 15998896
log P 2.3 3.11 5.95
MWT (g/mol) 270.2551432 292.33184 438.43482
amine pKA 6.56, 3.5 10.05, 0.90, ‐5.84  
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PubChem ID 5978130 15998274 760603
log P 0.2 6.86 3.33
MWT (g/mol) 352.47318 453.48922 292.33184
amine pKA 13.79, ‐0.34 0.83, ‐0.66, ‐5.91 18.90, 1.57, 0.36
Amodiaquine
PubChem ID 1098314 3799745 2165
log P 4.48 5.45 4.53
MWT (g/mol) 374.48196 424.40824 355.86118
amine pKA 3.39, 2.78, 0.96, 0.23 10.05, 0.90, ‐5.83 6.9
Chloroquine
PubChem ID 4436435 4104558 2719
log P 4.78 5.93 3.93
MWT (g/mol) 461.51122 381.44816 319.87214
amine pKA ‐5.64 9.57, ‐1.04 7.73
PubChem ID 6815125 2858622
log P 6.33 5.59
MWT (g/mol) 490.30554 459.35946
amine pKA 11.49, 0.77 12.61, 8.91, ‐0.25, ‐1.96
PubChem ID 3287443 3238973
log P 5.22 2.31
MWT (g/mol) 346.76654 281.31088
amine pKA 0.64, ‐6.09 12.70, 8.48, ‐4.05, ‐5.49  
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